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 Neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s 
disease (HD), amyotrophic lateral sclerosis (ALS), and spinocerebellar ataxias (SCAs), are a group of diseases 
that remain incurable despite the enormous research effort into the underlying pathological mechanisms. The 
pathology includes progressive neuronal cell death, hence the name “neurodegeneration”, but the underlying 
cause is still mainly unknown.
SCAs are autosomal dominant disorders that lead to the atrophy of Purkinje cells (PCs) in the cerebellar 
cortex and successive neuronal loss in spinocerebellar tracks. The disease pathology is characterized by cerebellar 
ataxia, which means unsteady gait, clumsiness and eye movement defects (dysarthria). This ataxic disorder can 
be accompanied by various other symptoms including cognitive impairment, epilepsy, peripheral neuropathy 
or psychiatric problems, correlated with neuronal loss in other brain regions. Onset of the disease symptoms is 
usually in third or fourth decade of life [1]. 
The first neurological ataxic phenotype classification was proposed by Harding and it divides the 
autosomal dominant ataxias (ADCA) into three clinical subgroups (ADCA I-III; Table 1) [1]. This classification 
is sometimes still used, but it is not that useful as not all SCA phenotypes fit exactly into the three defined 
subgroups. Additionally, the genetic mechanisms underlying particular types of SCA do not correlate with 
Harding’s classification. For instance, the ADCA I subgroup comprises SCA types caused by coding and non-coding 
repeat expansions and conventional mutations. The current classification of the SCAs is therefore based on the 
underlying genetic defect and the definitive diagnosis relies on the outcome of the genetic analysis.
Table 1 The autosomal dominant cerebellar ataxia (ADCA) classification of Harding (1982) [2]
SCA type Clinical manifestations
ADCA I
1-4, 8, 10, 12-23, 25, 27, 28, 
DRPLA
Complex (spinal cord syndromes, peripheral nerve disease, cognitive 
impairment, ophthalmologic signs, psychiatric problems and seizures)
ADCA II 7 Pigmentary maculopathy
ADCA III 5, 6, 11, 26, 29, 30, 31 “Pure” cerebellar
SCA is genetically a very heterogeneous group of diseases (Fig. 1), and to date 32 different subtypes of 
SCA have been recognized (SCA9 and SCA33 are unassigned, SCA15 and 16 were proved to be allelic, also SCA19 
and 22 were linked to the same gene, and SCA24 was proved to be recessively inherited) (Table 2). The disease 
gene has been identified for 22 SCA types. Phenotypically similar SCAs are not only caused by mutations in various 
genes, but the mutation mechanism can also be different, including coding and non-coding repeat expansions, 
missense and nonsense mutations, deletions and duplications.
 







Fig. 1 Localization of various spinocerebellar ataxias-associated mutations in different gene regions.
Despite the recent advances in genetic techniques, the genetic diagnosis for SCA remains problematic. 
Screening of the more common SCA genes (SCA types 1-3, 6, 7, 12, 14, and 17) yields mutations in only 60-70% 
of the cases. Additionally, the identification of new disease genes is not always straightforward, as even after 
the disease locus has been mapped, the disease genes cannot always be found in the linkage regions. These 
loci are often large and contain too many candidate genes, which cannot be screened individually as this is too 
costly and labour-intensive. The development of deep sequencing technologies has greatly advanced the search 
for mutations and led to the identification of new genes in which mutations are responsible for SCAs, including 
SCA19/22 (Chapter 3), SCA26 [3], and SCA35 [4].
SCAs caused by polyglutamine repeat expansions
 The most common genetic cause of SCA is the expansion of a coding CAG trinucleotide repeat tract 
resulting in abnormally long polyglutamine (polyQ) stretches in the corresponding proteins. This expansion is 
associated with SCA1-3, 7, 6, and 17 (and occurs in exons of the genes encoding for ataxin-1, 2, 3 and 7, Cav2.1, 
and TBP, respectively) [5-11]. 
These SCA types are therefore considered to be polyQ diseases, just like HD, spinal and bulbar muscular 
atrophy (SBMA), and dentatorubral pallidoluysian atrophy (DRPLA) [12]. In polyQ diseases, the expansion of the 
CAG repeat tract has to surpass a certain threshold to become pathological (reviewed in [13]). The size of the CAG 
repeat tract and age of disease onset are negatively correlated (when the repeat tract is not interrupted) [1], with 
longer repeat tracts associated with earlier disease onset. Another feature of polyQ diseases is genetic anticipation 
(with paternal transmission), which means that in each subsequent generation, the disease onset occurs earlier 
and with more severe symptoms, and this is correlated with longer CAG repeat tracts [1]. Discrepancies in these 
correlations (between severity of the symptoms and CAG repeat length) were reported, caused by alternate 
codons disrupting the expanded CAG repeat tract (interrupted alleles) [14].
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Table 2 Overview of the genes and mutation effects in different types of SCAs
SCA Locus Gene Type of mutations References
SCA1 6p22.3 ATXN1 Coding CAG expansion [5]
SCA2 12q24.13 ATXN2 Coding CAG expansion [6]
SCA3/MJD 14q32.12 ATXN3 Coding CAG expansion [8]
SCA4 16q22.1 unknown - [91]
SCA5 11q13.2 SPTBN2 Deletion, missense mutation [35]
SCA6 19p13.13 CACNA1A Coding CAG expansion [9]
SCA7 3p14.1 ATXN7 Coding CAG expansion [92]
SCA8 13q21 ATXN8 3’ UTR repeat expansion [93]
SCA10 22q13.31 ATXN10 intronic repeat expansion [18], [94]
SCA11 15q14-21.3 TTBK2 Deletion*, nonsense mutation [95], [96]
SCA12 5q32 PPP2R2B 5’ UTR repeat expansion [19]
SCA13 19q13.33 KCNC3 Missense mutation [37]
SCA14 19q13.42 PRKCG Missense mutation [38]
SCA15/16 3q24.2-pter ITPR1 Deletion, missense mutation [97], [ 98]
SCA17 6q27 TBP Coding CAG expansion [99]
SCA18 7q31-32 unknown - [100]
SCA19/22 1p21-q21 KCND3 Missense mutation [101], [102], [103], [104]
SCA20 11p11.2 unknown Duplication [40]
SCA21 7p21.3-15.1 unknown - [105]
SCA23 20p13-12.2 PDYN Missense mutation [106]
SCA25 2p21-15 unknown - [107]
SCA26 19p13.3 EF2 Deletion, missense mutation [108], [3]
SCA27 13q13.1 FGF14 Missense mutation [109]
SCA28 18p11.21 AFG3L2 Missense mutation [110], [54]
SCA29 3p26-pter unknown - [111]
SCA30 4q34.3-q35.1 unknown - [112]
SCA31 16q22.1 TK2, BEAN Intronic insertion of repeats [20]
SCA32 7q32 unknown -
SCA34# 6q12.3-q16.2 unknown - [113]
SCA35 20p13-12.2 TGM6 Missense mutation [44] 
SCA36 20p13 NOP56 Intronic repeat expansion [21]
SCA37 1p32 unknown - [114]
* leading to premature codon stop and expression of truncated protein                        #Reserved lately, not yet published [57]
The coding CAG repeat expansion is thought to be a toxic gain-of-function mutation, as proteins with 
expanded polyQ stretches show pathological interactions with other proteins, are prone to aggregate, and 
subsequently form cytoplasmic or intranuclear inclusions [15]. Although the precise mechanisms by which these 
expanded proteins exert toxicity is still unknown, the aggregates are known to sequester important proteins for cell 
function, such as transcription factors, chaperones and members of degradation systems (i.e. proteasomes and 
ubiquitin ligases), leading to depletion of these factors in the cell [12]. The trapped chaperones and proteasomes 
can no longer perform their function, what induces further accumulation of misfolded and un-degraded proteins. 
Sequestration of transcription factors results in dysregulation of important pathways and subsequent cell death 
(reviewed in [16] and [12]). The protein aggregates may also physically disrupt intracellular membranes, leading 
to mitochondrial dysfunction, or hinder axonal transport (reviewed in [12]), and as such impair neuronal 







functioning and cause degeneration.
The toxic structure of the aggregated polyQ proteins is not sufficient to explain the selective 
neurodegeneration of specific brain areas and neuronal populations. Despite the fact that many of the disease-
related proteins are ubiquitously expressed through the whole central nervous system, specific subpopulations of 
neurons are affected, for example, striatal neurons in HD, and PCs in SCA. Therefore, other, context-dependent 
factors probably trigger the disease-related neurodegeneration.
SCAs caused by non-coding repeat expansions
Besides coding expansions, other SCA types such as SCA8, 10, 12, 31 and 36 (Table 2) are caused by 
non-coding repeat expansions, leading to the transcription of abnormally long RNA molecules [16-21]. SCA8 and 
SCA12 are caused by triplet (CTG/CAG) repeat expansions in the 3’ untranslated region (UTR) of the SCA8 gene of 
unknown function and 5’ UTR of the PPP2R2B gene encoding for brain-specific regulatory subunit of phosphatase 
PP2A, respectively [22, 23]. SCA10 is caused by a very long expansion of the pentanucleotide repeat ATTCT in 
intron 9 of ATXN10 (also of unknown function). SCA31 is caused by a pentanucleotide TGGAA repeat insertion in 
intron of overlapping genes BEAN (brain-expressed gene associated with Nedd4) and TK2 (encoding for thymidine 
kinase 2) which are transcribed in opposite directions [20]. SCA36 is caused by large expansions of a GGCCTG 
repeat tract in the first intron of the NOP56 gene, encoding for nucleolar protein 56 involved in biogenesis of 
ribosomal RNA [24].
In SCA10 and 31 the repeat length negatively correlates with the age of disease onset, while anticipation 
with paternal transmission was reported for SCA31 [18, 20]. In SCA8, 12 and 36 there is no clear correlation 
between the repeat length and age of onset or severity of the disease [23-25].
For non-coding repeat expansion-associated SCAs, a toxic RNA-gain-of-function mechanism was proposed, 
in which the repeat expansions are toxic on the RNA level. Abnormally long RNA molecules often accumulate in 
RNA foci, as has been described in SCA8, 10, 31, and 36 [20, 21, 26]. However, how and if these RNA foci cause 
neuronal dysfunction and subsequent cell death is still unclear and needs to be determined. One of the hypotheses 
is that these RNA foci sequester important RNA-binding proteins leading to transcription and splicing dysregulation, 
which might contribute to disease pathogenesis [20]. For example, the expanded ATXN10 RNA accumulates in PCs 
and binds to heteronuclear ribonuclear protein K (hnRNP K) causing loss of its function and subsequent cell death 
[16, 27]. In SCA8, the SCA8 transcript is an antisense RNA to Kelch-like protein-1 gene (KLHL1) [28] and controls 
the expression of KLHL1 protein, which is suggested to be important for stabilizing calcium (Ca2+) channels on the 
neuronal membrane. Expansion in SCA8 RNA causes KLHL1 silencing [29, 30]. Moreover, the SCA31 insertion contains 
a paracentromeric satellite sequence of a pentanucleotide TGGAA repeat that might have an essential role in the 
maintenance of chromatin conformation [20]. It has also been proposed that this mutation alters the expression of 
other, neighbouring genes by inducing structural changes in DNA structure, leading to a conformational change that 
is hardly recognizable by transcription factors, such as non-B DNA [20].
SCA8 and 12 are unique among the SCAs caused by the non-coding expansions. In SCA8, the bidirectional 
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transcription through the repeat region results in two overlapping mechanisms: a toxic RNA gain-of-function and 
a toxic protein gain-of-function through polyQ expanded protein (reviewed in [31]). However, some controversy 
exists about the pathogenicity of this non-coding repeat expansion, as expanded SCA8 alleles have been found 
to be more common in patients suffering from other types of SCAs, including SCA1 and 6 [32, 33]. In SCA12, 
the pathology does not seem to be associated with the RNA, but only with the protein. The SCA12-associated 
repeat expansion results in overexpression of the PP2A phosphatase regulatory subunit that is important for 
mitochondria fusion-fission homeostasis [34].
SCA types caused by missense mutations and chromosomal rearrangements (conventional mutations)
Historically, SCAs were thought to be caused only by (tri-)nucleotide repeat expansions. However, the 
more recently identified SCA mutations are mainly either missense mutations or chromosomal rearrangements, 
such as deletions or duplications, that can be found in SCA5, 11, 13, 14, 15/16, 19/22 (Chapter 3), 20, 23 (Chapter 
4), 26, 27, 28 and 35 (Table 2), causing changes in the function of the corresponding proteins [3, 35-44].
In most cases, neuronal signalling pathways are compromised due to mutations in the genes encoding 
for potassium channels (Kv3.3 in SCA13 and Kv4.3 in SCA19/22), Ca
2+ transporters (IP3R in SCA15/16), proteins 
responsible for stabilizing receptors/channels on plasma membrane (βIII-spectrin in SCA5 and FGF14 in SCA27), 
proteins involved in intracellular signal transduction (TTBK2, PKCγ, and FGF14 in SCA11, SCA14, and SCA27, 
respectively), or proteins involved in mitochondrial energy pathways (AFG3L2 in SCA28). Since the disease 
proteins implicated in this subgroup have been identified only relatively recently and they show a fair degree of 
functional diversity, not much is known yet about the underlying pathomechanisms.
Loss-of-function and haploinsufficiency was proposed as the underlying cause of SCA5 [45, 46], SCA15/16 
[47-49] and SCA28 [50]. In SCA28, partial loss of mitochondrial metalloproteinase AFG3L2 can result in respiratory 
chain dysfunction leading to PC death due to oxidative stress [50]. In SCA5, haploinsufficiency/loss of βIII-spectrin, 
which is important for stabilizing membrane proteins, causes alterations in glutamatergic transmission and subsequent 
Ca2+ imbalance due to loss of functioning glutamate receptors and transporters on the plasma membrane [45, 46]. 
SCA15/16-associated missense mutations in ITPR1 encoding for inositol-triphosphate receptor (IP3R) subunit were 
shown to cause loss of function of this transporter resulting in motor coordination problems in flies [48]. However, 
enhanced Ca2+ conductance of wild type subunits was observed in the presence of the SCA15/16-mutant subunits 
[47, 49], suggesting a gain-of-function mechanism or dominant negative effect. Moreover, SCA13-mutant potassium 
channel subunit Kv3.3 was shown to have a dominant-negative effect on wild type subunits and reduced neuronal 
excitability leading to locomotor dysfunction [51]. In SCA14, it was also proposed that mutant protein kinase C 
gamma (PKCγ) has a dominant-negative effect on wild type PKCγ molecules, leading to dysregulation of oxidative 
homeostasis, caspase activation and PCs degeneration [52].
Together, this evidence shows that SCAs caused by conventional mutations do not seem to have a 
directly identical underlying genetic mechanism.








 SCA is a rare disorder that occurs between 1 and 3 per 100,000 people in Europe [2]. However, the 
prevalence of particular SCA types can vary drastically in different populations, probably due to founder effects. 
For instance, SCA3 frequency was calculated to be ~1.5% of all SCA cases in South Africa, but ~60% in Brazil and 
Portugal [53]. Worldwide the polyQ-related SCAs are more common (Fig. 2), with SCA3 as the most frequent type, 
representing 44% of all SCA cases in Europe [1]. The incidence of the more recently identified SCA types caused by 
conventional mutations also seems to be highly variable based on geographical location/population, but it is difficult 
to establish accurately due to the low numbers of affected families and family members. The worldwide prevalence 
is only known for three SCA types: for SCA14 it was calculated to be 1.5% of all SCA cases (<1% in Europe [1]), for 
SCA15/16 1% (3% in Europe [1]), and for SCA28 3% (1.5% in Europe [54]) (see www.internaf.org). 
Fig. 2 Worldwide prevalence of spinocerebellar ataxias with different underlying genetic mechanisms (according 
to [1] and www.internaf.org).
Pathology of SCAs
 The different SCA mutations seem to be correlated with slightly different disease manifestations [1, 
55-57]. In SCAs caused by coding repeat expansions, the ataxic phenotype was accompanied by additional 
pathological features like peripheral neuropathy in SCA3 or retinal degeneration in SCA7, and, in addition to the 
pronounced cerebellar degeneration, it also displayed widespread brain degeneration (Fig. 3). In contrast, the 
SCAs caused by conventional mutations showed much purer cerebellar ataxia, with a slower disease progression 
and often later disease onset (Table 3) [1, 55-57]. Additionally, in these SCAs the neurodegeneration seems to be 
restricted to the cerebellum (Fig. 3).




Difference in SCA caused by coding expansions and conventional mutations
Coding expansions Conventional mutations Exceptions
Types of SCA 1, 2, 3, 6, 7, and 17 5, 11, 13, 14, 15/16, 19/22, 20, 23, 26, 27, 28, 35
Prevalence Common Rare
Anticipation Yes No
Relative onset of symptoms Earlier onset Late onset SCA6 (late); SCA11, SCA13 (earlier)
Disease progression Fast Slow SCA6 (slow)
Relative severity of symptoms More severe Milder
Neuropathology Widespread Isolated/global cerebellar
Additional symptoms to 
cerebellar ataxia Yes No
SCA14, 15/16, 19/22, 
20, 23, 27, 28 (yes)
[55, 56]
Fig. 3 Brain neurodegeneration regions in various types of SCAs. 
Illustrations represent midsaggittal sections through the cerebrum, cerebellum and brainstem of human brain. Red circles 
indicate regions of neuronal loss in SCA1, 2, 3, 6, 7, 8, 17, and pure cerebellar SCAs, including loss in the cerebral cortex, 
thalamus, cerebellum and brainstem. Figure adapted with permission from [57].
 The wide functional range of genes implicated in SCA indicate that multiple pathways can cause 
degeneration of PCs and induce the cerebellar dysfunction underlying the ataxic phenotype (Table 4). However, 
common pathomechanisms leading to SCA were also suggested [12, 13, 16, 58]. The pure cerebellar phenotype 
of SCAs associated with conventional mutations offers the rare opportunity to study the PC pathophysiology 







underlying ataxia without the additional pathological features involved in other, repeat expansion-related SCA 
types. Why SCA pathology is restricted primarily to PCs is still an open question and will be discussed below.
Table 4 Pathomechanisms underlying different types of SCAs
SCA types associated with:
Coding expansions Non-coding expansions Conventional mutations
Protein aggregation SCA1, 2, 3, 7, 17 SCA8 -
RNA foci - SCA8, 10, 31, 36 -
Transcription dysregulation and RNA 
alterations SCA1, 2, 3, 7, 17 SCA8, 10, 31, 36 -
Disturbance of calcium homeostasis SCA2, 6 SCA12 SCA5, 13, 14, 15/16, 27
Problems with synaptic transmission SCA1, 3, 7, 17 - SCA5
Mitochondrial dysfunction SCA2, 6, 7 SCA12 SCA28
Axonal transport deficits - - SCA5, 11
Channelopathy SCA6 - SCA13, 19/22
[1, 55, 56]
Purkinje cell signalling
PCs represent the sole inhibitory output of the motor cortex, thus a functional deficit of these cells is 
directly associated with the impairment of motor coordination, as observed in SCA patients [59]. PCs form a one-cell 
layer in the cerebellum localized between the granule cell (GC) layer and molecular layer (ML, Fig. 4). They play a 
critical role in integrating cortical signals in the regulation of motor function and motor learning [60]. PCs receive 
stimulating glutamate-mediated input from parallel fibers (PFs, the axons of GCs) and climbing fibers (CFs, axons 
from inferior olive; Fig. 4). Stimulation of ionotropic glutamate receptors leads to ion fluxes and depolarization of 
the PC membranes, which subsequently activates voltage-dependent Ca2+ channels (Fig. 5) [59, 61, 62]. The major 
Ca2+ channel that takes part in this step of glutamate/Ca2+ signalling belongs to the P/Q-type channel family (Cav2.1, a 
subunit of this channel, is directly associated with SCA6). Activation of P/Q-type channels results in a local increase in 
intracellular Ca2+ concentration, which is important for local signalling [60, 61, 63]. Glutamate-mediated stimulation 
of Group I metabotropic glutamate receptors (mGluR1 and 5) provides a signal for activation of phospholipase C 
(PLC), which produces diacylglycerol (DAG) and inositol-triphosphate (IP3). DAG is known to activate protein kinase 
C (PKCγ; SCA14) and IP3 binds to its receptor (IP3R; SCA15/SCA16) that acts as a signal for release of Ca
2+ from the 
endoplasmic reticulum (ER) [60, 61]. Ca2+ signalling regulates the inhibitory activity of PCs and is also important for 
the formation of the specific, fast-repetitive, firing patterns of these neurons [60].
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Fig. 4 Cerebellar morphology.
Like the cerebrum, the cerebellum has an outer cortex, an inner white matter, and deep nuclei below the white matter. The 
illustration shows layers of cerebellar folds: molecular layer (dendritic trees of Purkinje cells), Purkinje cell layer (cell bodies 
of Purkinje cells), granule cell layer, and white matter.
Neuronal calcium homeostasis and excitotoxicity
Neuronal Ca2+ influx is regulated via two distinct mechanisms (from extracellular space or intracellular 
ER stores [64-67]) and neurons tightly regulate these mechanisms to maintain low intracellular Ca2+ concentrations 
in the resting or almost inactive state (30-100 nM) [68]. Excitation will lead to a rise in cytoplasmic Ca2+, ranging 
from highly localized, transient Ca2+ levels to long-lasting and more global alterations in the neuron [69]. Ca2+ 
has a wide range of downstream targets and signalling pathways, the activation of which depends on the source, 
timing, synchronicity, localization, and the final concentration of Ca2+ in the cytosol. The control of intracellular Ca2+ 
levels is thus crucial for neurons that are, therefore, equipped with pumps, exchangers, cytoplasmic Ca2+-binding 
proteins, and display ER and mitochondrial Ca2+ sequestration [70-72]. Ca2+ imbalance is cytotoxic and marked 
alterations in Ca2+ homeostasis underlie neuronal cell death (reviewed in [73]). Marked increase in cytoplasmic 
Ca2+ levels triggers various neurotoxic pathways, including uncoupling of mitochondrial electron transfer from 
ATP synthesis, and activation of proteases, such as calpains, and other enzymes, including nitric oxide synthases, 
calcineurin or endonucleases [74]. These processes may all lead to energy loss, protein damage, oxidative stress 
or DNA fragmentation.
Excitotoxicity is suggested to be one of the common pathomechanisms leading to PC loss in SCA, by 
which excessive synaptic release of glutamate leads to dysregulation of intracellular Ca2+ homeostasis and cell 
death (reviewed in [73]). Postsynaptic ionotropic glutamate receptors, such as α-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid receptors (AMPARs) or N-methyl-D-aspartate receptors (NMDARs) control PC Ca
2+ 
signalling [74-76]. Activation of these receptors may lead to excitotoxicity through enhanced permeability for 
Ca2+ ions, causing intracellular Ca2+ overload and subsequently selective and progressive neuronal loss (reviewed 
in [74]). The alterations in glutamatergic/Ca2+ signalling have been reported in SCA1 [77], SCA5 [45, 46], SCA6 







[78], and SCA15/16 [47]. Although Ca2+ dysregulation has been clearly linked to neuro degeneration, the exact 
mechanisms by which alterations in intracellular Ca2+ levels lead to selective PC death in SCA still remain unclear.
Purkinje cells vulnerability for calcium changes
PCs are the biggest cells in the brain, with large dendritic trees that receive massive excitatory input. One 
PC forms hundreds of thousands synapses with PFs and multiple synapses with CF, which are thought to be one of 
the strongest connections in human brain [63]. PCs are exposed to large amounts of intracellular Ca2+, which can 
rise up to concentrations of 400 μM upon stimulation [79], while other neuronal cells show Ca2+ concentrations 
around 1 μM [79]. It was suggested earlier that PCs are specifically vulnerable for CF-hyperexcitability and die 
earlier than other neurons due to excitotoxicity, microglia activation, or axonal degeneration [80, 81].
The PC-specific excitatory amino acid transporter, EAAT4, could play an important role in PC excitotoxicity, 
as its main function is to remove excessive glutamate from the synaptic cleft and prevent sustained PC excitation 
and Ca2+ influx. Thus, EAAT4 has a neuroprotective role [82]. Notably, loss or altered trafficking of EAAT4 seem to 
be a common deficit in various SCA types [35, 83, 84]. This strengthens the hypothesis that excitotoxicity may be 
one of the major pathomechanisms underlying SCA disease.
Some SCA proteins are directly involved in Ca2+ signalling pathways, such as Cav2.1 in SCA6, and IP3R in 
SCA15/16, or indirectly influence this pathway by stabilizing EAAT4, which controls the glutamate concentration 
in synaptic clefts, such as βIII-spectrin in SCA5, or by controlling the potassium flux that leads to suppression 
of the glutamate/Ca2+ signal, such as Kv3.3 in SCA13 (Fig. 5). Other SCA proteins are involved in intracellular 
signal transduction and synaptic transmission, including TTBK2 in SCA11, PKCγ in SCA14, and FGF14 in SCA27, 
or in mitochondrial homeostasis, such as AFG3L2 in SCA28 (Fig. 5 ). Clearly, alterations in intracellular Ca2+ 
concentrations contribute to the pathology of various SCA types, and this implies that deficits in Ca2+ homeostasis 
underlie PC degeneration.
Different models for SCA and their contribution to unravelling the pathways underlying the disease pathogenesis
 Experimental model systems are used to study specific functional aspects of genes or proteins (often 
of unknown function) identified in neurodegenerative diseases. In general, such studies are carried out in 
cell culture, slices and organotypic cultures, and in vivo. Whilst the in vitro studies give insight into cellular and 
molecular mechanisms, experiments in whole living animals would reflect the human disease more closely, 
providing insights into physiological and phenotypical aspects of the disease. The best animal models are those 
which mimic the human disease in symptoms and development over time. However, in most cases, these models 
reflect only some aspects of the disease and provide only partial insight into the pathophysiology. For a full 
understanding of the pathomechanisms of SCA disease, studies on various models will be needed to provide 
complementary information that can be integrated into a satisfactory model of disease pathology.
 To study the underlying mechanisms of neurodegenerative diseases including SCA, the in vitro models 
usually include neuronal cells (for a comparison of different model systems see Table 5), either immortalized 
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Fig. 5 Neuronal signalling on postsynaptic membrane of Purkinje cell.
The illustration shows various routes of Ca2+ entry and its further signalling after excitatory stimulation of ionotropic 
glutamate receptors (i.e. AMPAR) or metabotrobic glutamate receptors (mGluR1). The numbers indicate proteins involved in 
SCA pathology: 1) mutations in the gene encoding for Cav2.1 cause SCA6, 2) mutations in the gene encoding for PKCγ cause 
SCA14, 3) mutations in the gene encoding for IP3R cause SCA15/16, 4) changes in Ca2+ permeability of IP3R were reported 
in SCA2 and 3, 5) down-regulation of the gene encoding for Ca2+ pump SERCA1 is a hallmark of SCA1, 2, and 3, 6) the down-
regulation of KLHL1, a protein stabilizing P/Q-type Ca2+ channels was reported in SCA8, 7) mutations in the gene encoding 
for βIII-spectrin, a protein stabilizing glutamate transporters on membrane, cause SCA5, 8) membrane deficits of EAAT4 
are common in the pathology of SCA1, 5, and 23, 9) mutations in genes encoding for potassium channels cause SCA13 and 
SCA19/22, 10) mutations in metalloproteinase AFG3L2 cause SCA28 and disrupt fusion-fission balance of mitochondria, and 
11) mutations in phosphatase PP2A cause SCA12 leading to excessive mitochondrial fission.
neuronal cell lines or primary cultures differentiated into neurons. Cell lines provide long-lasting and easy to 
manipulate tools, but they are genetically modified and hardly reflect the physiological situation. Primary cultures 
are more physiologically relevant, but the genetic manipulation is harder (transduction with viruses), the lifespan 
is limited, and the cells are not of human origin. Although improvements are still necessary in order to produce 
a reliable in vitro model that accurately reproduces the cellular mechanisms of neurodegeneration, the induced 
pluripotent (iPS) cells derived from SCA patients and differentiated into neurons seem to be the most relevant. 
This recently developed technique is not yet well established, but will probably be used more often in the future. 
The latest iPS cells derived from SCA2 patients offer means to study the concept of disease neuronal specificity, 
as SCA2 neuronal stem cells (NSCs) showed decreased levels of ataxin-2 and a shorter lifespan than control NSCs 
or SCA2 fibroblasts [85].
 The in vivo models provide a more complex, tissue-dependent background of the disease and usually 
involve worms (Caenorhabditis elegans), fruit flies (Drosophila melanogaster), zebrafish (Danio rerio), or mice (Mus 
musculus), but they can be used only when the disease-associated protein and corresponding pathways are 
evolutionarily conserved. Worms, flies and zebrafish are easier to breed and have a higher number of progeny 
(summarized in Table 5). Moreover, worm- and zebrafish embryos are transparent, making in situ imaging easier. 
Worms and flies are well-established models for polyQ diseases, including SCA [86, 87], and provide a means of 







validating genetic findings and of screening for genetic modifiers or chemical compounds that prevent or reduce 
disease symptoms [47, 48, 88]. The latter is usually obtained by monitoring the apparent signs of neurotoxicity in 
these models (motor phenotype impairment in both models; aggregation in worms, and retina degeneration in 
flies).
Table 5 Advantages of various models to study neurodegeneration
In vitro In vivo
Neuronal cell 
lines iPS cells Worms Fruit flies Zebrafish Mice
Low relative cost Yes Yes Yes Yes
Generation/ culturing/ 
breeding
Easy, short Easy, short Easy, short Easy, short
Manipulation Easy Easy Easy Easy
Number of cells/ progeny Many Many Many Many Many
Variability No/less No/less Yes 
Lifespan Short Short Short Relative*
Vertebrates - - No No Yes Yes
Other Patient-derived Transparent Big eyes
External development, 
transparent embryos Mammals
* Physiologically-relative lifespan, the human disease span can be mimicked.
 Although zebrafish are normally used to study developmental aspects of patho physiology of diseases 
in vivo due to their relatively short lifespan and their transparent embryos and external development, recent 
studies on SCA13 [89] showed that this animal model can also be used for SCA research and that it is suitable for 
performing all types of experimental studies, including electrophysiological characterization, motor phenotyping, 
and protein tracking during and after embryonic development [51].
 Mouse models are thought to be the most relevant for human disease studies, because they are not 
only vertebrates, but also mammals, and therefore closer to humans. Knock-out mice are relatively easier to 
obtain and were developed, for example, for SCA5 [46] and SCA6 [90], reflecting the disease symptoms seen in 
humans, including impaired motor coordination, changes in cerebellar and brain morphology, PC degeneration, 
and alterations in glutamatergic signalling. However, in the case of gain-of-function or dominant-negative 
mutations, the simple knock-out models are not sufficient. To study neurodegenerative diseases such as SCAs, 
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usually the knock-in or conditional transgenic animals are generated. Mice also offer the opportunity to study the 
disease in the context of population variability and provide a way of identifying disease dependence on tissue or 
cell types.
 To study all the complexity of neurodegenerative diseases such as SCAs, one has to choose models that 
offer the best possibility of establishing valid correlations between molecular and cellular alterations and motor 
behaviour (the advantages of different models are summarized in Table 5).
Aim and overview of the thesis
The aim of this thesis was to unravel the genetic and molecular mechanisms underlying different types of SCA, 
with the main focus being on SCA23 and the pathology of the Dynorphin A peptide.
In Chapter 2, “SCA14 mutation V138E leads to partly unfolded PKCγ associated with an exposed 
C-terminus, altered kinetics, phosphorylation and enhanced insolubilization”, I present the molecular 
mechanism underlying SCA14, in which the V138E mutation in PKCγ kinase causes an open protein, resulting 
in its aberrant maturation and processing. In Chapter 3, “Mutations in voltage-gated potassium channel KCND3 
cause spinocerebellar ataxia type 19”, I describe the identification of the mutations/gene responsible for 
SCA19 and discuss the underlying molecular mechanism. In Chapter 4, “Prodynorphin mutations cause the 
neurodegenerative disorder spinocerebellar ataxia type 23”, we found that the causative mutations for SCA23 
are localized to the PDYN gene, which encodes for the precursor protein for opioid peptides. In Chapter 5, 
“Identification and characterization of novel PDYN mutations in dominant cerebellar ataxia cases”, we studied 
the PDYN gene and sequenced 371 European ataxia patients in order to identify other mutations underlying 
SCA23. In Chapter 6, “Elevated Dynorphin A levels lead to Purkinje cell loss in spinocerebellar ataxia type 23 
mice”, I present the generation and characterization of our unique conditional transgenic mouse model for SCA23, 
which gives insights into the pathology underlying this disease, and, in Chapter 7, “SCA23-mutant Dynorphin A 
peptides cause cell death via non-opioid excitotoxic mechanisms”, I discuss the molecular mechanisms of SCA23-
mutant Dynorphin A action that lead to neurotoxicity. Finally, in Chapter 8, “Conclusions, General Discussion and 
Future Perspectives”, I summarize and discuss the outcomes of the work on the different types of SCA caused by 
conventional mutations and the future perspectives for studying the pathology of SCAs. This work may eventually 
lead to new therapies to treat these devastating and incurable diseases.
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Abstract
The protein kinase C γ (PKCγ) undergoes multi-step activation and participates in various cellular processes in 
Purkinje cells. Perturbations in its phosphorylation state, conformation or localization can disrupt kinase signaling, 
such as in Spinocerebellar ataxia type 14 (SCA14) that is caused by missense mutations in PRKCG encoding for 
PKCγ. We previously showed that SCA14 mutations enhance PKCγ membrane translocation upon stimulation due 
to an “open” protein conformation. Since the faster translocation did not result in an increased function, we 
examined how SCA14 mutations induce this “open” conformation of PKCγ and what the consequences of this 
conformational change are on PKCγ life cycle. Here, we show that the SCA14-related PKCγ-V138E exhibits an 
exposed C-terminus as shown by FRET-FLIM microscopy in living cells. This conformational change was associated 
with faster PMA-induced translocation and accumulation of fully phosphorylated PKCγ in the insoluble fraction, 
which could be rescued by co-expressing PDK1 kinase, that normally triggers PKCγ autophosphorylation. We 
propose that the SCA14 mutation V138E causes unfolding of the C1B domain and exposure of the C-terminus of 
the PKCγ-V138E molecule, resulting in a decrease of functional kinase in the soluble fraction.




The protein kinase C γ (PKCγ) is a brain-specific serine/threonine kinase that responds to calcium and diacylglycerol 
(DAG) and is important for development and function of Purkinje cells in the cerebellum [1]. It contains an 
N-terminal regulatory part and a catalytic domain on the C-terminus. The regulatory part includes a tandem of 
two C1 domains (C1A and C1B), which are responsible for DAG binding and translocation to the membrane (Fig. 
1a) [2]. 
Fig. 1 Structure and lifecycle of PKCγ protein. 
(a) Domain structure of the PKCγ protein. The regulatory part contains the pseudosubstrate sequence (psS), DAG-binding C1A 
and C1B domains and calcium-binding C2 domain. The catalytic part consists of the catalytic domain (CD) with the N-terminal 
lobe (N-l) and C-terminal extension (CT). The SCA14 mutation (V138E) and (auto)phosphorylation sites (T514, T655 and 
T674) used in this study are indicated. (b) Model of the life cycle of PKCγ. Inactive PKCγ protein is loosely tethered at the 
plasma membrane, where it binds kinase PDK1 (1). PDK1 phosphorylates PKCγ at T514, which allows 2 autophosphorylation 
events to occur at T655 and T674 (2). This results in a closed inactive, but mature, conformation of fully phosphorylated PKCγ 
(3). In response to calcium and DAG (or PMA in laboratory conditions) PKCγ translocates and binds to the plasma membrane, 
which triggers an open conformation (4). The open conformation makes PKCγ more susceptible for dephosphorylation and 
the proteins are targeted to the insoluble fraction upon dephosphorylation (5). Dephosphorylated proteins bind chaperones 
HSP70, which allow PKCγ recycling (6) or are degraded (7).
PKCγ undergoes a complicated lifecycle to become active and perform its kinase function (summarized 
in Fig. 1b). The first step in the lifecycle is phosphorylation at T514 by phosphoinositide-dependent protein 
kinase 1 (PDK1) [3]. This is followed by two autophosphorylation events at T655 and T674, which result in a 
closed conformation and mature PKCγ protein (reviewed in [4]). Once phosphorylated, PKCγ binds its second 







messengers, calcium and DAG, and translocates to the plasma membrane, which subsequently causes an open 
active conformation of PKCγ that allows for kinase activity followed by phosphorylation of downstream targets. 
In this open conformation, PKCγ is more susceptible to dephosphorylation and the dephosphorylated PKCγ 
molecules are rapidly ubiquitinated and targeted for degradation [2].
Alterations in phosphorylation state, conformation or cellular localization of PKCγ can disrupt signaling 
pathways and lead to pathological states, such as spinocerebellar ataxia type 14 (SCA14). SCA14 is an autosomal 
dominant neurodegenerative disease, which is caused by missense mutations in PRKCG gene, encoding for PKCγ 
[5-11]. SCA14 patients suffer from a slowly progressive cerebellar ataxia accompanied by slurred speech and 
abnormal eye movements caused by degeneration of Purkinje cells in the cerebellum [12]. Interestingly, the 
majority of SCA14 mutations are localized in the region encoding for the C1B domain (Fig. 1a) [5-11]. Recently, 
the protein structure of full length PKCβII was resolved, which showed that the C1B domain, and not C1A, interacts 
directly with N-lobe and C-lobe of the catalytic domain, C-terminus, and C2 domain, forming the so-called C1B 
clamp [13]. This C1B clamp controls PKC protein conformation and activity, which can be affected by mutations in 
the C1B domain. In fact, we previously showed that SCA14 mutations in isolated C1B domains do not translocate in 
response to phorbol 12-myristate 13-acetate (PMA) stimulation, suggesting that the enhanced PMA translocation 
of the mutant PKCγ molecules is solely driven by more accessible C1A domains, due to an “open” PKCγ protein 
conformation [14]. Intriguingly, this “open” conformation did not result in a constitutively active kinase, but led 
to decreased kinase activity, causing aberrant downstream signaling in vitro [14]. This suggests that this “open” 
conformation of SCA14-mutant PKCγ is rather non-native, partly unfolded or misfolded, and does not reflect 
the physiological open state. Here, we examined the effect of the V138E mutation in the C1B domain in PKCγ in 
relation to the SCA14 disease pathology.
Materials and Methods
Materials
Phorbol 12-myristate 13-acetate (PMA) was purchased from Sigma-Aldrich (Milwaukee, WI, USA). The 
primary antibodies specific for the PKCγ (rabbit, 1:1,000) and GST (rabbit, 1:2,000) were obtained from Santa 
Cruz Biotechnology (Heidelberg, Germany), and for FLAG (mouse, 1:5,000) from Sigma-Aldrich. The anti-
phosphorylation (p)-specific antibodies pT514-, pT655- and pT674-PKCγ (rabbit, 1:5,000), and anti-myc (mouse, 
1:2,000) were acquired from Cell Signaling Technology (Leiden, the Netherlands). Living Colors for anti-GFP/CFP 
staining (mouse, 1:5,000) was purchased from Clontech (Saint-Germain-en-Laye, France).Secondary antibodies 
were conjugated with horseradish peroxidase (HRP) and used in 1:10,000 dilutions (Jackson Immunoresearch 
Inc., Suffolk, UK).
DNA constructs
Previously described constructs encoding for wild type (wt) PKCγ and SCA14-mutant PKCγ-V138E proteins fused 
to green flurorescent protein (GFP) were used for most experiments [14]. For intramolecular fluorescence 
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resonance energy transfer (FRET) experiments, mutations T655A or T674A were introduced into YFP-PKCγ-SCFP3A 
constructs described previously [14], using the Quickchange II Site-Directed Mutagenesis kit (Stratagene, La Jolla, 
CA, USA) and the following primer pairs:  T655A-For 5’-GCGCCAGCGCTGGCCCCTCCAGACCG-3’ and T655A-Rev 
5’-CGGTCTGGAGGGGCCAGCGCTGGCGC-3’, and  T674A-For 5’-GATTTCCAGGGCTTCGCCTACGTGAACCCC-3’ and 
T674A-Rev 5’-GGGGTTCACGTAGGCGAAGCCCTGGAAATC-3’.
 For the GST pull-down experiments, PKCβII’s C-terminus (CT-PKCβII-GST), PKCβII’s catalytic domain 
(CD-PKCβII-GST), and myc-tagged PDK1 were kindly provided by Dr. A. Newton (University of California at San Diego, 
La Jolla, CA, USA) [15]. To generate wt-PKCγ-GST and PKCγ-V138E-GST, the wt-PKCγ cDNA sequence were cloned into 
backbone pEBB-C-GST/FLLG plasmid using the following primers: For 5’-GGATTCACCATGGCTGGTCTGGGCCCC-3’ 
and Rev: 5’-GCGGCCGCCATGACGGGCACAGGCACTG-3’, generating a BamHI site at the 5’ end and a NotI site 
at the 3’ end. The V138E mutation was introduced using the Quickchange II Site-Directed Mutagenesis kit and 
the primers described previously [14]. Moreover, a FLAG-tag (DYKDDDDK) was inserted on the C-terminus 
of both wt and V138E C1 domains of PKCγ. The C1 cDNAs were amplified from the corresponding PKCγ-GFP 
constructs by PCR using the following primers: For 5’-GGATTCACCATGCACAAGTTCACCGCTCGCTTC-‘3 and 
Rev 5’-GCGGCCGCGCACAGGGAGGGCACGCT-3’ generating a BamHI site at the 5’ end and a NotI site at the 3’ end. 
This facilitated cloning into the pEBB-C-FLAG plasmid. 
All constructs were verified by sequencing. 
Cell culture and transfection
HEK293T, HeLa and COS7 cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, 
Gibco, Bleiswijk, the Netherlands) implemented with 10% fetal bovine serum and 5% penicillin (100 U/ml) 
and streptomycin (100 mg/ml). The cultures were maintained at 37°C in an atmosphere of 5% CO2. The cells 
were detached using trypsinization and plated in six-well plates (for Western blotting or fractionation), 100x20 
mm tissue culture dishes (BD Biosciences, Breda, the Netherlands) for GST pull-down experiments, or on to 24 
mm glass coverslips (Fisher Scientific, Braunsweg, Germany) in a six-well plate for microscopy. The transient 
transfection was performed 24 h after plating using polyethylenimine (PEI; 0.6 μg/ml in serum-free medium). 
Protein sample preparation and fractionation
Cells were harvested 48 h after transfection and lysed with ice-cold fractionation buffer (buffer A: 50 mM Na2HPO4, 
1 mM Na4P2O7, 20 mM NaF, 2mM EDTA, 2 mM EGTA, 1% Triton X-100, 1 mM DTT) supplemented with complete 
protease inhibitor cocktail (Roche, Woerden, the Netherlands) and phosphatase inhibitor cocktail (Sigma-Aldrich). 
For GST pull-down, cell lysates were incubated for 20 min on ice and centrifuged at 9,200 g for 15 min in 4°C for 
supernatant collection. For fractionation experiments, cell lysates were sonicated 2 x 5 s, incubated for 20 min on 
ice, and centrifuged at 9,200 g for 15 min in 4°C to obtain the Triton-insoluble fraction containing membranes 
and cytoskeleton proteins in the pellet. Protein concentrations in the soluble fractions were determined using the 
Pierce BCA Protein Assay Kit (Thermo Scientific, Etten-Leur, the Netherlands) and equal protein amounts were 







loaded on SDS-PAGE gels (same volume for soluble and insoluble fractions of one sample).
GST pull-down 
Pull-down was performed using GST-beads (Glutathione sepharose 48, GE Healthcare, Hoevelaken, the 
Netherlands), prepared according to the manufacturer’s protocols. The cell lysates were incubated with the 
beads overnight. After centrifuging (1,300 g, 10 min, 4°C) and washing (4 times with buffer A), the beads and 
precipitates were dissolved in 2x Leammli buffer followed by boiling at 98°C for 5 min. The immunoprecipitates 
were loaded on 8% SDS-PAGE gels. 
Western blotting
After electrophoresis, the proteins were transferred to the nitrocellulose membrane (Schleicher & Schuell, Dassel, 
Germany) and blocked with 5% milk in TBS-Tween. The blots were analyzed with primary antibodies according to 
manufacturer’s protocol, followed by incubation with secondary antibody solution  for 1 h in room temperature. 
The bands were visualized by enhanced chemiluminescence Western blotting detection system (LumiLight, Roche). 
The Fiji software (National Institutes of Health, http://fiji.sc/) was used to quantitatively analyze the protein levels.
Fluorescence resonance energy transfer and live cell microscopy
We used YFP-PKCγ-SCFP3A constructs (described previously [14]) encoding for PKCγ sandwiched between the 
FRET pair CFP and YFP. Fluorescence lifetime imaging microscopy (FLIM) was used to measure FRET efficiencies 
using untagged CFP as a control, in transiently transfected HeLa cells. Confocal imaging was performed as 
described previously [14]. Fluorescence lifetime imaging microscopy (FLIM) experiments and calculation of the 
FRET efficiency were performed as described before [16], with the exception that a 63x (NA 1.4) oil immersion 
objective was used.
Statistical analysis
All data are expressed as mean of at least three experiments ± standard error of the mean (SEM), unless stated 
otherwise. We used the unpaired, two-tailed Student’s t-test or two-way ANOVA, followed by post-hoc Bonferroni 
correction for multiple testing, to determine the significance of the observed differences between the groups 
(considered statistically significant at p < 0.05).
Results
Exposed C-terminus of SCA14-mutant PKCγ-V138E proteins
We previously showed that SCA14-related mutations located in the C1B domain enhanced the membrane association 
kinetics of PKCγ, which is caused by a yet not understood induction of an “open” and more PMA-accessible protein 
conformation [14]. We therefore hypothesized that this altered protein conformation is at the basis of the etiology of 
SCA14 disease. Since mutant PKCγ-V138E showed the strongest effects [14], we continued with this particular mutant 
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by investigating how the V138E mutation alters the processing and structure of PKCγ.
 Since previous reports showed that a negative charge on the C-terminus (autophosphorylation) 
is important for PKC protein conformation and intracellular localization [17-19], we started by examining the 
autophosphorylation levels of the SCA14-mutant PKCγ-V138E, which could still be phosphorylated at both 
autophosphorylation sites, the T655 and T674, although staining efficiency with phosphorylation-specific 
antibodies was reduced by about 20% when compared to wt-PKCγ (Suppl. Fig. 1a and b). We generated 
autophosphorylation site mutants (T655A and T674A) of wild type PKCγ (wt-PKCγ) and SCA14-mutant PKCγ-V138E 
that lack the phosphorylation pT655 or pT674, respectively. The PKCγ-T655A mutant could not be phosphorylated 
at position 655 as indicated by the loss of immunostaining with the pT655-specific antibody, and consequently 
also showed loss of pT674 (Suppl. Fig. 1a; [2]), similar to the double mutant PKCγ-V138E-T655A. The PKCγ-T674A 
did not display any pT674, but could still be phosphorylated at T655, in contrast to the double mutant PKCγ-
V138E-T674A that could no longer be phosphorylated at T655. This data showed that the V138E mutation leads to 
reduced autophosphorylation levels and suggests that loss of pT674 on top of a (subtle) conformational change 
induced by the V138E mutation affects the accessibility of the C-terminus to the kinase active site.
To visualize these apparent effects on PKCγ protein conformation, we used intramolecular FRET to detect 
changes in the proximity of the N- and the C-terminus. PKCγ was tagged at its termini by the FRET pair CFP and 
YFP, as described before [14]. When the donor CFP and acceptor YFP moieties are in close proximity, this leads 
to a relative high FRET efficiency and a decrease in the lifetime of the donor (which is measured by Fluorescence 
Lifetime Imaging Microscopy or FLIM). Conversely, alterations in the protein conformation due to mutations that 
separate the donor from the acceptor fluorophore will result in a lower FRET efficiency and therefore a higher 
donor fluorescence lifetime.
We first examined the effect of loss of negative-charge on the C-terminus on PKC protein conformation. 
The autophosphorylation-deficient mutant PKCγ-T655A showed significantly lower FRET efficiency than wt-PKCγ 
(Fig. 2) similar to the control (unquenched CFP), reflecting an altered conformation, in which the C-terminus 
is dissociated from the kinase core and N-terminus [2]. PKCγ-T674A, that could still be phosphorylated at T655 
(Suppl. Fig. 1a), did not display a markedly altered protein conformation, however, still significantly lower FRET 
was observed than in wt-PKCγ (Fig. 2). As published previously [14], PKCγ-V138E showed a lower FRET efficiency 
than wt-PKCγ, but the addition of either T655A and T674A mutations in PKCγ-V138E did not significantly further 
decrease the FRET efficiency compared to PKCγ-V138E (Fig. 2). This suggests that the mutation V138E induces 
a PKCγ molecule that already exhibits a C-terminus that is dissociated from the kinase core and N-terminus. 
Moreover, loss of FRET was not due to degradation of the mutant PKCγ proteins (Suppl. Fig. 2).
PDK1 interacts with the exposed and thus preferentially non-phosphorylated C-terminus of PKC, 
subsequently phosphorylating T514 and promoting PKC protein activation [15]. To confirm the exposed C-terminus 
of PKCγ-V138E, GST pull-down experiments were performed with PDK1 and various PKCγ proteins. Cell lysates of 
HEK293T were co-transfected with PDK1-myc and wt and mutant PKCγ-GST, or the isolated C-terminus of PKCβII 
(CT-PKCβII) as a positive control. As expected, a strong interaction was observed between PDK1 and CT-PKCβII 







(lane 2, Fig. 3a), and in line with our hypothesis, PDK1 preferentially interacted with proteins that exhibited 
exposed C-termini such as PKCγ-T655A and PKCγ-V138E, compared to wt-PKCγ and PKCγ-T674A (respectively: lane 
Fig. 2 Changes in PKCγ protein conformation corresponding 
to removal of negative charge on the C-terminus. 
The tables summarize the average CFP phase and modulation 
lifetimes (± SD) of each construct. The number of cells 
measured is  indicated by n. The FRET efficiencies (mean 
± SEM) are calculated based on the CFP phase lifetimes 
relative to unquenched CFP lifetimes. (a) CFP lifetimes 
and FRET efficiencies of wt-PKCγ. Autophosphorylation-site 
mutant PKCγ-T655A showed lower FRET efficiency than wt-
PKCγ indicating that removal of C-terminal phosphorylation 
causes an open protein conformation. Similarly PKCγ-T674 
also displayed lower FRET efficiency, but only slightly, 
however, still statistically significant. (b) CFP lifetimes and 
FRET efficiencies of SCA14-mutant PKCγ-V138E. PKCγ-
V138E already exhibits open conformation and additional 
mutations on the C-terminus do not decrease further the 
FRET efficiencies, suggesting that PKCγ-V138E already has an open C-terminus. (c) CFP lifetimes and FRET efficiencies of the 
known mutant PKCγ-A24E with an open N-terminus. Introduction of C-terminal autophosphorylation-site mutation causes 
further decrease in FRET efficiency of PKCγ-A24E, indicating that even in the presence of an open N-terminus the effect 
of T655A mutation on the C-terminus could be detected. Significant differences (unpaired t-test) from control values are 
indicated as * for p < 0.05 and ** for p < 0.0001.
Fig. 3 PDK1 binding to the exposed C-terminus of SCA14-mutant PKCγ-
V138E. 
(a) Representative immunoblot of GST pull-down of PDK1-myc 
by different GST-fused PKCγ proteins, including wt-PKCγ (lane 3), 
PKCγ-V138E (lane 4), PKCγ-T655A (lane 5) and PKCγ-T674A (lane 6), 
analyzed with anti-myc and anti-GST antibodies, shows increased 
PDK1 affinity to the more open PKCγ mutants (PKCγ-V138E and PKCγ-
T655A). The isolated C-terminus of PKCβII was used as a positive 
control (lane 2). (b) The relative PDK1/PKCγ ratio is presented (mean 
± SEM). Significant differences (unpaired t-test) from control values, 
* p < 0.05.
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4 and 5 versus lane 3 and 6; Fig. 3b). The weak interaction between PDK1 and PKCγ-T674A can be explained since 
T674 is located near the PDK1-binding site  [15], and PKCγ-T674A showed only a slightly dissociated C-terminus 
shown in our FRET experiment (Fig. 2a). Altogether, these data are in agreement with our previous findings and 
confirm that the V138E mutation exposes the C-terminus of PKCγ, which favours the binding to PDK1.
Next, we examined whether the exposed C-terminus would affect the kinetics of PKCγ upon PMA 
activation in living cells as SCA14-mutant PKCγ showed enhanced PMA-induced translocation kinetics before 
(Verbeek et al., 2008). To do so,  COS7 cells were transiently transfected with wt-PKCγ or PKCγ-V138E constructs 
with T655A or T674A mutations. These last mutant proteins were used as others have shown that the level of 
autophosphorylation can determine the subcellular localization of PKC and that lack of autophosphorylation alters 
the PMA-induced translocation kinetics of PKCα and β [17-19, 21]. Subsequently, PMA-induced translocation 
kinetics was investigated upon adding 400nM PMA. Mutation of either autophosphorylation site significantly 
increased the PMA-induced translocation kinetics of wt-PKCγ to the plasma membrane (Fig. 4a). However, both 
T655A and T674A mutations did not significantly alter the PMA-induced kinetics of PKCγ-V138E (Fig. 4b). This is 
in line with the observed FRET experiments, as the T655A and T674A mutations did not alter PKCγ-V138E FRET 
efficiencies (Fig. 2b), underscoring our model that primarily the exposed C-terminus accelerates PKCγ-V138E 
translocation kinetics due to more accessible PMA-binding sites in the C1A domain. It must be noted though that 
PKCγ-V138E might have an additional structural changes as the protein still translocates faster than either one of 
the autophosphorylation-site mutants. 
Altogether these results strongly suggest that the V138E mutation results in a partially unfolded or 
misfolded PKCγ protein with an exposed C-terminus that drives enhanced PMA-induced translocation.
Accumulation of SCA14-mutant PKCγ-V138E proteins in the Triton-insoluble fraction
We next tested whether the presumably partially unfolded or misfolded PKCγ-V138E proteins are aggregation-
prone and accumulate in the Triton-insoluble fraction like the other SCA14 mutants [22]. The lysates of HEK293T 
cells expressing the various wt and mutant PKCγ constructs were fractionated with Triton X-100 before or after 
stimulation with 400 nM PMA. Indeed, increased levels of PKCγ-V138E were detected in the Triton-insoluble 
fraction of HEK293T cells already without PMA stimulation (Fig. 5a and b), and these PKCγ-V138E proteins were 
more phosphorylated at T655 and T674 than wt-PKCγ proteins (Fig. 5a and c). PMA treatment targeted a large 
amount of the wt-PKCγ proteins to the Triton-insoluble fraction, but did not seem to cause further accumulation of 
PKCγ-V138E (Fig. 5a and b). Thus, as previously reported [23], PMA is able to promote the dephosphorylation of 
wt-PKCγ leading to accumulation in the Triton-insoluble fraction, but it does not act on PKCγ-V138E. These results 
show disrupted down-regulation of SCA14-mutant PKCγ-V138E and suggest that PKCγ-V138E proteins are resistant 
to PMA-induced dephosphorylation and therefore accumulate in insoluble fraction in phosphorylated state.
 To investigate if the SCA14-mutant PKCγ-V138E proteins are resistant to dephosphorylation, HEK293T 
cells transiently transfected with either wt-PKCγ or PKCγ-V138E were stimulated with 400 nM PMA for 1, 3, 5, or 
7 hours. Long-term PMA stimulation induces dephosphorylation of PKCγ via activation of various phosphatases, 







including membrane-associated protein phosphatase 2A (PP2A) [24]. Successive dephosphorylation of both T655 
and T674 was observed in wt-PKCγ upon PMA stimulation, and at T655 only ±30% of the starting phosphorylation 
levels were detected after 7 hours of PMA treatment (left panel; Fig. 6a and b).Dephosphorylation of both T655 
and T674 in PKCγ-V138E was (partially) delayed, still showing ±60% of pT655 7 hours after PMA treatment (p < 
0.05; right panel; Fig. 6a and b). Also, over the entire time-course dephosphorylation kinetics were significantly 
different between wt-PKCγ and PKCγ-V138E (Two-way ANOVA: genotype x time; F = 3,10, p < 0.01), and both T655 and 
T674 phosphorylation could still be detected after overnight stimulation with PMA in PKCγ-V138E, but not in wt-PKCγ.
Fig. 4 The effect of an open C-terminus on PMA-induced translocation kinetics of PKCγ.
Confocal images of COS7 cells transfected with different PKCγ-GFP constructs (including wt-PKCγ, PKCγ-T655A, PKCγ-T674A, 
PKCγ-V138E, PKCγ-V138E-T655A, or PKCγ-V138E-T674A) were recorded prior to (t = 0), and 240 and 520 s after addition of 400 
nM PMA. The scale bars are 5 μm. (a) Introduction of autophosphorylation mutations in wt-PKCγ causes faster translocation 
upon stimulation with PMA. (b) The additional T655A or T674A mutations in SCA14-mutant PKCγ-V138E have no effect on 
already faster (than wt- PKCγ) translocation kinetics. Changes were evaluated in at least 20 cells per condition by time-lapse 
imaging and the mean values are presented. Significant differences (unpaired t-test) are indicated as * (p < 0.05)
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Fig. 6 Dephosphorylation of wt-PKCγ (left 
panel) and SCA14-mutant PKCγ-V138E (right 
panel) induced by PMA stimulation. 
(a) Immunoblots showing the time-course 
of dephosphorylation of PKCγ proteins. 
Dephosphorylation analysis was conducted 
by stimulation with 400 nM PMA that induces 
endogenous phosphatases, including PP2A. 
Whole-cell lysate samples were collected 
before (0), and after 1, 3, 5, 7 hours and 
overnight stimulation. Representative 
immunoblots were analyzed using anti-
PKCγ and anti-phosphorylation (pT655 or 
pT675) antibodies. (b) Quantification of the 
dephosphorylation in time. The starting point 
(at 0 hours) was set to 100%. Significance 
was assessed using two-way ANOVA 
(genotype x time) followed by Bonferroni 
multiple comparison tests and showed an 
overall significant effect for genotype (F = 
3.10; p < 0.01), for time (F = 4.74; p < 0.05), and also for interaction (F = 3.10; p < 0.05). Data are presented as the mean 
±SEM. Significant differences (post-hoc t-test) from control values, * p < 0.05.
Fig. 5 Accumulation of phosphorylated PKCγ-
V138E proteins in the Triton-insoluble fraction. 
(a) Representative  immunoblots of 
Triton-insoluble fractions of HEK293T cells 
transiently transfected with wt-PKCγ or 
PKCγ-V138E constructs and stimulated with 
400 nM PMA were analyzed using anti-PKCγ 
and specific anti-phosphorylation (pT655 or 
pT675) antibodies. (b) Quantification graph 
of PKCγ-V138E accumulation in the Triton-
insoluble fraction. (c) Quantification graph 
of autophosphorylation levels of PKCγ-V138E 
in the Triton-insoluble fraction. Data are 
presented as relative (to wt-PKCγ) mean ± 
SEM. Significant differences (unpaired t-test) 
from control values are indicated as * for p < 
0.05 and ** for p < 0.005.







 To further examine this effect, we investigated whether PKCγ-V138E proteins could be dephosphorylated 
by type 1 protein phosphatase (PP1), known to dephosphorylate PKC at both autophosphorylation sites [25]. 
Wt-PKCγ or PKCγ-V138E proteins fused to GST were isolated from HEK293T cell lysates using GST pull-down and 
incubated with recombinant PP1 (5U). While both pT655 and pT674 were efficiently dephosphorylated in time 
in wt-PKCγ (left panels in Suppl. Fig. 3a and b), this was again significantly delayed in PKCγ-V138E, especially for 
pT655 (Two-way ANOVA: genotype x time; F = 4,066, p < 0.05 for genotype and interaction; right panels in Suppl. 
Fig. 3a and b). These data demonstrate that the partly unfolded and more “open” PKCγ-V138E molecules are less 
efficiently dephosphorylated by PP1 and PP2A. 
Since the altered protein conformation of PKCγ-V138E seems to underlie the accumulation in the Triton-
insoluble fraction, we investigated whether overexpression of heat shock proteins (HSPs) could prevent this event 
by facilitating the proper folding of PKCγ-V138E. However, overexpression of HSPs from various families, including 
HSP90, HSP70, HSP40, and small HSP did not yield any significant improvement in the solubility of PKCγ-V138E 
(data not shown). This indicates that SCA14-mutant PKCγ-V138E is rather partially unfolded and cannot be folded 
to its native conformation.
 We next hypothesized whether PDK1 might be the natural chaperone that could prevent or rescue the 
accumulation of phosphorylated PKCγ-V138E from the Triton-insoluble fraction, as PDK1 has been shown to slow 
down the PKC processing rate [26, 27]. To explore this hypothesis, HEK293T cells were transiently transfected 
with PKCγ-V138E and PDK1, without or with PMA treatment (400 nM, 4 hours) followed by Triton-fractionation. 
Overexpression of PDK1 significantly decreased the levels of accumulated PKCγ-V138E in the Triton-insoluble 
fraction before and after PMA treatment (right panel; lanes 7 and 8 compared to lanes 5 and 6, Fig. 7a and b). 
Notably, the PKCγ-V138E proteins that were still detected in the Triton-insoluble fraction of cells co-expressing 
PDK1 showed decreased pT655 and pT674 levels compared to cells without PDK1 (Fig. 7a and c). These data 
suggest that PDK1 is able to prevent or rescue PKCγ-V138E protein insolubilization, as PDK1 seems to favour PKCγ 
dephosphorylation and subsequently enhance the degradation of the insoluble PKCγ-V138E proteins.
Discussion
 In the present study, we aimed to reveal what deficits underlie the “open” PKCγ protein conformation and 
enhanced PMA-induced translocation kinetics of PKCγ -V138E, as we showed previously [14]. We demonstrated 
that the V138E mutation alters the native protein conformation of PKCγ leading to exposure of the C-terminus, 
affecting its proper processing and leading to accumulation of phosphorylated PKCγ molecules in the Triton-
insoluble fraction.
 Our work shows that quantitative FRET-FLIM measurements are uniquely suited to measure altered 
conformational states of PKC in single living cells. These measurements revealed that the V138E mutation, located 
in the C1B domain, results in an exposed C-terminus of PKCγ. This can be explained by the, recently reported, 
C1B clamp that plays a crucial role in keeping the proper protein conformation of PKC, as it makes extensive 
contacts with catalytic domain, C-terminus and C2 domain [13]. The Val138 is buried in the hydrophobic core 
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in the native conformation of C1B domain of PKC [13], and therefore the V138E mutation would disrupt the 
domain folding by introducing a highly negative charge into the hydrophobic moiety. Therefore, we propose that 
the V138E mutation induces partial unfolding or misfolding of the C1B domain of PKCγ, leading to dissociation 
of the C-terminus from the kinase core. As a consequence, the PMA-binding sites of the C1 domains should have 
become more accessible, as PKCγ-V138E translocates faster than wt PKCγ. However, this translocation is probably 
solely driven by the C1A domain, as we previously showed that mutant C1B-V138E does not respond to PMA, 
lacking membrane translocation ability upon stimulation [14]. 
 In addition, we showed that PKCγ-T655A, but not PKCγ-T674A, exhibited similar properties as PKCγ-
V138E as both proteins demonstrated clearly dissociated C-termini and enhanced PMA-induced translocation 
kinetics. Thus, phosphorylation of T655 seems to be crucial to maintain PKCγ native protein conformation, as was 
suggested by the FRET and translocation assays. This would be consistent with published data on PKCβII in which 
phosphorylation of the same turn motif (T655 in PKCγ) was already found to be important for proper priming of 
PKCβII protein conformation and activity [19].
 Our data suggest that alterations in the conformation of the C1B domain affect PKCγ-V138E 
autophosphorylation levels and may lead to decreased kinase activity, as reported before [14]. This conformational 
Fig. 7 The effect of PDK1 overexpression on 
the accumulation of SCA14-mutant PKCγ-
V138E in Triton-insoluble fraction. 
(a) Immunoblots of Triton-soluble (left 
panel) and Triton-insoluble (right panel) 
fractions of HEK293T cells transiently 
transfected with PDK1-myc and either 
wt-PKCγ or PKCγ-V138E with or without 
400nM PMA stimulation. Immunoblots 
were analysed using anti-PKCγ, anti-myc, 
and specific anti-phosphorylation (pT655 
or pT675) antibodies. (b) Quantification 
of the relative amount of PKCγ-V138E in 
Triton-insoluble fraction. (c) Quantification 
of relative amount of phosphorylated PKCγ-
V138E in Triton-insoluble fraction. Data are 
expressed as relative (to wt-PKCγ) mean 
± SEM. Significant differences (unpaired 
t-test) are indicated as * (p < 0.05).







changes caused by the V138E mutation did not enhance, but rather delayed, phosphatase sensitivity of PKCγ, 
despite the exposed C-terminus of PKCγ-V138E, and in turn, led to accumulation of highly phosphorylated PKCγ 
species in the Triton-insoluble fraction. Our work suggests that the V138E mutation affects the proper folding 
of the C1B domain, and proper (in-)activation and degradation of PKCγ, promoting its insolublization. In line 
with our work, SCA14-mutant PKCγ proteins were suggested before to be resistant to ubiquitine-proteasome 
system degradation [28], and phosphorylated PKC proteins could not be properly down-regulated [29]. These 
findings imply that proteasomes cannot handle phosphorylated PKCγ molecules, as was shown for PKCγ-V138E. 
Additionally, HSPs could not restore the native solubility of the PKCγ-V138E protein, whereas the “natural 
chaperone” of PKC, PDK1, did prevent PKCγ-V138E accumulation in the Triton-insoluble fraction by facilitating 
its processing and subsequent dephosphorylation that may lead to degradation. These results further support 
the hypothesis that the C1B domain in SCA14-mutant PKCγ-V138E is unfolded, and that is not recognized by 
HSPs or cannot be folded to its native conformation. Further investigation is required to clarify if PDK1 can rescue 
the accumulation of other SCA14-mutant PKCγ proteins harbouring mutations outside the C1B domain from the 
Triton-insoluble fraction. 
 In summary, the V138E may cause an unfolded C1B domain, which disrupts the C1B clamp, and results 
in a loss of C-terminus interaction with the kinase core. This exposed C-terminus leads to increased accessibility of 
the C1A domain for phorbol esters and induces enhanced translocation kinetics. This altered protein conformation 
very probably affects proper protein processing and degradation, leading to accumulation of the mutant proteins 
in the Triton-insoluble fraction. Molecules that can modify PKCγ processing, rather than modifying protein folding, 
like PDK1, are potential candidates to prevent the accumulation of phosphorylated PKCγ proteins in the Triton-
insoluble fraction. Additional studies will be required to examine whether this is a general mechanism that will 
work for all SCA14 mutant proteins and whether overexpression of PDK1 will reduce PKCγ-related Purkinje cell 
death and ataxia.
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Suppl. Fig. 1 Phosphorylation levels of PKCγ. 
(a) Representative immunoblot of whole-cell lysates of HEK293T transiently transfected with wt-PKCγ, PKCγ-T655A, PKCγ-
T674A, PKCγ-V138E, PKCγ-V138E-T655A, or PKCγ-V138E-T674A and analyzed with anti-PKCγ and specific anti-phosphorylation 
(pT655 or pT675) antibodies. (b) Data are expressed as relative (to wt-PKCγ) mean ± SEM. Significant differences (unpaired 
t-test) from control values are indicated as * (p < 0.05).
Suppl. Fig. 2 
Immunoblot of HEK293T whole-cell lysates transiently transfected with YFP-PKCγ-CFP (including wt-PKCγ, PKCγ-T655A, PKCγ-
T674A, or PKCγ-V138E) and analyzed with anti-CFP antibody, shows no protein degradation that could explain lower FRET 
efficiencies.







Suppl. Fig. 3 Dephosphorylation of PKCγ proteins by PP1 recombinant phosphatase in time. 
Phosphorylation levels of wt-PKCγ (left panel) and PKCγ-V138E (right panel) were assessed before (0) and after 5, 15, and 30 
minutes of treatment with recombinant PP1 phosphatase (5U) in vitro. (a) Representative immunoblots were analyzed using 
anti-PKCγ and anti-phosphorylation (pT655 or pT675) antibodies. (b) Time-course of dephosphorylation of PKCγ proteins by 
PP1 is presented as the mean ± SEM of each time-point. Two-way ANOVA (genotype x time) followed by Bonferroni multiple 
comparison tests showed overall significant effects for genotype (F = 4.06; pT655: p < 0.05; pT674: p < 0.005), but was not 
significant for time. The dephosphorylation in time was significantly different between wt and SCA14-mutant PKCγ for both 
pT655 and pT674 (interaction: F = 4.06; T655: p < 0.05; T674: p < 0.01). Significant difference from control values in the post-
hoc t-test analysis is indicated as * (p < 0.05).
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Abstract
Objective: To identify the causative gene for the neurodegenerative disorder spinocerebellar ataxia type 19 (SCA19) 
located on chromosomal region 1p21-q21.
Methods: Exome sequencing was used to identify the causal mutation in a large SCA19 family. We then screened 
two hundred and thirty ataxia families for mutations located in the same gene (KCND3, also known as Kv4.3) 
using high-resolution melting. SCA19 brain autopsy material was evaluated, and in vitro experiments using ectopic 
expression of wild-type and mutant Kv4.3 were used to study protein localization, stability and its channel activity 
by patch-clamping.
Results: We detected a T352P mutation in the third extracellular loop of the voltage-gated potassium channel 
KCND3 that co-segregated with the disease phenotype in our original family. We identified two more novel 
missense mutations in the channel pore (M373I) and the S6 transmembrane domain (S390N) in two other ataxia 
families. T352P cerebellar autopsy material showed severe Purkinje cell degeneration, with abnormal intracellular 
accumulation and reduced protein levels of Kv4.3 in their soma. Ectopic expression of all mutant proteins in HeLa 
cells revealed retention in the endoplasmatic reticulum and enhanced protein instability, in contrast to wild-
type Kv4.3 that was localized on the plasma membrane. The regulatory β subunit KChIP2 was able to rescue the 
membrane localization and the stability of two of the three mutant Kv4.3 complexes. However, this either did not 
restore the channel function of the membrane located mutant Kv4.3 complexes or only partially.
Interpretation: KCND3 mutations cause SCA19 by impaired protein maturation and/or reduced channel function. 




Patients with a dominantly inherited spinocerebellar ataxia (SCAs) are characterized by a late-onset, progressive 
atrophy of the cerebellum, affecting their motor coordination, balance, speech, eye coordination movements, 
and with many other symptoms.1 To date, 36 SCA loci have been described, for 21 of these the corresponding 
disease gene and causative mutation has been identified.1-4 The majority of SCAs represent repeat expansion 
diseases, including a coding CAG repeat (SCA1–3, 6, 7, and 17) causing misfolding of the encoded protein due 
to the expanded polyglutamine tracts, or groups of non-coding CAG, CTG, ATTCT, and GGCCTG repeats (SCA8, 10, 
12, and 36), or large TGGAA repeat insertions (SCA31) that induce RNA-mediated gain-of-function mechanisms.1 
The remaining known SCA types are caused by missense mutations or chromosomal rearrangements (SCA5, 11, 
13–15, 20, 23, 27, 28, 31, and 35) in genes displaying a wide range of protein functions, often causing alterations 
in synaptic transmission via calcium, potassium and glutamate signaling.1,5-7
 We previously mapped SCA19 in a large Dutch family (four generations with thirteen affected members) 
to a region of approximately 38 Mb located in chromosomal region 1p21-q21.8 The SCA19 locus shows significant 
overlap with the SCA22 locus later reported in a single Chinese family,9 suggesting that SCA19 and SCA22 might 
be caused by mutations in the same gene and lead to an ataxia type with a worldwide distribution.10 Clinical 
investigation and magnetic resonance imaging of our SCA19 family revealed a relatively mild, cerebellar ataxic 
syndrome with cognitive impairment, pyramidal tract involvement, tremor and peripheral neuropathy, and 
mild atrophy of the cerebellar hemispheres and vermis.11 The SCA19 locus comprises some five hundred genes 
and transcripts, but we could not identify the causative gene and mutation by candidate gene sequencing (data 
unpublished). We therefore applied exome sequencing to two affected family members and identified a novel 
missense mutation in KCND3 (also known as Kv4.3) as causing SCA19 in our family.8 Later, we identified two 
different missense mutations in this gene in two other families from our Dutch ataxia cohort. Kv4.3 is a Shal-related 
subfamily, voltage-gated potassium channel, involved in the transient outward A-type K+ current in the neurons. 
It is highly expressed in the cerebellum.12-14 The three mutations in KCND3 either impaired proper endoplasmatic 
reticulum (ER)-golgi-membrane trafficking and/or reduced Kv4.3 channel functioning. Together, our genetic and 
functional studies provide evidence that mutations in KCND3 cause SCA19.
Material and Methods
Subjects 
The participants of our original SCA19 family all gave informed written consent, as required by the Medical Ethics 
Committee of the University Medical Centre Utrecht, the Netherlands. The additional 230 ataxia patients screened 
in this study were obtained from the Genome analysis laboratory, Department of Genetics, University Medical 
Center Groningen. All extended DNA analyses were performed in a diagnostic setting (accredited diagnostic DNA 
lab). Only DNA samples from patients who were referred for genetic testing for SCA1-3, 6-12, 14, and 17 were 
used. The additional tests were thus performed in line with the original diagnostic request. Moreover, patients 







were asked whether they agreed to their DNA being used for future (anonymous) studies to help develop or 
improve diagnostics. If they objected, this was indicated on the original “Request for DNA test” form and their 
DNA was not used. The unrelated 400 control individuals were obtained from the Dutch blood bank. DNA was 
extracted from peripheral blood by a routine salting-out procedure.
Exome sequencing and mutation screening
The genomic DNA samples (individuals IV:1 and II:10 marked by * in pedigree 1, Suppl. Fig. 1A) were randomly 
fragmented using nebulization. The resulting fragments were bar-coded, using the standard NEBNext DNA Library 
Prep Master Mix Set for Illumina (New England Biolabs, Ipswich, MA, USA). Fragments with an average insert size 
of 220 bp were amplified by PCR, and the quality was verified on an Experion machine (BioRad, Richmond, CA, 
USA). Exome capturing was performed using the Agilent SureSelect All exon V2 kit. After PCR amplification of the 
enriched products paired-end sequencing was performed on a HiSeq2000 (Illumina, San Diego, CA, USA) with 
100 bp reads. Image files were processed using standard Illumina base-calling software and the generated reads 
were ready for downstream processing after de-multiplexing. 
The reads were aligned to the human reference genome, build 37, using BWA software.15 To clean the 
aligned data and perform variant calling, we applied Picard duplicate removal and the genome-analyzer toolkit 
(GATK)16, 17 containing quality score recalibration, indel realignment, and an unified genotyper. Using snpEff 
(http://snpeff.sourceforge.net) the variants were annotated with information from dbSNP132, 1000 Genomes 
Project (phases 1, 2 and 3) and Ensembl, build 37.64. These programs are all integrated in our MOLGENIS 
Compute analysis pipeline developed by the Genomics Coordination Center, Department of Genetics, University 
of Groningen (http://wiki.gcc.rug.nl/wiki/GccStart).18 Pathogenicity predictions for variants were obtained from 
PolyPhen 2.0, SIFT, and Align GVD.19-23 Variations were validated by direct Sanger sequencing and analyzed using 
DNA Variant Analysis Software Mutation Surveyor. The high resolution melting technology with the LightScanner 
(Idaho Technologies, Salt Lake City, UT, USA) was used to identify additional mutations in KCND3 according to the 
manufacturer’s instructions. The primers used to amplify the amplicons are listed in Suppl. Table 1. Aberrant 
melting curves were checked by direct Sanger sequencing, and the sequences were aligned to reference sequence 
NM_172198. 
Post-mortem human brain specimens
SCA19 cerebellar tissue (hemispheres and vermis) from the patient (Individual II:1 in pedigree 1 in Suppl. Figure 
1A) with a T352P mutation and an age-matched, non-degenerative control subject were obtained from the 
University Medical Center St Radboud, Nijmegen, the Netherlands. The samples were collected with full clearance 
from their Medical Ethics Committee. The frozen brain tissue was used for Western blot, quantitative real-time 
PCR analysis and for making paraffin-embedded sections for histochemistry and immunohistochemistry tests. 




Wild-type KCND3 cDNA cloned into the pCMV6 plasmid (short isoform; 636 amino acids, NM_172198) was 
purchased from Origene (Rockville, MD, USA). The cDNA was amplified using primers (Suppl. Table 2) containing 
XhoI and EcoRI, or EcoR1 and EcoRV sites, to facilitate cloning into pcDNA3.1(-), and pIRES-EGFP/Cherry plasmids, 
respectively. The PCR product was first subcloned into pJET1.2/blunt (Fermentas, Vilnius, Lithuania). Mutations 
were introduced into the pJET-KCND3 cDNA using side-directed mutagenesis (for primers see Suppl. Table 3) 
followed by further subcloning into pcDNA3.1(-) and pIRES-EGFP/Cherry. The pcDNA3.1-Kv4.3 plasmids were used 
for Western blot and immunohistochemistry and the pIRES-Kv4.3-EGFP/mCherry plasmids for patch-clamping. 
The constructs were checked for correctness by direct sequencing. The Emerald-C1 and Emerald-ratKChIP2b/c 
plasmids were kindly provided by Dr. K. Takimoto (Nagaoka University of Technology, Kamitomioka, Japan).24 
Cell culture and transfection 
HeLa and HEK293T cells were grown in DMEM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10 % 
FBS (Invitrogen) and 1% Pen/Strep (Gibco, Rockville, MD, USA) in a 37°C with 5% CO2. Cells were grown in 6-well 
plates for Western blot or on glass cover slips in 12-well plates for immunohistochemisty and single cell patch 
clamping for 24 hours following transfection with PEI (Polysciences Inc., Warrington, PA, USA), according to the 
manufacturer’s instructions.
Western blot 
After 48 hours of transfection, cell extracts and human cerebella were homogenated using a 2% SDS/PBS buffer 
containing protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) and incubated for 1 hour at room 
temperature. Cell and tissue lysates were centrifuged for 10 minutes at 13,000 rpm. Proteins were quantified 
using the BCA kit (Thermo Fisher Scientific, Rockford, IL, USA) and the supernatant was mixed with loading sample 
buffer containing 10% β-mercaptoethanol and incubated for 5 minutes at 65°C. 
For protein analysis 50 μg of cell extract or 200 μg of brain proteins was loaded on 10% SDS-PAGE gel 
followed by immunoblot analysis. Nitrocellulose membranes were incubated with mouse anti-Kv4.3 (K75/41, 
NeuroMab, Davis, CA UAS, 1:1000), mouse anti-Calbindin (Abcam, Cambridge, UK, 1:2500), mouse anti-Actin (MP 
Biochemicals, Solon, OH, USA, 1:5000), mouse anti-p53 (Santa Cruz, Santa Cruz, CA, USA, 1:1000), and mouse 
anti-KChIP2 (Abcam, Cambridge, UK, 1:1000). Final quantification was performed using the program Quantity 
One (Bio-Rad).
Immunochemistry and Sevier-Munger silver staining
After 48 hours of transfection, HeLa cells were used for immunocytochemisty as previously described but 
with some modifications.26 Briefly, cells were fixed with PBS containing 4% paraformaldehyde for 15 minutes, 
permeabilized and blocked with 10% BSA 0.1% Triton X-100 in PBS for 1 hour at room temperature. Primary 
and secondary antibodies were diluted in blocking buffer and incubated overnight at 4°C and 1 hour at room 







temperature, respectively. The antibodies used were: mouse anti-Kv4.3 (K75/41, NeuroMab, Davis, CA, USA, 
1:250), rabbit anti-Calnexin (Sigma, Milwaukee, WI, USA, 1:200), goat anti-mouse FITC, goat antimouse Cy3 (all 
1:500, Jackson ImmunoResearch, West Grove, PA, USA).
 Cerebellar immunohistochemistry was performed on human cerebellar tissue 10 μm thick sections 
embedded in paraffin. After deparaffination, rehydratation, and antigen retrieval, tissues were blocked with 10% 
normal goat serum in TBS for 1 hour at room temperature. Primary and secondary antibodies were diluted in 
blocking buffer and incubated overnight at 4°C in a humidified chamber and for 2 hours at room temperature, 
respectively. 
 The antibodies used were: rabbit anti-Kv4.3 (Alomone labs, Jerusalem, Israel, 1:100) and mouse 
anti-Calbindin (Abcam, Cambridge, UK, 1:200), goat anti-mouse FITC and goat anti-rabbit Cy3 (1:500, Jackson 
ImmunoResearch, West Grove, PA, USA). All the slides were mounted in Vectashield medium with DAPI (Vector 
Laboratories, Burlingame, CA, USA). For the silver staining, after deparaffination and rehydration, the cerebellar 
slides were placed in a 20% solution of AgNO3 for 20 minutes at 60°C. After rinsing in distilled water, the slides 
were placed in a solution of 10% AgNO3 (to which ammonia was added until the precipitate was dissolved) + 1 
ml of 25% sodium carbonate solution. While stirring, drops of 3.7% formalin were added until the slides stained 
gold-brown. After rinsing in distilled water, the slides were placed in 5% sodium thiosulphate solution for 2 
minutes. Then the slides were rinsed again, followed by dehydration, xylene and mounting. 
Membrane localization scoring assay
The percentage of transiently transfected HeLa cells with Kv4.3 membrane localization versus cells without 
membrane localization were scored using an IRB inverted fluorescent microscope (Leica, Mannheim, Germany). 
The scoring assay was de-coded and performed in triplicate by an independent scorer. On average a minimum of 
250 cells were counted per experiment.
Electrophysiological measurements
Whole-cell patch clamp recording was used to quantify Kv4.3 potassium currents. All the experiments were 
performed at room temperature (22–24°C) using an Axopatch 200B amplifier, a Digidata 1320A interface, and 
pClamp version 8.2 software (Axon Instruments, Foster City, CA, USA). The extracellular (bath) solution contained 
(mmol/L) 140 NaCl, 4 KCl, 5 glucose, 2 CaCl2, 1 MgCl2, and 10 HEPES, and the pH was adjusted to 7.4 with 
NaOH. The pipette solution contained (mmol/L) 140 KCl, 10 EGTA, 1 CaCl2, 1 MgCl2 and 10 HEPES, and the pH 
was adjusted to 7.2 with KOH. Microelectrodes were made of GC120F-10 borosilicate glass (Harvard Apparatus, 
Holliston, MA, USA) and pulled on a P-87 puller (Sutter Instruments, Novato, CA, USA) having a final resistance of 
4–5 MΩ. Series resistance was compensated by 80–85%. Currents were filtered at 5 kHz and digitized at 10 kHz. 
Data were analyzed using Clampfit (Axon Instruments, Sunnyvale, CA, USA) and Microsoft Excel software.




In order to identify the causative gene for SCA19, the genomic DNA of two affected individuals from our large 
Dutch family (IV:1 and III:10 in pedigree 1 and indicated with * in Suppl. Fig. 1A) was analyzed by whole exome 
capturing. An average of 3 Gb of sequence was generated per individual, with an average coverage depth of 70x 
per targeted base. At least 85% of the total target region was covered more than 20x. The data were filtered for 
SNPs that were not previously reported to dbSNPv132 or found in the 1000 Genomes Project (phases 1, 2 and 3), 
yielding 4,382 and 5,830 novel SNPs per individual (Suppl. Table 4).
Figure 1 SCA19 mutations lead to 
amino acid substitutions in highly 
conserved parts and domains of 
Kv4.3.
A) Schematic representation of the 
Kv4.3 channel and the location of the 
three SCA19 mutations. Segments (S) 
1-4 form the voltage sensor domain, 
and S5 and S6, together with the 
pore loop, form the ion-selective 
pore. Positively charged residues in 
S4 detect the voltage change. The 
numbers indicate the amino acid 
numbers defining the beginning 
and end of the transmembrane 
segments. The c.1054A>C; p.T352P 
mutation is located in the third 
extracellular loop, the c.1119G>A; 
p. M373I and c.1169G>A; p.S390 
are located in the channel pore, 
and the S6 transmembrane domain, 
respectively. B) Electropherograms 
of the wild-type and mutant DNA 
sequences (NM_172198). C) Amino 
acid comparison of Kv4.3 channels 
across species reveals that amino 
acids T352, M373, and S390 are 
100% conserved from human to fish. 
Since the SCA19 disease gene had already been mapped to 1p21-q21, further analysis focused on those 
variations shared between the two SCA19 cases from the large Dutch pedigree and present within the linkage 
interval. This analysis resulted in a total of 33 shared SNPs not reported in any database (Suppl. Table 5). Of these, 
25 SNPs were detected in a heterozygous state (Suppl. Tables 6 and 7). After exclusion of the non-coding variants, 
validation by Sanger sequencing, a co-segregation check with the disease phenotype in the original SCA19 family 
(Suppl. Fig. 1A) and, screening of 400 Dutch blood bank controls, only one heterozygous missense T>G variation 
located at chromosome 1: 112,524,295 remained unique for SCA19 (Suppl. Table 7). This variation led to a c.1054A>C 







(p.T352P) substitution in the third extracellular loop of the voltage-gated potassium channel KCND3, also known as 
Kv4.3 (Fig. 1A and B). 
To obtain further genetic evidence for KCND3 as the gene underlying SCA19, we screened 230 Dutch 
ataxia cases with no mutation in the known SCA genes (SCA1-3, 6, 7, 14, 17, and 23) by high-resolution melting. 
This ataxia cohort contains 30 cases with an autosomal dominant (AD) inheritance pattern and 200 cases with 
an unknown family history. In the probands of two AD families (Pedigrees 2 and 3, Suppl. Fig. 1B and C), we 
identified two novel mutations, c.1119G>A; p. M373I and c.1169G>A; p.S390N, located in the channel pore, 
and the S6 transmembrane domain, (Fig. 1A and B), respectively. The c.1119G>A mutation was detected in two 
affected individuals and in one apparently asymptomatic carrier (Suppl. Fig. 1B). The segregation of the other 
mutation c.1169G>A could not be tested due to non-availability of family members (Suppl. Fig. 1C). All three 
mutated residues of human Kv4.3 are 100% conserved between different species (Fig. 1C). None of the KCND3 
mutations were found in 800 Dutch control chromosomes, nor in several genetic databases (dbSNPv132, 1000 
Genomes Project, and Exome Variant Server (NHLBI Exome Sequencing Project, http://evs.gs.washington.edu/
EVS/). 
 The M373I proband, (Pedigree 2: II:1; Suppl. Fig. 1B) had ambiguous neurological signs on testing at 
the age of 44. At the age of 52, he was re-examined but was found to be without neurological symptoms. His 
father (I:1) had a progressive gait disorder from age 55 onwards, including clear dysarthria, as well as ataxia 
of the arms and of gait. Computer tomography at that time demonstrated mild cerebellar atrophy. Comorbid 
conditions included hearing impairment and vascular atherosclerotic disease. He died at the age of 80. This 
paternal father was said to have had gait instability as well from about age of 60 onwards, deceasing at the age 
of 90. Of the proband’s sisters, the eldest was found to have very mild gait impairment at the age of 64, with 
equivocal dysdiadochokinesia of the hands (II:3). The youngest sister was unaffected (II:2). 
The S390N proband (Pedigree 3: II:1; Suppl. Fig. 1C) suffered from a slowly progressive, spastic ataxic 
syndrome, including dysarthria, saccadic eye movements and downbeat nystagmus, cognitive impairment, and 
hearing deficits. The disease symptoms started between 30-35 years of age. An MRI scan of the brain revealed 
cerebellar vermis atrophy. In addition, his brother and mother were diagnosed with the same disease. 
 Kv4.3 has been reported to be expressed in the cerebellum14,27 and immunohistochemistry of autopsy 
material from control cerebellum revealed a weak, punctuated staining of the Purkinje cell (PC) bodies, whereas 
a more intense Kv4.3 signal in larger puncta was observed in the soma of T352P-mutant  PCs (Fig. 2A). Sevier-
Munger silver staining revealed many empty baskets indicative of PC loss (Fig. 2B; arrows). The anterior part of 
the vermis was most severely affected, followed by the posterior vermis and the cerebellar hemisphere. The PC 
loss in the hemisphere had a more patchy appearance. The cerebellar tonsils were the least affected. In this same 
order of PC loss, we observed degeneration/atrophy in both the molecular and internal granular layers. In the 
areas with remaining PCs, axonal torpedoes were observed (Fig. 2B; arrows). In addition, Kv4.3 protein levels in 
cerebellar lysates were lower in the patient’s sample, which seemed to be the result of PC loss as shown by the 
reduced PC-specific marker Calbindin expression (Fig. 2C-E).
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Figure 2 Immunocytochemistry, immunohistochemistry and Western blot analysis demonstrate the effect of the T352P 
mutation on Kv4.3 protein expression and cerebellar degeneration in human autopsy material. 
A) Control cerebellar sections stained with Kv4.3 antibody (in red) and Calbindin (in green) showed punctuated staining 
of the Purkinje cell (PC) bodies. Stronger and more accumulated kv4.3 staining was observed in PCs soma of the SCA19 
cerebellum of a T352P patient. (Scale bar: 25 μm) B) Micrographs of Sevier-Munger silver stainings showing overviews (left-
hand side) and details (right-hand side) of degenerating cerebellar cortex. Note the atrophy of the folia in the vermis with 
empty baskets or torpedoes (arrows). The cerebellar hemisphere was less affected, although empty baskets and torpedoes 
(arrows) were still encountered. The cerebellar tonsils were least affected and showed relatively normal numbers of Purkinje 
cells. (Scale bars left: 500 μm and right: 100 μm) C) Western blot analysis of cerebellar protein extracts of control and 
T352 Kv4.3 mutant cerebella demonstrated markedly reduced Kv4.3 and Calbindin protein levels. D) Quantification of Kv4.3 
protein levels in both control and the T352P mutant cerebella. Data is normalized against Actin levels using Quantity One. E) 
Data normalized against Calbindin levels.
 In episodic ataxia type 2, missense mutations have already been reported as causing ER retention of 
the α-subunit Cav2.1 of the P/Q voltage activated calcium channel.
28 We therefore assessed whether the SCA19 
missense mutations (T352P, M373I, and S390N) would also affect the subcellular localization/maturation of 
Kv4.3. Confocal microscopic analysis of transiently transfected HeLa cells revealed that, unlike wild-type Kv4.3 







that was mainly located on the plasma membrane (74.5% ± 3.5; Suppl. Fig. 2), all three mutant proteins showed 
almost no or markedly reduced cell surface expression (T352P: 4.9% ± 0.6, M373I: 40.4% ± 6.7, and S390N: 
5.0% ± 2.7; Suppl. Fig. 2), and rather accumulated in perinuclear foci (Fig. 3A). These data suggest that the SCA19 
mutations cause ER retention of Kv4.3, causing impaired trafficking of the channel to the plasma membrane. 
Indeed, our studies showed perfect co-localization of the SCA19 mutant Kv4.3 foci and the ER marker Calnexin, 
but not with wild-type Kv4.3 (Fig. 3B). In addition, all the Kv4.3 mutants were more rapidly degraded, upon 
inhibition of protein synthesis, than wild-type Kv4.3 (Fig. 3C and D). The remaining Kv4.3 protein after 9 hours of 
cyclohexamide treatment was 54%  ± 10 for wild-type versus 15% ± 3, 27% ± 10, and 16% ± 4 for T352P, M373I, 
and S390N mutant Kv4.3, respectively. The cycloheximide treatment led to an efficient translational block as was 
demonstrated using Western blot analysis against p53 (Suppl. Figure 3). This suggests that the SCA19 mutant 
proteins are recognized as misfolded proteins and are subsequently degraded, most likely via endoplasmatic 
reticulum-associated degradation (ERAD). 
 Functional channels do not comprise Kv4.3 alone, since tetrameric Kv4.3 complexes form a hetero-
octamer complex together with the regulatory β subunits, Kv channel-interacting proteins (KChIPs), in which 
KChIPs drive the complex formation.29,30 Since KChIPs are absent in HeLa cells, we wondered whether co-
expression of Kv4.3 together with KChIP could improve the ER-golgi-plasma membrane trafficking of the Kv4.3 
mutants as was seen for wild-type K4v.3 (Fig. 4A). When co-expressing KChIP2b, but not its inactive isoform 
KChIP2c, T352P and M373I (88.8% ± 1.5 and 82.6% ± 1.0 ) were detected at the plasma membrane like wild 
type Kv4.3 (87.8% ± 0.4 ; Fig. 4B, C, and Suppl. Fig. 2). However, the mislocalization of the S390N Kv4.3 mutant 
could not be rescued by co-expression of KChIP2b as only 21.2% ± 8.4 of the cells showed cell surface expression, 
but it rather trapped the regulatory β subunit in the same intracellular compartment (Fig. 4D and Suppl. Fig. 2). 
In addition, KChIPs not only drive the tetramerization of Kv4.3 subunits, but they also regulate Kv4.3 protein 
expression and stability.31,32 KChIP2b co-expression led to increased protein expression for all Kv4.3 proteins (Fig. 4D) 
and also clearly improved the protein stability of wild-type, T352P and M373I-mutant Kv4.3 with the exception of 
S390N (Fig. 4F and G). The remaining Kv4.3 protein levels after 9 hours of cyclohexamide treatment were 96% ± 
4 for wild-type Kv4.3 and 93% ± 20, 87% ± 3, and 13% ± 3 for T352P, M373I, and S390N, respectively. These data 
indicate that KChIP2b can ameliorate the folding defect of the SCA19 mutant proteins (except that of S390N) and 
thereby prevent protein degradation.  
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Figure 3 Endoplasmatic reticulum (ER) retention and enhanced protein degradation of SCA19 mutant Kv4.3.
A) Confocal images of HeLa cells expressing wild-type (WT) or T352P, M373I, and S390N mutant Kv4.3 subunits. All Kv4.3 
mutants clearly showed intracellular retention in the perinuclear region with only 4.9 % (T352P), 40.4 % (M373I), and 5.0 
% (S390N) membrane expressing cells, whereas the WT Kv4.3 channel was mainly expressed on the cell surface (74.5 % 
of the cells) detected using anti-Kv4.3 (in red). The quantification of the membrane localization is shown in Suppl. Fig. 2. 
B) Co-localization with the ER-marker Calnexin (in green) revealed that all three T352P, M373I and S390N mutant Kv4.3 
proteins (in red) were retained in the ER, as was shown by the merged picture (in yellow). C)  Time-course of protein 
degradation experiments were performed in HeLa cells transfected with either WT or T352P, M373I, and S390N mutant 
Kv4.3 treated with the protein synthesis inhibitor cyclohexamide (100 μg/ml) for the indicated time periods, and the existing 
cellular pool of all Kv4.3 were detected by Western blot. The pool of T352P, M373I and S390N mutant Kv4.3 proteins was 
degraded more rapidly than WT Kv4.3, which is a characteristic of misfolded ER-retained proteins. D) Quantification of the 
Western blot degradation experiment normalized by Actin, showing the % of remaining protein in time. The graphs show the 
average of three independent experiments and the error bars represent the Standard Deviation (SD) (Mean ± SD). 







Figure 4 The regulatory 
β subunit, KChIP2b 
rescues the trafficking 
and stability of T352P 
and M373I mutant 
Kv4.3 channels.
A - D) Confocal 
images of HeLa cells 
expressing wild-
type (WT) or T352P, 
M373I, and S390N 
mutant Kv4.3 subunits 
detected using anti-
Kv4.3 antibody (in 
red), co-expressed 
with either empty 
control Emerald-C1 
(Emd), KChIP2b or 
the non-functional 
isoform KChIP2c 
(in green) (Scale 
bar: 10 μm). Only 
KChIP2b expression 
resulted in a marked 
change in subcellular 
distribution of T352P 
(B) and M373I (C) 
mutant Kv4.3, as the 
remaining intracellular 
Kv4.3 pool was no 
longer associated with 
the endoplasmatic 
reticulum, but showed 
a significant increase in 
cell surface expression 
up to 88.8 % (T352P) 
and 82.6 % (M373I) of cells (merge in yellow). In contrast, almost no effect of KChIP2b on the subcellular distribution of S390N 
mutant Kv4.3 was detected as now only 21.2 % of cells showed Kv4.3 cell surface expression (D). The quantification of the 
membrane localization is shown in Suppl. Fig. 2. E) Western blot data showed that KChIP2b is able to regulate the expression 
levels of WT and all SCA19 mutant Kv4.3 proteins in HeLa cells, as for all Kv4.3 proteins increased Kv4.3 levels were detected 
in the presence of KChIP2b. C = empty control Emerald-C1 and 2b = KChIP2b. F) Time-course Kv4.3 protein degradation 
experiment. Western blot showed that co-expression of WT, T352P and M373I mutant Kv4.3 with KChIP2b resulted in a 
significant increase in protein stability (rescue up to almost 90% for WT, T352P, and M373I mutant Kv4.3) in HeLa cells during 
9 hours of cyclohexamide treatment. This effect was not observed for S390N mutant Kv4.3. Here, co-expression with KChIP2b 
led to about 13% and thus a similar percentage of remaining S390N mutant Kv4.3 proteins levels without KChIP2b after 9 
hours of cyclohexamide treatment. G) Quantification of the Kv4.3 protein degradation in the presence of KChIP2b normalized 
by Actin using Quantity One. The graphs show the average of three independent experiments and the error bars represent 
the Standard Deviation (SD) (Mean ± SD). 
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To test for Kv4.3 channel activity in the presence of KChIP2b, we recorded its K+ currents by patch 
clamping in HEK293T cells. Activation of the wild-type Kv4.3-KChIP2b complex was detected at approximately -40 
mV followed by more positive potentials up to +28 mV (Fig. 5A and E). In contrast, almost no detectable channel 
activity was detected for T352P-KChIP2b and S390N- KChIP2b complexes (1% and 13% channel activity compared 
to wild type, 100%; Fig. 5B, D, and E), whereas strongly reduced activity (up to 75% of reduction) was measured 
for M373I-KChIP2b (Fig. 5C and E). All mutant Kv4.3 complexes showed significantly decreased current amplitude 
at 28mV from 4541 ± 599 (wild-type), to 44 ± 27 (T352P), 1150 ± 393 (M373I), and 571 ± 174 (S390N) (Fig. 5F). 
These results demonstrate that although T352P mutant Kv4.3 and the regulatory β subunit KChIP2b co-assemble 
and are present at the plasma membrane, the T352P-KChIP2b complex is not functional. The M373I-KChIP2b 
complex seem to be functional, but it produces Kv4.3 channels with marked reduced activity. Notably, very weak 
S390N-KChIP2b activity was detected, despite the fact that about all S390N-KChIP2b complexes are ER-retained 
as was observed by microscopy. Therefore, we speculate that probably a few S390N-KCHIP2b complexes escape 
the ER and reach the plasma membrane but still display almost no Kv4.3 channel activity.  To confirm that the 
observed loss of channel activity is not due to enhanced T352P, M373I or S390N Kv4.3 protein degradation, the 
Kv4.3 expression levels were checked using Western blot. No differences in expression levels were observed 
between wild-type and all mutant Kv4.3 subunits (Suppl. Fig. 4). 
Figure 5 SCA19 mutations cause 
loss of the Kv4.3-KChIP2b channel 
complex activity and lead to reduced 
outward K+ currents. 
A-D) Representative whole-cell 
potassium currents recorded in 
HEK293T cells transfected with wild-
type (WT) (A), T352P (B), M373I 
(C), and S390N (D) mutant Kv4.3 
co-expressing KChIP2b. The traces 
are generated by step depolarization 
of 200 ms duration from a holding 
potential of -82mV to +28mV. E) The 
current-voltage relationship for WT, 
T352P, M373I, and S390N mutant 
Kv4.3-KChIP2b complexes. Clearly, 
the T352P, M373I, and S390N mutant 
Kv4.3-KChIP2b complexes showed 
almost no or strongly reduced channel activity. All values shown in the graph are the average of at least 10 independent 
measurements and the error bars represent the Standard Error of the Mean (Mean ± SEM). F) The bar graph shows the 
mean peak current density at 28mV for WT, T352P, M373I, and S390N mutant Kv4.3-KChIP2b complexes. All mutant-KChIP2b 
complexes showed significant reduced peak current density at 28mV when compared to wild-type Kv4.3-KChIP2b. The 
significance was calculated using a Student’s t-test, * = 0.05 (Mean ± SEM).








Our studies provide evidence that missense mutations in KCND3 cause SCA19 by either altering Kv4.3 ER-golgi-
plasma membrane transport, leading to enhanced protein degradation suggestively by endoplasmatic reticulum 
associated degradation (ERAD), and/or by loss of Kv4.3 channel functioning. KCND3 encodes for Kv4.3, a highly 
conserved ShaI-related subfamily, voltage-gated potassium channel, that is known to regulate cardiac and 
neuronal membrane excitability.33 KCND3 mRNA is highly expressed in cerebellum, including Purkinje cells, basket 
cells, stellate cells and deep neurons,34 and is thought to be important for its development.14,35 The Kv4 channel 
family consists of three pore-forming α subunits, Kv4.1, Kv4.2, and Kv4.3.36 These α subunits form tetrameric 
channel complexes and bind regulatory β subunits, KChIPs, that change intracellular trafficking of the Kv4 
channels from ER to plasma membrane and channel activity.29,37 The neuronal Kv4 channel complex mediates the 
A-type K+ current, that are important for dendritic excitability, somatodentritic signal integration, and long-term 
potentiation (LTP).33,38-42 
 KCND3 knockout mice have already been generated but they do not display any neurological deficits,43 
probably due to redundancy of the other Kv4 family members. This implies that the SCA19 mutants described 
here must have a dominant negative effect on the maturation and/or function of the other complex members and 
cause a loss of Kv4.3 function. Indeed, our S390N mutant data support such a hypothesis as this mutant leads to 
the trapping of the regulatory β subunit in the ER.
 The question remains how defects in a voltage-gated potassium channel can lead to cerebellar 
neurodegeneration. We are considering three potential mechanisms. First, altered dendritic excitability due to 
reduced A-type K+ currents and subsequent initiation and a longer duration of action potentials might lead to 
changes of intracellular calcium homeostasis that may trigger PC death.44 Secondly, SCA19 mutations could induce 
LTP deficits at the PC synapse. This would affect one of the important tasks of the cerebellum – fine adjustment 
of motor coordination – that indeed requires intact long-term depression (LTD) and LTP processes.45,46 Thirdly, 
the misfolded Kv4.3 channels may lead to a chronic form of ER stress and over-induction of the unfolded protein 
response, thereby activating pro-apoptotic factors leading to PC cell death.47
 The different SCA19 mutations were found to affect Kv4.3 ER-golgi-plasma membrane maturation and 
channel activity differently, ranging from an almost complete inability to reach the plasma membrane (S390N), 
to almost complete absent (T352P), or only marked reduced (M373I) channel activity. This may, to some extent, 
explain the diverse disease phenotypes observed in the three SCA19 families. The patients with the T352P and S390N 
mutations showed more severe disease phenotypes than those with the M373I, given the presence of cognitive 
impairment, myoclonus, and tremor in most of the T352P patients, cognitive impairment and spasticity in the S390N 
case and the absence of these symptoms in M373I cases. In addition, the age of onset of the M373I family is relatively 
late (average of 55 years) compared to an average 30 or 35 years of age in the T352P and S390N cases. 
Interestingly, the three different cellular phenotypes of the mutants are partially reminiscent of what 
is seen for mutations in the cAMP-regulated chloride channel (CFTR) that cause cystic fibrosis, in which both 
CFTR maturation defects and reduced channel activities were also found.48 Different therapeutic strategies that 
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interfere with either the folding or degradation of maturation defective mutants or that stimulate channel opening 
of membrane-associated mutants with impaired function may also be of value for the Kv4.3 mutants and are 
currently being investigated. 
Besides being expressed in brain, Kv4.3 is also expressed at relatively high levels in heart tissue. 
Although, the SCA19 cases have not (yet) been reported  to exhibit cardiomyopathy, it is notable that rare genetic 
variations have been associated with a gain of Kv4.3 function that is associated with Brugada syndrome,49 implying 
that Kv4.3 may well play a role in human heart disease.
In conclusion, our current findings significantly contributes to reveal the importance of voltage-
gated potassium channels in cerebellar ataxias, including episodic ataxia type 1 and SCA13 20,50 and show that 
mutations in KCND3, only required to prevent the fast repolarization of neurons, is sufficient to cause cerebellar 
neurodegeneration. We therefore speculate that more Kv4 family members or interacting proteins of Kv4.3 may 
also be involved in the etiology of other cerebellar ataxias. 
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Abstract
Spinocerebellar ataxias (SCAs) are dominantly inherited neurodegenerative disorders characterized by progres-
sive cerebellar ataxia and dysarthria. We have identified missense mutations in prodynorphin (PDYN) that cause 
SCA23 in four Dutch families displaying progressive gait and limb ataxia. PDYN is the precursor protein for the opi-
oid neuropeptides, a-neoendorphin, and dynorphins A and B (Dyn A and B). Dynorphins regulate pain processing 
and modulate the rewarding effects of addictive substances. Three mutations were located in Dyn A, a peptide 
with both opioid activities and nonopioid neurodegenerative actions. Two of these mutations resulted in excessive 
generation of Dyn A in a cellular model system. In addition, two of the mutant Dyn A peptides induced toxicity 
above that of wild-type Dyn A in cultured striatal neurons. The fourth mutation was located in the nonopioid 
PDYN domain and was associated with altered expression of components of the opioid and glutamate system, as 
evident from analysis of SCA23 autopsy tissue. Thus, alterations in Dyn A activities and/or impairment of secretory 
pathways by mutant PDYN may lead to glutamate neurotoxicity, which underlies Purkinje cell degeneration and 
ataxia. PDYN mutations are identified in a small subset of ataxia families, indicating that SCA23 is an infrequent 
SCA type (~0.5%) in the Netherlands and suggesting further genetic SCA heterogeneity.




The dominant spinocerebellar ataxias (SCAs) are a genetically heterogeneous group of neurodegenerative disorders 
characterized by progressive cerebellar ataxia, dysarthria, oculomotor abnormalities, and many additional symp-
toms.1 The ataxia results from selective atrophy of the Purkinje cells in the cerebellum. To date, 31 different SCA 
loci have been described, but the causative mutation and corresponding gene has only been identified in 19 SCA 
types.2,3 Nine of the 19 SCAs are caused by coding CAG repeat (SCA1–3, SCA6, SCA7, and SCA17; MIM #164400, 
MIM #183090, MIM #109150, MIM #183086, MIM #164500, and MIM #607136) or noncoding CAG, CTG, or ATTCT 
repeat expansions. These coding CAG (glutamine) repeat expansions lead to elongated polyglutamine tracts that 
subsequently cause misfolding of the corresponding proteins. The functional implication of the noncoding repeat ex-
pansions is suggested to induce RNA-mediated gain-of-function mechanisms, leading to neurotoxicity. However, the 
remainders of the known SCA types are due to missense mutations or chromosomal rearrangements (SCA5, SCA11, 
SCA13–15, SCA20, SCA27, SCA28, and SCA31; MIM #600224, MIM #604432, MIM #605259, MIM #605361, MIM 
#606658, MIM #608687, MIM #609307, MIM #610246, and MIM #117210).2 The SCA genes involved play a role in 
a wide range of biological processes. Recent studies into the function of the disease proteins revealed the existence 
of common pathways leading to ataxia consisting of changes in gene transcription and RNA processing or synaptic 
transmission via calcium and glutamate signaling.4,5
Currently, only 70% of the Dutch SCA families can be diagnosed by mutation analysis of seven of the known 
SCA genes (SCA1–3, SCA6, SCA7, SCA12, and SCA14). The identification of causal mutations and novel genes in the 
group of genetically undiagnosed families will provide additional insights into the underlying pathological pathways 
leading to cerebellar neurodegeneration and will perhaps indicate therapeutic approaches. 
We previously mapped the SCA23 locus (MIM #610245) to a 6 Mb region located on chromosomal region 
20p12.3-p13 in a single, large Dutch ataxia family without mutations in the SCA genes that were recognized at the 
time.6 MRI and neuropathological examination of SCA23 autopsy tissue revealed neuronal loss in the Purkinje cell 
layer, dentate nuclei, and inferior olivary nuclei. The patients showed a relatively slowly progressive, isolated, cerebel-
lar ataxia. Additional neurological examination revealed dysarthria, oculomotor problems such as slowing saccades, 
and ocular dysmetria. Decreased vibration sense below the knee was observed in three affected individuals, hyper-
reflexia was observed in four patients, and two patients displayed Babinski’s signs. Because no affected individuals 
of the first generation were still alive at the time of the assessment, clinical anticipation could not be confirmed. The 
SCA23 locus comprises 97 genes and transcripts, of which at least 54 are expressed in the cerebellum. Previous at-
tempts to identify one or more mutations causing the disease did not yield any results.6,7
In the present study, we identified four missense mutations in prodynorphin, PDYN (MIM #131340), in the 
originally reported SCA23 family and in three families from a Dutch ataxia cohort. PDYN is the precursor protein for the 
opioid neuropeptides a-neoendorphin, Dyn A, and Dyn B, ligands for the k-opioid receptor (OPRK1; MIM #165196).8 
Neuropeptides constitute a large family of signaling molecules that mediate and modulate neuronal communication 
by acting on cell surface receptors and thus regulate diverse physiological functions and behavior.9,10 Neuropeptides 
and their precursor molecules have not yet been identified as causative factors for neurodegenerative disorders.









The participants from the SCA23 family all gave informed consent, as approved by the Medical Ethical Commit-
tee of the University Medical Centre Utrecht. The 1100 ataxia patients (single index cases) screened in this study 
were obtained from the genetic diagnostic centers in Utrecht and Groningen in The Netherlands. All extended 
DNA analyses were performed in a diagnostic setting (accredited diagnostic DNA laboratory). Only DNA samples 
from patients who were referred for genetic testing for SCA were used and had no mutations in seven known SCA 
(SCA1–3, SCA6, SCA7, SCA12, and SCA14) genes. This cohort is comprised of 10% familial cases (8% dominant 
and 2% recessive) and 90% seemingly sporadic cases. The additional tests were thus performed in line with the 
original diagnostic request. Moreover, when the blood samples were taken, patients were asked whether they 
had objections to the use of their DNA for future (anonymous) studies to help develop or improve techniques. If 
they had objections, this was indicated on the original “Request for DNA Test” form, and the DNA was not used. 
The unrelated 500 control individuals were obtained from the Dutch blood bank.
Postmortem human specimens
SCA23 cerebellar tissues from the subject with a p.R138S mutation and from a control subject were obtained 
from the University Medical Center Nijmegen, Nijmegen, The Netherlands. Samples of the cerebellum (Cb), dor-
solateral prefrontal cortex (PFC; Brodmann area 9), and nucleus accumbens (NAc) from three control subjects, 
all females of European descent (for demographic data, see Table S6), were collected at the Karolinska Institute, 
Stockholm, Sweden, by qualified pathologists. The collection was performed under full ethical clearance from the 
University Medical Center Nijmegen and the Stockholm Ethical Review Board. Informed written consent from the 
next of kin was also obtained. 
PDYN sequencing
DNA was extracted from peripheral blood by a routine salting-out procedure. The genomic DNA of all par-
ticipating subjects in this study was used to amplify the PDYN coding exons 3 and 4 (GenBank accession 
number:NM024411.3) by PCR. The resulting amplicons, including the intron-exon boundaries, were screened for 
mutations via Sanger sequencing on an ABI 3700 (Applied Biosystems). The PCR, primer sequences, and condi-
tions are shown in Table S7.
Dynorphin radioimmunoassay
The radioimmunoassay (RIA) procedure was described elsewhere.11,12 Briefly, cells were extracted in 1 M acetic 
acid, extracts were run through an SP-Sephadex ion exchange C-25 column, and peptides were eluted and ana-
lyzed by RIA.




Dyn A peptides were synthesized at the Leiden University Medical Center, Leiden, The Netherlands, purified 
by reverse-phase chromatography and Superdex column, and analyzed by reverse-phase chromatography and 
MALDI-TOF MS. The purity of all peptides was ~98%. 
Neuron-enriched cultures, peptide treatment and assessment of neuron viability
Neurons were isolated from E15–E16 imprinting control region CD-1 mouse striatum as published.13 Briefly, the 
tissue was enzymatically and mechanically dissociated and filtered through a 70 μm pore nylon mesh. Neurons 
were plated onto poly-L-lysine (Sigma-Aldrich) coated glass coverslips inserted into a 24-well multiwell plate (5 x 
105 neurons suspended per well). Neurons were maintained in Neurobasal media with added B27 supplement 
(Invitrogen), antibiotics, 0.5 mM L-glutamine, and 0.025 μM glutamate (both Invitrogen) at 37°C in 5% CO2 at 
~95% humidity. Cultures matured for 1 week prior to the start of experiments and were almost exclusively neu-
rons when assessed by immunostaining for either NeuN or MAP2a/b (glial contamination < 1%). Neurons were 
treated with wild-type or mutant Dyn A peptides (p.L211S, p.R212W, or p.R215C) at 100 nM for 60 hr. 
Time-lapse digital images of the same neuron were recorded at 20 min intervals for 60 hr with a Zeiss 
AxioObserver Z.1 microscope equipped with an automated, computer-controlled stage encoder, digital camera 
(Zeiss MRm), and environmental control chamber (PeCon Instruments) at 37°C with 95% humidity and 5% CO2. 
In each experiment, cells from 2–3 pups were pooled and distributed across treatments such that the neurotoxic 
effects of each peptide variant were directly compared in the same population of cells. Approximately 50 healthy 
neurons with welldefined dendritic and axonal arbors were identified within ≥8 overlapping fields (40x magnifi-
cation; Mark&Find and Time Lapse modules Zeiss AxioVision 4.6) in each individual culture well prior to treatment 
(0 hr). Individual neurons were tracked throughout the experiment, and death was defined by the culmination of 
a series of events resulting in nuclear fragmentation and destruction of the cell body. Events preceding neuronal 
death included dendritic and axonal pruning, the dissolution of the Nissl substance, appearance of cytoplasmic 
swelling and vacuolization, nuclear damage and pyknosis, and eventual destruction of the cell body.13,14 Death 
was confirmed by viability markers such as ethidium homodimer, ethidium monoazide, or trypan blue (data not 
shown). These markers all possess inherent cytotoxicity and cannot be used to monitor cells during the entire 
course of the experiment. The effect of each treatment on neuron survival (percent pretreatment value) was ana-
lyzed statistically at 4 hr intervals via one-way repeated-measures analysis of variance (ANOVA; Graphpad Prism 
software) and was reported as mean neuron survival 5 standard error of the mean (SEM) from n = 2–4 separate 
experiments (100–200 total neurons per treatment).
mRNA analysis by quantitative Real-time PCR using TaqMan low density arrays 
RNA preparation was performed with RNeasy Lipid Tissue Mini Kit (QIAGEN). RNA was quantified with 
microspectrophotometry by Nanodrop. RNA Quality Indicator (RQI) was measured with Bio-Rad Experion. RNA 
samples with RQI values above 5.0 are generally considered to be suitable for qRT-PCR.15–17 Average RQI was 7.28 







± 1.55 (mean, standard deviation [SD]), demonstrating high quality of isolated RNA. cDNA was synthesized with 
the High-Capacity cDNA Archive Kit (Applied Biosystems). mRNA levels were quantified by TaqMan low-density 
arrays (Applied Biosystems). For each gene, every sample was run in triplicate on the same array. To measure 
the quantity of a given RNA species, we monitored the threshold cycles (Ct) by the Applied Biosystems 7900HT 
Fast Real-Time PCR System. mRNA levels were calculated by relative quantification by using a normalization 
factor (geometric mean of four reference genes: beta-actin, ACTB; ribosomal large P0, RPLP0; polymerase (RNA) 
II [DNA-directed) polypeptide A, POLR2A; and ubiquitin C, UBC) and the qBASE program for internal and external 
calibration and for easy care of large RT-PCR data sets.
Immunohistochemistry
The cerebellar tissue was obtained from an SCA23 patient with a p.R138S6 and from a control subject via 
a rapid autopsy protocol with a warm postmortem interval of 4 or 5 hr (Table S4). The control subject was 
without cerebellar ataxia or other neurological disorders. Fresh-frozen cerebellar tissue samples were fixed 
in 4% phosphate-buffered paraformaldehyde, frozen, cut in 5 mm thick sections, and processed as described 
previously, with modifications.18,19 Briefly, the sections were incubated with PBS/0.2% triton and 0.1 M sodium 
citrate buffer (pH = 4.5) exposed to microwave irradiation and incubated with rabbit polyclonal anti-PDYN, Dyn A, 
or Dyn B antibodies (IgG fraction)12,19 or mouse monoclonal anti-SLC1A6 (alias EAAT4; MIM #600637) antibodies 
(Abcam). After incubation with peroxidase-labeled secondary antibodies (Santa Cruz Biotechnology), the staining 
was visualized by 3-amino-9-ethylcarbazole (AEC; Sigma-Aldrich) and counterstained with hematoxylin. The 
sections were analyzed with a bright-field microscope (Leica; DM3000).
Cell culture, transfection, and plasmids
 RINm-5F cells were grown in RPMI-1960 (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) in a 
37°C incubator with 5% CO2. Transfections were carried out with Lipofectamine (Invitrogen). pCMV4 empty plas-
mid was used for mock transfection. The wild-type pCMV4-fl-h-PDYN construct was described previously.19 The 
p.R138S, p.L211S, p.R212W, and p.R215C mutations were introduced into the PDYN cDNA with the Quickchange 
II Site-Directed Mutagenesis kit (Stratagene). The mutagenesis primers that were used to generate the mutant 
PDYN constructs are listed in Table S8. Sequencing was performed to verify the presence of the mutations and to 
check PDYN cDNA sequence.
Western blot analysis 
To enrich PDYN in extracts of the cerebellum characterized by low PDYN expression levels, we extracted the tis-
sues with 1 M acetic acid followed by SEP-PAC C18 reverse-phase chromatography or with Buffer C, as described 
before.12,19 Both procedures gave essentially the same results. Tissues for analysis of EAAT4 and calbindin (MIM 
#114050) and cell pellets for analysis of PDYN were extracted with 4% SDS buffer supplemented with DTT and 
Compete Inhibitor Cocktail (Roche), as described previously.20 Protein concentration was determined with DC pro-
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tein assay (Bio-Rad Laboratory). Proteins were resolved by SDS-PAGE on 10% Tricine gels, transferred onto nitro-
cellulose membranes (Schleicher and Schuell), and stained with MemCode reversible Protein Stain Kit (Pierce), 
as described previously.12,19 Membranes blocked with 5% nonfat dry milk were probed with anti-PDYN, anti-Dyn 
B, and anti-EAAT4 antibodies (Santa Cruz Biotechnology) or anti-calbindin antibody (Sigma-Aldrich) and were 
incubated with peroxidase-conjugated anti-rabbit, anti-mouse (Bio-Rad Laboratory), and anti-goat secondary an-
tibodies (Sigma-Aldrich). Densitometric analysis was performed with Image Gauge V3.12 (Fujifilm). Protein levels 
were calculated as the ratio of optical density (OD) of protein immunoreactivity to MemCode OD. Measurements 
of all proteins were performed within the linear range of detection. The correlation coefficient between protein 
immunoreactivity measured as OD and protein load measured as MemCode OD was 0.98 or higher.
Sample preparation for mass spectrometry analysis
 Powdered brain tissue samples were sonicated in the extraction buffer (6Murea, 2Mthiourea, and 1% octyl-b-D-
glucopyranoside [all Sigma-Aldrich] in 10 mM Tris-HCl) and further exchanged to 50 mM NH4HCO3 (Sigma-Aldrich) 
with PD SpinTrap G-25 columns (GE Healthcare). The protein was measured via the microBCA assay (Pierce). The 
samples were processed via a modification of protocol described elsewhere.21 The samples were reduced with 
15 mM 1,4-dithiothreitol (Roche), alkylated by incubation with 30 mM iodoacetamide (Sigma-Aldrich), and then 
processed on the 10 kDa cutoff filters (Millipore). Stepwise washing with 2% acetonitrile (Sigma-Aldrich) in 50 
mM NH4HCO3, 50% acetonitrile in 50 mM NH4HCO3 and 50 mM NH4HCO3 was followed by incubation with trypsin 
(1 μg per 50 μg protein; Roche) for 20 hr at 37°C. Peptides were eluted from the filters with 0.1% formic acid 
(Sigma-Aldrich) and were dried on SpeedVac. The aliquots of each sample containing the same amount of protein 
(3 μg) were prepared by dilution in 0.1% trifluoroacetic acid.
High-performance liquid chromatography/tandem mass spectrometry and key-node analysis
Experiments were performed on an LTQ-FT Ultra mass spectrometer (ThermoFisher Scientific) used online with 
an Agilent 1100 nanoflow high-performance liquid chromatography and a nano electrospray ion source (Proxeon 
Biosystems). A 15 cm C18 nanocolumn (75 μM inner diameter, 375 μm outer diameter) was used for peptide 
elution at a flow of 200 nL/min with a gradient from 2% to 50% acetonitrile for 100 min. Mass spectrometric 
analysis was performed by recording of high-resolution (100,000) survey mass spectrum in Fourier transform 
mass spectrometry and consecutive low-resolution, collision-induced dissociation of up to five of the most 
abundant ions in the LTQ. Acquired data (.RAW files) were converted to the Mascot search engine (version 
2.1.3, Matrix Science). Monoisotopic mass tolerance was set to 10 ppm, and for fragment ions it was ±0.9 Da. 
A protein was considered to be positively matched by using the stringent threshold of 27 for the Mowse score 
for all its peptides (p ≤ 0.05). The Mascot htm output and .RAW files of each sample were used as input files for 
quantification with an in-housewritten program package (C++). The area of the chromatographic peak was taken 
as the peptide abundance. Sum of the abundances of all “bold red” nonidentical peptides was attributed to the 
protein expression level (≥1 peptide per protein). Protein expression data are shown in Table S4. Protein IDs and 







protein abundances were loaded into ExPlain 2.4.1 tool (BIOBASE GmbH), where protein IDs were substituted by 
respective gene IDs. Then we searched upstream for the key nodes most relevant for the input gene products.22 
Key nodes are signaling molecules found on pathway intersections in the upstream vicinity of the genes from 
the input list. Each key node found was given a score reflecting its connectivity, i.e., how many input-list genes 
are reached and the proximities to those genes. The score calculation also included the abundances of the 
downstream proteins. Changes in the key node scores thus reflected the changes in the activation levels of the 
corresponding signaling networks.22
Results
We previously reported the mapping of the SCA23 locus to chromosomal region 20p12.3-p13.6 After excluding 32 
prioritized genes via sequencing,7 we identified a c.414G>T (p.R138S) transition resulting in a missense mutation 
in exon 4 of PDYN in all affected family members (n = 10), but not in unaffected relatives (n = 4) of the originally re-
ported SCA23 family (Fig. 1A and 1B). To confirm a possible role of PDYN in cerebellar degeneration, we screened 
the coding region of PDYN in a panel of Dutch ataxia patients (n = 1100). The panel consists of ataxia patients 
who applied for regular DNA diagnostics and had no mutations in seven known SCA genes (SCA1–3, SCA6, SCA7, 
SCA12, and SCA14). Only in 10% of these cases was a clear familial history of the disease described (8% dominant 
and 2% recessive), and 90% seemed apparently sporadic. 
We identified three additional missense mutations, c.632T>C (p.L211S), c.634C>T (p.R212W), and 
c.643C>T (p.R215C), among the 1100 screened Dutch ataxia patients (one familial case with dominant inheri-
tance of the disease and two apparently sporadic cases with an unknown family history; Fig. 1C–1E).We were 
able to show segregation of the p.R215C substitution in two affected siblings (patients II-1 and II-2 in Fig. 1E). For 
the other two families (Fig. 1C and 1D), no additional family members were available. The man with the p.L211S 
mutation (Fig. 1C, patient II:3) suffered from progressive gait and upper limb ataxia, oculomotor abnormalities, 
distal sensory neuropathy, and pyramidal signs of the legs. In addition, subtle parkinsonian features were noted. 
The disease symptoms started at age 73. The family history was incomplete, and ataxia was not mentioned. The 
woman with the p.R212W mutation (Fig. 1D, patient II:3) displayed a slowly progressive cerebellar ataxia of the 
legs and arms, as well as a progressive mixed axonal polyneuropathy. The onset of the symptoms started at age 
54, and the family history was negative for ataxia. An MRI scan of the brain, performed 4 months prior to death, 
revealed generalized cerebral cortical and subcortical atrophy, agenesis of the corpus callosum, and prominent 
atrophy of the cerebellar vermis, the pons, and the inferior olivary nucleus. The woman carrying the p.R215C 
mutation (Fig. 1E, patient II:1) was initially diagnosed with an essential tremor of head and postural arms. From 
about age 50 onward, memory and word finding deteriorated. A neurological exam at age 53 revealed slowed 
mental processes, slight dysarthria, mild ataxia of upper and lower limbs, postural arm tremor and a tremor of the 
head, proximal paresis of the legs with mild signs of sensory neuropathy, and a bilateral pes cavus. Her brother 
(Fig. 1E, patient II:2) was already considered clumsy at school age. Around age 54, mild gait impairment and slow-
ing were noted. The neurological examination at age 56 revealed head tremor, fixation instability at neutral gaze, 
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Fig. 1. PDYN Mutations Causing SCA23 
(A) PDYN exons 3 and 4 encode PDYN, which gives rise to the opioid peptides a-neoendorphin (a-NE), dynorphin 
A (Dyn A), dynorphin B (Dyn B), and big dynorphin (Big Dyn), which encompasses Dyn A and Dyn B. DNA sequence analysis 
identified four missense mutations (c.414G>T, c.632T>C, c.634C>T, and c.643C>T) in SCA23 subjects. (B) Sequence elec-
tropherogram and pedigree of original Dutch SCA23 family. The c.414G>T; p.R138S mutation was identified in 10 affected 
individuals, but not in the four unaffected family members. (C–E) Sequence electropherograms and pedigrees of the patients 
with Dyn A mutations: c.632T>C; p.L211S, c.634C>T; p.R212W, and c.643C>T; p.R215C. At the moment, no DNA material of 
additional family members was available for mutation screening in the p.L211S and p.R212W families. The p.R215C mutation 
was identified in two affected siblings. Closed symbols denote affected; open symbols denote unaffected; ? denotes disease 
status unknown; / denotes deceased. (F and G) Conservation of the mutated amino acids. Arginine 138 is human specific; 
other species analyzed have Glycine 138. Leucine 211, Arginine 212, and Arginine 215 are conserved across species. (H) 
Localization of mutations in Dyn A. 







very mild dysarthria, action tremor of the hands, and a subtle ataxia of the hands and arms. The mother of 
these two patients (not examined by us) suffered from mild late-onset ataxia and head and limb tremor since 
primary school, and her mother likely suffered from dementia. The clinical details are summarized in Table S1. 
All four mutations were absent in 1000 Dutch blood bank control chromosomes. In addition, three known SNPs 
(rs77155664, rs45469293, and rs6045819) were identified in exon 4, and no difference in their distribution was 
observed between ataxia cases and controls (data not shown). 
Of the four altered amino acids, Arg138 is confined to humans (Fig. 1F), whereas Lys211, Arg212, and Arg215 
were conserved across the vertebrate species examined (Fig. 1G and 1H). In silico analysis with four different bio-
informatics programs (polyPhen, SIFT, SWAP, and Align GVD) predicted three (p.L211S, p.R212W, and p.R215C) 
of the four missense mutations to have damaging effects on protein structure and function, whereas the p.R138S 
mutation was predicted to be benign (Table S2). In addition, the p.R138S and p.L211S mutations were also pre-
dicted to increase PDYN phosphorylation levels by generating potential phosphorylation sites (Table S3). 
Proprotein convertases 1 and 2 cleave PDYN at both paired and single basic residues, resulting in de-
fined sets of neuropeptides.8,23 The human-specific Arg138 is located in the nonopioid domain of PDYN and may 
affect N-terminal trimming of the 8 kDa and 10 kDa PDYN processing intermediates. The p.L211S, p.R212W, and 
p.R215C mutations in PDYN substitute amino acid residues Leu5, Arg6, and Arg9 to Ser5, Trp6, and Cys9, respectively, 
in the 17 amino acid Dyn A sequence (Fig. 1H). These changes may abrogate Dyn A conversion to Dyn A(1–8), 
Leu-enkephalin-Arg, or Leu-enkephalin; Dyn A is cleaved between the 8th and 9th, 6th and 7th, and 5th and 6th 
amino acid residues, and both Arg6 and Arg9 are critical for Dyn A processing.23,24
To examine whether the mutations affect PDYN synthesis and processing, we transfected the cDNA wild 
type (WT) or mutant PDYN cDNA into rat insulinoma RINm-5F cells. Protein and peptide products were analyzed 
by immunoblotting with anti-PDYN and Dyn B antibodies and by RIA for Dyn A, Dyn B, and the dynorphin conver-
sion product Leu-enkephalin-Arg (Fig. 2A–2D).19 RINm-5F cells do not produce endogenous PDYN and efficiently 
process ectopic PDYN into opioid peptides.19 Analysis of cells transfected with PDYN plasmids demonstrated that 
WT and all mutants produced the 28 kDa PDYNs at similar levels (Fig. 2A). However, the efficiency of processing 
of these proteins to opioid peptides was dramatically affected by the mutations (Fig. 2B–2D). The levels of Dyn 
A produced by PDYN p.L211S and p.R212W were 10- to 18-fold elevated compared to WT, whereas the levels of 
Dyn B produced by PDYN p.R138S, p.R212W, and p.R215C, as well as the levels of Leu-enkephalin-Arg produced 
by PDYN p.R138S and p.R215C, were decreased approximately 2-fold. Thus, all three Dyn A mutants resulted in a 
2- to 35-fold higher Dyn A production compared to Dyn B.
Previous studies have shown that Dyn A can induce toxicity and neuronal cell death.25–27 To examine 
whether mutant Dyn A would be more neurotoxic, we analyzed effects of WT and mutant Dyn A peptides on the 
viability of striatal neurons via environmentally controlled timelapse imaging. Although mild toxic effects were 
induced by WT Dyn A, we observed marked increases in neuronal losses following exposure to p.R212W and 
p.R215C mutant Dyn A peptides compared to vehicle-treated controls or the WT peptide after 60 hr of exposure 
(Fig. 2E and 2F). No significant differences in cell viability were observed between control and the p.L211S Dyn 
JJezierska.indd   72 8/16/2013   9:52:02 AM
73
SCA23 mutation identification
A-treated neurons. Thus, two mutations in Dyn A may enhance the intrinsic neurotoxicity of WT Dyn A.
Fig. 2. SCA23 Mutations Af-
fect PDYN Processing and 
Enhance Dyn A Toxicity
(A) Expression and 
processing of WTand 
mutant PDYNs in RINm-5F 
cells. Immunoblotting was 
performed with anti-PDYN 
(against C-terminal fragment; 
top) or anti-Dyn B (bottom) 
antibodies. Synthetic big 
dynorphin (a 32 amino acid 
peptide consisting of Dyn 
A and Dyn B) and Dyn B 
were loaded on the same 
gel as peptide markers and 
produced the 4 and 2 kDa 
bands identified by anti-Dyn 
B antibodies (data not shown; 
however, their positions are 
shown on the right). The 10, 
4, and 2 kDa PDYN processing 
products were detected in 
RINm-5F cells transfected 
with PDYN expression 
plasmids. (B–D) Peptide 
levels in cells expressing WT 
PDYN were taken as 100%. 
One-way ANOVA followed by 
Dunnett’s multiple comparison test; **p < 0.01, ***p < 0.001; mutant versus wild-type. Data are shown as means ± SEM. 
(B) RINm-5F cells expressing PDYN p.L211S and p.R212W showed significant elevation in levels of Dyn A compared to cells 
expressing WT PDYN (ANOVA; p < 0.001). The Dyn A RIA was not hindered by the mutations because they did not affect 
the binding of the mutant peptides to the Dyn A antibodies. The antibodies were generated against the C-terminal Dyn A 
fragment.12,19 (C) Dyn B levels showed significant decrease in cells expressing PDYN p.R138S, p.R212W, and p.R215C (ANOVA; 
p < 0.001). (D) PDYN p.R138S and p.R215C produced lower levels of Leu-enkephalin-Arg compared to WT PDYN (ANOVA; p < 
0.005). Leu-enkephalin-Arg peptides derived from PDYN p.L211S and p.R212W were not analyzed by RIA because these two 
mutations are located within the Leu-enkephalin-Arg antigenic epitope and may hinder the binding of these mutant peptides 
to anti-Leu-enkephalin-Arg antibodies.12,19 (E and F) Time-lapse imaging of striatial neurons treated with Dyn A peptides (100 
nM) revealed marked loss of neuronal viability induced by Dyn A p.R212W and Dyn A p.R215C peptides compared to vehicle-
treated control or WT Dyn A (one-way repeated-measures ANOVA; p < 0.005). Data are represented as the means ± SEM. (F) 
Neuronal death at 60 hr induced by mutant Dyn A peptides. The level of neuronal death as a result of excess WT Dyn A was 
considered as 1. Bonferroni’s multiple correction test, *p < 0.05. Data are represented as the means ± SD. 







Fig. 3. Impact of the PDYN p.R138S Mutation on Expression of the Opioid Genes and PDYN Levels in Human Brain
(A) Levels of opioid mRNA in the nucleus accumbens (NAc), prefrontal cortex (PFC), and cerebellum (Cb) were quantified 
by TaqMan lowdensity arrays in postmortem samples from three control subjects. PDYN expression was substantially lower 
in Cb compared to NAc and PFC, the two brain areas with high and moderate gene expression. In the Cb, PENK showed 
high expression levels compared to the PFC but lower expression levels compared to the NAc. Both OPRK1 and OPRM1 are 
expressed in Cb, NAc, and PFC at similar levels, whereas OPRD1 expression was not detectable in the Cb. Data bars represent 
the means ± SEM. (B) Comparison of mRNA levels in the Cb between three control and SCA23 cerebella. The data is shown 
as the ratio of levels in SCA23 to those in controls. Mean levels in controls were set to 1, as indicated by the dashed line. 
PENK, OPRK1, and OPRM1 expression was 2- and 3.5-fold increased, whereas PDYN expression was slightly decreased in the 
SCA23 Cb compared to controls. (C) Analysis of PDYN in the human NAc, PFC, and Cb by immunoblot analysis. Tissue samples 
were pooled from three control subjects and purified on SEP-PAC reverse-phase columns prior to SDS-PAGE. PDYN levels in 
cerebellum are intermediate between those in NAc and PFC. (D) No differences were evident between PDYN levels in control 
(C1-3) and SCA23 cerebella. 
The bias, based almost exclusively on data in mature rodents, is that the endogenous opioid peptides 
and their receptors are not produced and do not regulate neuronal activity in the cerebellum.28 To gain insight 
into pathophysiological mechanisms of PDYN actions, we characterized these systems in three controls and SCA23 
cerebella. Only a single brain of a SCA23 PDYN p.R138S subject was available for postmortem analysis.6 Our re-
sults showed that PDYN was expressed in the human cerebellum, although at low levels compared to the nucleus 
accumbens (NAc) and prefrontal cortex (PFC; Fig. 3A). In contrast to animals, the κ- and μ- (OPRM1; MIM #600018) 
opioid receptors and proenkephalin (PENK; MIM #131330) were expressed in human cerebellum at levels that 
were comparable with those in the NAc and PFC, whereas the δ-opioid receptor (OPRD1) was not expressed (Fig. 
3A).29 In SCA23 tissue, cerebellar OPRK1, OPRM1, and PENK were 2- to 3.5-fold upregulated, whereas the level of 
PDYN mRNA was slightly lower than in controls (Fig. 3B). In contrast to mRNA, cerebellar PDYN levels were inter-
mediate between those in PFC and NAc and were similar in controls and SCA23 (Fig. 3C and 3D). The high protein 
levels in relation to PDYN expression in cerebellum in comparison to NAc and PFC suggest slower processing of 
PDYN to mature peptides in this area.
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To determine in which cell types PDYN, Dyn A, and Dyn B are localized in cerebellum, we performed 
immunohistochemistry. This analysis demonstrated that PDYN and its major peptide products are mainly located 
in the Purkinje cells in both control and SCA23 cerebellum (Fig. 4A). The SCA23 cerebellum showed significant 
loss of Purkinje cells and atrophic dendrites, as was described previously.6 No marked differences in the localiza-
tion and generation of PDYN and the Dyn A and B peptides were observed between control and SCA23 cerebella.
Fig. 4. Localization of PDYN and Dynorphins, and Analysis of the Purkinje Cell-Specific Excitatory Amino Acid Transporter, in 
SCA23 Cerebellum
(A) Immunohistochemistry of cerebellum from the PDYN p.R138S subject and a control individual without neurological dis-
ease. Immunoperoxidase labeling with anti-Dyn A, anti-Dyn B, or anti-PDYN antibodies was visualized by 3-Amino-9-ethyl-
carbazole as the chromogen and was counterstained with hematoxylin. (B) Immunoblot analysis of excitatory aminoacid 
transporter (EAAT4) and calbindin, both Purkinje cell markers. High molecular weight species were detected in the SCA23 
cerebellum (*). (C) Immunoperoxidase labeling of EAAT4 in SCA23 and control cerebellum. Scale bars represent 30 mm (A 
and C).
Dyn A has been shown to induce neurodegeneration through a nonopioid mechanism that may involve 
glutamate receptors and acid-sensing ion channels.9,30 To unravel cellular pathways affected by PDYN p.R138S, 
we performed shotgun proteomic analysis of control and SCA23 cerebella. Proteins involved in cell adhesion, 
synaptogenesis, secretory pathways, and signal transduction were up- or downregulated in SCA23 (Fig. S1 and 
Table S4). Key node molecules in cellular pathways affected in SCA23 cerebellum identified by pathway analysis 
include enzymes regulating glutamate cycling and proteins involved in neuroprotection, apoptosis, and signal 
transduction (Table S5). The solute carrier, SLC1A6 (alias EAAT4; excitatory amino acid transporter), a marker 
of Purkinje cells that has been previously found to be downregulated or aggregated in SCA1 and SCA5,31,32 was 
decreased in the proteome of SCA23 PDYN p.R138S (Table S4). Immunoblotting confirmed a reduction in the 
65 kDa EAAT4 in the SCA23 cerebellum by 3-fold (Fig. 4B). About 70% of EAAT4 was accumulated as aggregated 
or polyubiquitinated protein in SCA23 (Fig. 4C). EAAT4 showed strong staining in perikarya and dendrites of 







the Purkinje cells in control and SCA23 cerebella (Fig. 4C). Calbindin is another protein marker of the Purkinje 
cells and was also found to be downregulated in SCA1 and SCA5 cerebella.31,32 Although the proteomic analysis 
showed only marginal 1.6-fold decrease in calbindin levels in SCA23, further immunoblot analysis demonstrated 
substantial 7-fold downregulation of this protein in the pathological cerebellum (Fig. 4B).
Discussion
We have shown that missense mutations in PDYN cause a relatively slowly progressive, cerebellar ataxia with 
some distinctive features such as distal sensory neuropathy and pyramidal signs, proximal paresis of the legs, and 
tremors of the head and upper limbs. SCA23 was assumed to be a relatively pure cerebellar ataxia. However, our 
findings showed that the clinical phenotype of SCA23 can be highly variable and that no common starting symp-
tom was present in our four different SCA23 families. Mutations in PDYN are identified here in a small subset of 
Dutch ataxia families (4 of 1100), indicating that SCA23 seems an infrequent SCA type (± 0.5%) in the Netherlands 
and suggesting further genetic heterogeneity. However, the syndromes present in our ataxia panel are phenotypi-
cally not well defined, which is reflected in the low success rate (~20%) to identify mutations in known SCA genes 
via diagnostic screening. This may explain why we have identified only 4 ataxia families exhibiting PDYN mutations 
in 1100 cases. Although we can only speculate about the frequency of SCA23 in a phenotypically better-defined 
cohort, we assume that SCA23 is a rare cause of ataxia and will not account for more than ~0.5% of the Dutch 
ataxia cases. To exclude the possibility that the PDYN p.R138S mutation would be a random sequence variation 
that cosegregates with the true disease mutation within the linkage interval, we sequenced 1000 unrelated blood 
bank control chromosomes in which this variation was not observed, and we did not identify any other additional 
coding sequence variation in 31 previously sequenced candidate genes that perfectly cosegregated with the dis-
ease phenotype in this family.7 In two families (PDYN p.R138S and p.R215C), we could confirm that the mutations 
segregated with the disease. 
The in silico analysis predicts damaging effects of three Dyn A mutations (p.L211S, p.R212W, and 
p.R215C) on protein structure and possibly function, whereas the p.R138S mutation was assessed as benign. The 
negative prediction may be due to the insufficient sensitivity of the programs used in analysis, because they are 
based on similar algorithms and may have the same limitation. The analysis may also be hindered by the absence 
of any structural information for this class of proteins. Formation of an additional phosphorylation site in PDYN 
by the p.R138S mutation may affect processing or trafficking of mutant protein, thus representing an alternative 
mechanism of the pathogenic activity of PDYN. 
Model cell experiments provided evidence that the PDYN mutations p.L211S (Leu5) and p.R212W (Arg6) 
result in enhanced Dyn A levels. This may be due to slow conversion of mutant Dyn A to short enkephalins. Indeed, 
conversion of Dyn A to short fragments generally occurs at di- and monobasic amino acid residues, including Leu5 
and Arg9, that are substituted by Ser and Cys in mutant PDYN.23 In addition, analysis of the effect of mutant Dyn 
A peptides on striatal neurons demonstrated high toxicity of Dyn A p.R212W and Dyn A p.R215C. The elevated 
neurotoxicity of Dyn A mutants compared to WT Dyn A suggests a dominant-negative effect of these mutations 
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rather than a loss of function. The increased stabilization of the mutant Dyn A peptides may not be the only factor 
underlying neurotoxicity, because Dyn A p.L211S, which is apparently resistant for conversion to a short fragment, 
does not induce any toxic response.
Immunohistochemical experiments revealed that PDYN, Dyn A, and Dyn B are mainly located in the 
Purkinje cells in both control and SCA23 cerebella. The absence of significant differences in PDYN and dynorphin 
localization and PDYN levels between control and PDYN p.R138S cerebella, observed by both the cell staining and 
immunoblotting, further argues against a possible loss of function and suggests that PDYN is strongly elevated in 
the Purkinje cells remaining in SCA23.
Further analysis of the endogenous opioid systems and the proteome in cerebellar autopsy tissue of 
the PDYN p.R138S subject revealed marked alterations in expression of crucial components of the opioid and glu-
tamate systems. These alterations were evident for OPRM1, OPRK1, enzymes regulating glutamate cycling, and the 
excitatory amino acid transporter, EAAT4. These findings are consistent with previous observations demonstrating 
alterations in expression and localization of EAAT4 in SCA1 and SCA5 cerebella and provide additional evidence 
for the hypothesis that the dysfunction of glutamate signaling is a common downstream mechanism for SCA.31,32
Two putative mechanisms may be envisaged to explain the pathogenic effects of mutant PDYNs. First, 
modifications of nonopioid neurodegenerative and/or opioid activities of Dyn A or its longer pathological form, 
such as the 32 amino acid big dynorphin, may lead to alterations in glutamate signaling and excitotoxicity.9,26,30,33 
Several lines of evidence support this notion. Thus, Dyn A, but not other dynorphins, elicits various pathological 
effects, including neurological dysfunction and cell death. Intracerebroventricular injection of this peptide induces 
abnormal motor effects such as wild running, barrel rolling, and ataxia in mice, whereas intrathecal infusion pro-
duces allodynia, paralysis, and neuronal loss.9,34–39 Consistently, increased production of Dyn A following trauma 
contributes to spinal cord injury and neuropathic pain.9,37–39 Dyn A is also upregulated in aging rodent brain, 
contributing to age-related impairment of spatial learning and memory.40 In the prefrontal cortex of Alzheimer 
disease patients, the elevated Dyn A levels correlate with neuritic plaque density.41 Second, synthesis of mutant 
PDYNs may affect secretory pathways, inducing endoplasmic reticulum stress and impairing maturation and traf-
ficking of glutamate transporters and other signaling proteins. Actions of mutant PDYNs accumulating over the 
years may ultimately lead to Purkinje cell degeneration. The p.R138S mutation located in the nonopioid PDYN 
domain supports the second hypothesis.
Neuropeptides are a large group of signaling molecules that regulate a wide variety of physiological and 
pathological processes.9,10 A mutation that causes early-onset obesity and adrenal insufficiency had been found 
in proopiomelanocortin, the protein precursor to adrenocorticotropin, α-melanocyte-stimulating hormone, and 
β-endorphin.42 Our findings demonstrate that mutations in a neuropeptide gene may cause an inherited neuro-
degenerative disorder. Neuropeptides usually exert their actions as ligands of G protein-coupled receptors. In the 
case of Dyn A, although physiological effects are largely mediated through the κ-opioid receptors, pathological 
effects may be generally mediated through direct action of this peptide on the plasma membrane, possibly by 
inducing pore formation and increased calcium influx in neurons.9,43–45 Remarkably, three mutations identified in 







SCA23 families alter the amino acid sequence of Dyn A in a domain associated with non-receptor-mediated, neu-
rodegenerative actions. Two peptides with these mutations cause significant toxicity in cultured neurons, raising 
the possibility that some SCA23 degenerative processes are due to direct effects of mutant peptides on neurons. 
We may speculate that mutations in other neuropeptide precursor genes are involved in the etiology of cerebellar 
ataxia and that their identification will provide further insight into mechanisms of synaptic neurotransmission and 
neurodegeneration.
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Abstract 
We have recently identified missense mutations in prodynorphin (PDYN), the precursor to dynorphin opioid 
peptides, to cause spinocerebellar ataxia (SCA23) in Dutch ataxia cases. Here, we screened PDYN for mutations 
in 371 cerebellar ataxia cases, with a positive family history and mostly of French origin. Sequencing revealed 
three novel putative missense mutations and one heterozygous two-base pair deletion in four independent SCA 
patients. These variants were absent in 400 matched controls and are located in the highly conserved dynorphin 
domain. To resolve the pathogenicity of the heterozygous variants, we assessed the peptide production of the 
mutant PDYN proteins. Two missense mutations raised dynorphin peptide levels, the two-base pair deletion 
terminated dynorphin synthesis, and one missense mutation did not affect PDYN processing. Given the outcome 
of our functional analysis, we may have identified at least two novel PDYN mutations in a French and Moroccan 
SCA patient. Our data corroborates recent work that also showed that PDYN mutations only account for a small 
percentage (~0.1%) of the European SCA cases. 




The spinocerebellar ataxias (SCA) are a large heterogeneous group of slowly progressive neurodegenerative 
disorders. All SCAs are characterized by selective neuronal loss in the cerebellum and/or the pons and patients 
suffer from motor coordination impairment, eye movement disorders, and dysarthria, but can exhibit as well 
several additional symptoms including pyramidal signs, peripheral neuropathy or cognitive impairment [1]. So 
far, 23 SCA disease genes have been reported [1-7]. Eight SCAs are caused by coding and non-coding CAG/CTG 
repeat expansions and three by extended intronic penta- and hexanucleotide repeats. The number of SCA types 
caused by conventional mutations including deletions, missense or frame-shift mutations is growing steadily, as 
yet twelve SCA types fall into this category.
Recently, missense mutations were identified in prodynorphin (PDYN) as causing SCA23 in Dutch ataxia 
families [2]. PDYN is the precursor protein for the opioid peptides α-neoendorphin, dynorphin A (Dyn A), and 
dynorphin B (Dyn B), ligands for the κ-opioid receptor [8]. Three of the four mutations were located in Dyn A, a 
peptide with both opioid and non-opioid neurodegenerative activities, and one missense mutation in the non-
opioid domain of PDYN. Two mutations resulted in excessive generation of Dyn A and two resulted in enhanced 
intrinsic toxicity of the peptide [2]. To date, others reported one additional putative SCA23 mutation, without any 
functional support, in large UK, German and USA cohorts [9-11]. 
 Here, we examined the prevalence of SCA23 in a large cohort of mostly French cerebellar ataxia cases 
with a positive family history, to define the range and pathogenicity of PDYN mutations and extend the clinical 
phenotype of SCA23 in Central Europe. 
Subjects and Methods
Patients
As part of the SPATAX (SPastic paraparesis and/or ATAXia) network, we recruited 371 unrelated index cases with 
progressive cerebellar ataxia and a dominant family history. Most patients originated from France (n = 327) 
or from other countries in Europe (n = 23), North-Africa/Middle-East (n = 13), French West-Indies (n = 6) and 
China (n = 2). Pathogenic expansions were excluded for SCA1, 2, 3, 6, 7, 17 and DRPLA. Informed consent of all 
participants was obtained with the approval of the Comité Consultatif pour la Protection des Personnes et la 
Recherche Biomedicale Paris-Necker (approval No. 03-12-07) and all persons gave their informed consent prior 
to their inclusion in the study. The controls are spouses of affected family members, of whom mostly no clinical 
data is available.  DNA was stored in the DNA and Cell Bank at the Pitié-Salpêtrière university hospital in Paris.
PDYN sequencing
Sequencing of the coding region and corresponding exon-intron boundaries of PDYN (NM_024411) was performed 
as described before [2]. The presence of the identified variants was assessed in 300 French and 100 North-African 
controls using small amplicon HiResolution melting (LightScanner; Bioke) using the following primers:







delGT-For 3’ACCTGTACAAACGCTATGG’5, delGT-Rev 3’CATAGCGCTTCTGGTTGTC‘5, G227D-
For: 3’CAAGCTCAAGTGGGACAAC‘5, G227D-Rev: 3’CCAGAGTAAGCATTCGGAT‘5, R206H/C-For: 
3’GACCTGTACAAACGCTATG’5 and R206H/C-Rev: 3’CGCTTCTGGTTGTCCCAC’5. Aberrant melting curves were 
analyzed using Sanger sequencing.
Biological molecular analysis
The pCMV4-PDYN plasmid was described previously [12]. The mutations were introduced in the cDNA of PDYN 
using site-directed mutagenesis. RINm-5F cells that may process PDYN to mature opioid peptides were transiently 
transfected with plasmids using PEI reagent (Sigma). Western blot and RIA procedures were described elsewhere 
[13].
Results 
We identified three novel heterozygous missense variants c.617G>A (p.R206H), c.616C>T (p.R206C), and 
c.680G>A (p.G227D), and one heterozygous two-base pair deletion c.658-659delGT (p.W220GfsX33) in four 
independent index cases (Fig. 1A). All variants were not detected in 400 ethnic matched controls and were not 
present in the Exome Variant Server, dbSNP and 1,000 genomes databases. The three missense variations affect 
100% conserved aminoacids in all vertebrates in and around the two dynorphin peptides, Dyn A and B (data not 
shown). Additionally, all variants were in silico predicted to affect protein function using the programs PolyPhen, 
AlignGVGD, and Sift (data not shown). In addition, the two basepair deletion causes a frame-shift that introduces 
a premature stop codon, affecting the last 4 amino acids of Dyn A and leads to total loss of the Dyn B sequence. 
All variants were predicted not to affect splicing (data not shown). We did not screen PDYN for large deletions or 
duplications. 
Co-segregation of the c.616C>T, c.680G>A, and c.658-659delGT variations with the disease phenotype was not 
tested because no family members were available for analysis. Surprisingly, mutational analysis did not detect 
the c.617G>A mutation in either mother or brother of the affected carrier (AAD-297), although they were also 
affected by frequent falls at older ages, mild to moderate gait problems, and mild cerebellar atrophy. Additionally, 
their clinical presentations differed from the index case by the absence of deafness and the later occurrence of 
the cerebellar deficit as well as the presence of normal reflexes. The main clinical features of the four index cases 
are shown in Table 1. The age at onset ranged from 15 to 54 years. The main presenting symptom was a slowly 
progressive cerebellar gait ataxia associated with a pyramidal syndrome in two patients; the first with spasticity in 
gait (c.616C>T, family AAD-745) and the second with bilateral extensor plantar reflexes (c.658-659delGT, family 
AAD-833). All patients had generalized increased reflexes. In addition, gait was impaired by altered sensory 
perception demonstrated by abolished vibration sense at ankles in two out of four patients. Brain MRIs showed 
cerebellar vermis and brainstem atrophy.
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Table 1 Clinical data from the four index cases and relatives with PDYN variations
Family AAD-745 AAD-297 AAD-833 AAD-751
Geographical 
origin Swiss France France Morocco
PDYN variation c.616C>T; p.R206C






Individual Index Index Brother Mother Index Index
Age at  
examination 
(years)
58 42 37 67 57 59
Age at onset 
(years) 50 15 28 45 45 54
Sign at onset 








ataxia Moderate Severe Mild Moderate Moderate Moderate
Dysarthria Spastic and cerebellar Cerebellar Cerebellar Cerebellar Cerebellar None
Nystagmus Multi-directionel Horizontal None None None None
Spastic gait None None None None None Moderate
Reflexes LL Increased Increased Normal Normal Increased Increased
Reflexes UL Increased Increased Normal Normal Increased Increased
Babinski sign n.a. None None None Extensor Indifferent
Wasting None None None None None LL prox. mild




Abolished None None None Abolished Normal
Urinary 
symptoms Incontinence None n.a. n.a. Urgency None
Additional 
features Tremor
Mild intellectual deficiency age 4,
abnormal behavior, psychiatric 
symptoms at age 28 attention and 























LL: lower limbs, UL: upper limbs, and n.a.: not assessed







 To test for functional effects of the mutations, we analyzed processing of mutant PDYN proteins into 
opioid peptides. All mutant PDYN proteins were expressed with the exception of p.W220GfsX33 PDYN in a model 
cell line transfected with respective PDYN plasmids (Fig. 1B and C). Dyn A (2.0-2.7 fold), Dyn B (1.2-1.6 fold) and 
Leu-enkephalin-Arg (5-6 fold) levels were markedly elevated in p.R206H and p.G227D PDYN expressing cells 
compared to those producing wild type protein. No significant changes were detected for p.R206C PDYN, and no 
peptides were cleaved from p.W220GfsX33 PDYN. The peptide levels were normalized to PDYN content (Fig. 1D).
Fig. 1 The localization and 
the effect of the newly 
identified PDYN variations 
on PDYN expression and 
processing in RINm-5F 
cells.
a) Schematic representation 
of the PDYN transcript 
and the location of the 
identified bariations. The 
functional neuropeptides, 
α-neoendorphin, dynorphin 
A (Dyn A), and dynorphin B 
(Dyn B) are indicated in grey. 
The mutations identified in 
this study are shown in bold. 
b) Western blot analysis 
with anti-PDYN C-terminus-
antibody identified the 
expected 28 kD protein in the 
WT, p.R206H, p.R206C, and 
p.G227D PDYN expressing 
RINm-5F cells. No protein was detected in the cells expressing p.W220GfsX33 PDYN. c) Quantification of Western blot data. 
PDYN immunoreactivity levels were normalized to total protein levels using Memcode staining. Shown are means ± SEM. 
obtained in three transfection experiments. WT protein levels were taken as 100%. d) Mature PDYN-derived opioid peptides 
Dyn A, Dyn B and Leu-enkephalin-Arg in RINm-5F cells transfected with WT and mutant PDYN plasmids measured using RIA. 
Peptide levels are normalized to the respective PDYN protein levels and are presented as % of those in WT PDYN expressing 
cells (Mean ± SEM.; n = 3 experiments). Post-hoc Dunnett’s Multiple Comparison Test demonstrated a significant increase 
in Dyn A (p < 0.05 for p.R206H, p < 0.01 for p.G227D), Dyn B (p < 0.01 for p.R206H), and Leu-enkephalin-Arg (p < 0.01 for 
p.R206H and p.G227D) peptide levels. Processing of p.R206C PDYN did not yield major changes and no detectable peptides 
were processed from p.W220GfsX33 PDYN.




We identified four novel heterozygous PDYN variations clustered in the Dyn A domain, c.617G>A (p.R206H), 
c.616C>T (p.R206C), and c.658-659delGT (p.W220GfsX33) or located in Dyn B, c.680G>A (p.G227D). None of 
these variations were detected in controls or any genetic database. The mutations affect amino acids that are 100% 
evolutionary conserved in all vertebrates. In silico analysis predicted the damaging effects of the mutations on the 
protein structure supporting the notion that they are pathogenic mutations rather than harmless polymorphisms. 
However, the two variants, c.617G>A and c.616C>T, that both modify the processing site just upstream of Dyn A at 
arginine 206 [14], might well be rare polymorphisms since the c.617G>A variation lacked co-segregation with the 
disease in family AAD-297, and the c.616C>T variant did not have any effect on processing of PDYN. Therefore, we 
cannot fully conclude that these variants exhibit pathogenic effects. On the other hand, the mother and brother 
may not suffer from the same disease as the index case from family AAD-297 and the c.616C>T variant might 
have functional consequences for the precursor for example by impairing trafficking rather than changing the 
peptide levels. The two other variants c.680G>A and c.658-659delGT showed either increased dynorphin and 
Leu-enkephalin-Arg levels or complete loss of Dyn A and Dyn B peptides. Since for both variants co-segregation 
could not be accessed, we can not completely exclude that those variants are rare polymorphisms. However, the 
c.658-659delGT variant leading to a truncated PDYN protein is very likely to be pathogenic and may be considered 
as disease-causing.
Notably, PDYN does not have a high degree of overall sequence variation, and a significant enrichment 
(Fisher’s exact test, p = 0.0238) was observed for rare variations in PDYN in ataxia cases (4 variants in 371 cases) 
compared to EVS controls (27 variants in 6,500 individuals). Up to date, 5 out of 9 rare PDYN variations are located 
in Big Dynorphin (Big Dyn) consisting of Dyn A and Dyn B, which is the most pathological neuropeptide compared 
to other dynorphin peptides [15-17]. Four of these 5 directly affect the Dyn A sequence, of which one also de-
stroys the Dyn B sequence and the fifth mutation changes the Dyn B sequence. The number of missense variations 
in Big Dyn including its arginine processing sites in this ataxia cohort (n = 371) or all sampled ataxia cases (n = 
2246) compared to 6,500 controls in the EVS database, is significantly higher than that found in the remaining 
coding region of PDYN (Fisher’s exact test, 2-tail; p = 0,0067 and p = 0,0025), which strongly suggests that the 
dynorphin/Big Dyn domain is a hotspot for rare variations and SCA23 mutations in ataxia cases. 
Altogether, our data suggest that SCA23 mutations could enhance the dynorphin opioid function, or 
may have dominant negative effects inducing non-opioid neurodegenerative actions. In addition, complete loss 
of dynorphin peptides due to the truncating c.658-659delGT mutation strongly indicates that loss of function or 
haploinsufficiency can also contribute to the pathogenesis of SCA23.
Our study confirms that SCA23 is a rare type in Caucasians and accounts for ~0.1% of the tested SCA 
cases. The clinical phenotype of the newly identified SCA23 patients showed progressive cerebellar ataxia associ-
ated with pyramidal features with a relatively late age of onset. The apparent heterogeneous disease etiology will 
not help to preselect SCA23 cases for diagnostic screening. Although, the contribution of SCA23 to the European 
ataxia population appears to be limited, we believe that it is advisable to include screening of PDYN in diagnostic 







settings, and to analyze co-segregation followed by functional analysis for verification of pathogenicity for the 
newly identified PDYN variants.
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Summary
Spinocerebellar ataxia type 23 (SCA23) is caused by mutations in PDYN, which encodes for the opioid neuropeptide 
precursor protein, prodynorphin. PDYN is processed into alfa-neoendorphin, Dynorphin (Dyn) A and B peptides, 
which participate in pain signalling and addiction via opioid-receptor mediated actions at physiological 
concentrations. However, the cerebellar non-opioid neurodegenerative function of PDYN or Dyn peptides is 
largely unknown. We have generated a conditional transgenic mouse model, expressing human PDYN, either 
wild type or carrying the SCA23-mutation R212W, and analyzed its motor performance and cerebellar morphology 
over a time-course of 12 months. We found that heterozygous PDYN-R212W mice reproduced the clinical features 
of SCA23 starting with gait deficits at three months of age, progressive loss of motor coordination and balance, 
and Purkinje cell loss by the age of 12 months. These findings correlated with pathologically elevated Dyn A levels 
in the cerebellum and reduced climbing fiber-Purkinje cell synapse distribution. Therefore, the elevated Dyn A 
levels probably underlie the etiology of SCA23 and affect climbing fiber-Purkinje cell synapse function. This results 
in synaptic alterations and Purkinje cell loss, leading to motor dysfunction. 




Spinocerebellar ataxia type 23 (SCA23) is a slowly progressive autosomal dominant neurodegenerative disorder 
caused by mutations in prodynorphin gene (PDYN) [1]. SCA23 patients suffer from a relatively slowly progressive 
motor coordination impairment and a generally isolated cerebellar ataxia due to Purkinje cell (PC) death in the 
cerebellum [1, 2]. PDYN is the precursor protein for the opioid neuropeptides α-neoendorphin, Dynorphin (Dyn) 
A, and Dyn B, which are endogenous ligands of the opioid receptors, and function in pain processing and addiction 
control [3]. Yet, the cerebellar function of these peptides is largely unknown. Notably, Dyn A exhibits neurotoxic 
effects, as pathologically increased levels caused pronounced cell death through mechanisms mediated by 
N-methyl-D-aspartate receptors (NMDARs) [4] or α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors 
(AMPARs) [5]. Moreover, Dyn A was shown to directly bind NMDARs and potentiate their glutamate-induced 
currents [6].
Interestigly, the majority of SCA23 mutations are located in the highly conserved Dyn A-coding region 
and lead to enhanced levels of Dyn A in vitro [1, 7]. These SCA23-mutant Dyn A peptides displayed elevated 
intrinsic neurotoxic properties in cultured striatal neurons [1]. However, the exact mechanism through which 
mutant Dyn A induces neuronal cell death has to be resolved.
 To further study the cerebellar role of PDYN and SCA23 disease pathology, we generated heterozygous 
conditional transgenic mice expressing PDYN-wt or SCA23-mutant PDYN-R212W. PDYN-R212W mice showed 
highly increased Dyn A levels in the cerebellum, which correlated with characteristic features of cerebellar 
ataxia including mild, but progressive motor coordination impairment, gait and balance abnormalities, and PC 
loss. Therefore, PDYN-R212W mice are a novel model for spinocerebellar ataxia, and our work suggests that 
pathologically elevated Dyn A levels in the cerebellum of SCA23-mutant mice are responsible for the ataxic 
phenotype and subsequent PC loss, recapitulating disease symptoms in humans.
Animals, materials and Methods
Animals
All animal experiments were performed according to the guidelines of the University of Groningen and Mayo 
Clinic College of Medicine. The experimental protocols were approved by Animal Welfare Committee of the 
University of Groningen. All efforts were made to reduce the number of animals and minimize their suffering. To 
generate heterozygous conditional transgenic mice carrying PDYN-wt or SCA23-mutant PDYN-R212W under Cre-
recombinase control, the human PDYN cDNA was cloned into the pCALL2 plasmid downstream of a neomycin-
resistance gene and transcription STOP signal (three tandemly arranged polyadenylation sites) flanked by loxP 
sites. Embryonic stem cell electroporation and clone selection was described previously [8, 9]. The blastocyst 
injections were performed at the Mayo Clinic College of Medicine, Rochester, Minnessota. For both, PDYN-wt 
and PDYN-R212W, two transgenic lines were generated, but the data is shown only for one line of each. To 
express PDYN, heterozygous transgene-inactive (Ti) PDYN-wt/R212W(Ti)  males were crossed with HPRTCre females. 







The same cross also produced wild type (WT) mice and Ti mice. The genotypes were assessed by PCR using the 
following primers:
PDYN-For 5’-TAGCAGTGGCGTTCATTTTG-3’, and PDYN-Rev 5’-TCTGAGCTCCTCTTGGGGTA-3’ and the 
loxP recombination was confirmed using the primers: For 5’-TCACTGCATTCTAGTTGTGGT-3’, and 
Rev 5’-CTTATCGATACCGTCGACCT-3’. 
All mice used for the experiments have a mixed 129Sv/E x C57Bl/6 genetic background. Four independent cohorts 
of 10-12 transgene-active (Ta) PDYN-wt/R212W(Ta), (and 12 WT/Ti control littermates) were aged for 3, 6, 9 and 12 
months. Each cohort contained equal numbers of female and male mice. 
Reverse transcription PCR and quantitative real-time PCR
Total RNA was isolated from snap-freezed mice cerebella using Trizol reagent (Invitrogen). The cDNA was 
generated using oligo-d(T) primers and RevertAid cDNA Kit (Fermentas). Quantitative real-time expression 
analysis was performed using SYBR-Green Mix (Life technologies, Applied Biosystems) and primer pairs listed 
below on Taqman ABI7900HT (Applied Biosystems) employing Standard Curve Quantification method and GAPDH 
as a reference gene. The primers used were: 
GAPDH- For 5’-AGGCCGGTGCTGAGTATGTC-3’, and GAPDH-Rev 5’-TGCCTGCTTCACCACCTTCT-3’; 
PDYN- For 5’-GCCTGCCTCCTCATGTTCC-3’, and PDYN-Rev 5’-CCTTCCCCAACCGACTTGC-3’; 
pdyn-For 5’-GTGCAGTGAGGATTCAGGATGGG-3’, and pdyn-Rev 5’-GAGCTTGGCTAGTGCACTGTAGC-3’. 
List of primers for genes from opioid pathway and others are presented in Suppl. Table 1. All procedures were 
performed according to provided manufacturers’ protocols.
Protein extraction and Western blotting
Proteins were isolated from snap-freezed mice organs. Organs were homogenized in ice-cold isolation buffer (320 
mM sucrose, 1 mM EDTA and 10 mM Tris-HEPES, pH7.4) supplemented with complete protease inhibitor cocktail 
(Roche, Woerden, the Netherlands). Protein concentrations were determined using the Pierce BCA Protein Assay Kit 
(Thermo Scientific, Etten-Leur, the Netherlands), sample buffer (12% SDS, 30% glycerol, 6% β-merkaptoethanol) 
was added to proteins and equal amounts were loaded on SDS-PAGE gels. After electrophoresis, the proteins 
were transferred to the Polyvinylidene difluoride (PVDF) membrane (Life technologies) and blocked with 5% 
bovine serum albumin (BSA, Sigma-Aldrich) in TBS-Tween. The blots were analyzed with primary antibodies 
against human PDYN (rabbit, 1: 500, kindly provided by G. Bakalkin), Dyn A (rabbit, 1:300, Abcam), VGlut2 
(rabbit, 1:1000, Synaptic Systems), EAAT4 (rabbit, 1:500, Alpha Diagnostics) or Calbindin (mouse, 1:500, Abcam). 
Secondary antibodies were conjugated with horseradish peroxidase (goat, 1:10 000, Jackson ImmunoResearch 
Laboratories).
Radioimmunoassay 
Proteins were extracted in 1 M acetic acid and gel filtration was performed in order to separate the peptides using 
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an SP-Sephadex ion exchange C-25 column. The radioimmunoassay procedure was performed as described 
before [10].
Histology, immunofluorescent stainings and microscopy
For immunofluorescent stainings, brains were dissected and fixed overnight in 15% picric acid, 4% paraformaldehyde 
and 0.05% gluteraldehyde in 0.1 M phosphate buffer (PB). After fixation, brains were cryopreserved in 10% and 
20% sucrose solutions in PB overnight, and then frozen on dry ice. Sectioning was performed on a HM550 microm 
cryostat (Thermo Scientific). Full cerebella were cut into 8 series of 30 μm-thick coronal sections. All stainings 
were performed free floating. For overall morphology studies, sections were stained with 1% Toluidine Blue 
(Sigma) for 2 min, washed with water, and mounted in Faramount mounting medium (Dako). For fluorescent 
stainings, sections were blocked with 3% normal donkey serum (Jackson ImmunoResearch Laboratories) for 30 
min, after which antigen retrieval was carried out in 10 mM citric acid buffer (pH 6) at 90°C for 20 min. Sections 
were incubated with primary antibody overnight at 4°C and subsequently with secondary antibodies for 1h at 
room temperature, followed by Sudan Black B incubation to eliminate autofluorescence (0.1% in 70% ethanol; 
Sigma), washing with PB + 0.02% Tween, and mounting (BrightMount mounting medium, Abcam). Primary 
antibodies were against: hPDYN (rabbit, 1:300, [1]), Dyn A (rabbit, 1:300, Abcam), VGlut2 (rabbit, 1:1000, 
Synaptic Systems), EAAT4 (rabbit, 1:500, Alpha Diagnostics) and α-Calbindin (mouse, 1:500, Abcam). Secondary 
anti-rabbit antibodies were conjugated with Alexa488 and anti-mouse with Cy3 (both: donkey, 1:250, Jackson 
ImmunoResearch Laboratories). Sections were imaged using a AxioObserver Z1 fluorescence microscope (Zeiss) 
and Leica TCS SP8 confocal microscope, and the images were analysed using the ImageScope (Aperio e-pathology 
solutions, http://www.aperio.com) and Fiji software (National Institutes of Health, NIH, http://fiji.sc/).
Motor performance analyses
Ledge and hindlimb clasping tests were performed according to the protocol described previously [11]. The 
scoring was performed three times by two independent researchers. Footprint patterns were analyzed using a 
runway (80 cm by 10.5 cm wide) with white paper at the bottom. Mice paws were deeped in non-toxic, water-
soluble ink (black for hind paws and magenta for front paws; Liquitex). Five consecutive strides were measured for 
each animal [12]. To assess motor performance the accelerating rotarod test was used (3-cm-diameter rotating 
cylinder; IITC). The training session contained 3 runs at stable 20 rpm at day 1, followed by a 2 day training session 
(each 3 runs per day) at accelerating speed (from 4 to 30 rpm within 180 seconds, and maximal 600 seconds 
at 30rpm). The actual experiment was done on day 4,identically to day 2 and 3. The minimal  interval time in 
between the runs was 15 min [12]. All tests were performed without genotype information.
Cerebellar examinations: Purkinje cell count, molecular layer thickness measurements and climbing fiber distribution
PCs were counted and averaged over 200 μm and the CF distribution was quantified by measuring the height 
of VGlut2 staining in the molecular layer relative to Calbindin staining in the same region. The PC length was 







measured as the distance from the top of PC soma to the tip of PC dendrite, and the CF distribution in the 
molecular layer was measured from the top of PC soma to the tip of CF arbor. In addition, the molecular layer 
thickness was measured. For molecular layer thickness and CF distribution, at least 10 measurements per section 
were taken in specific cerebellar regions. All images used for measurements were obtained using an AxioObserver 
Z1 fluorescence microscope (Zeiss) that scanned the full section. One series of cerebellar sections per animal and 
two animals per genotype (WT/Ti, hPDYNTa-wt and hPDYNTa-R212W) were used for one staining. Full cerebellar 
regions (including lobules II, IV/V, VI, and IX, paramedian lobule, paraflocculus, sim and crus) were present in 
different sections and two to five sections per region were analyzed. All measurements were done using Fiji 
software (NIH).
Statistical analysis
All data are expressed as mean ± standard error of the mean (SEM), unless stated otherwise. We used one-way 
ANOVA, followed by post-hoc multiple testing Bonferroni correction and Tukey’s Honestly Significant Difference 
(HSD) tests, to determine the significance of the observed differences between the groups (p < 0.05 is considered 
statistically significant).
Results
Generation of conditional transgenic PDYN-wt and PDYN-R212W mice
We generated conditional transgenic mice carrying PDYN-wt or SCA23-mutant PDYN-R212W downstream of 
a transcription STOP signal flanked by loxP sites (Fig. 1a). To express PDYN-wt/R212W, heterozygous PDYN-wt/
R212W Ti males were crossed with HPRTCre females, generating heterozygous PDYN-wt/R212W Ta mice that 
ubiquitously express the transgenes. The heterozygous PDYNwt/R212W Ta progeny was identified by PCR analysis 
(see Materials and Methods), and will be reffered to as PDYN-wt or PDYN-R212W. 
First, PDYN expression in the cerebellum was assessed by quantitative real-time PCR. Both PDYN-
wt and SCA23-mutant PDYN-R212W mice lines showed similar PDYN mRNA levels (Fig. 1b) and expression 
of PDYN did not change the levels of endogenous mouse pdyn (Fig. 1c). Overall, around  2-fold increase in 
PDYN mRNA levels was detected compared to pdyn mRNA in both lines (Suppl Fig. 1a). Western blot analysis 
confirmed  higher expression of PDYN in the PDYN-wt mice, whereas PDYN-R212W mice showed decreased 
levels of PDYN protein in the cerebellum (Fig. 1d), despite similar transcript levels in both lines. Reduced 
PDYN levels were detected also in brain of PDYN-R212W mice compared to PDYN-wt (Suppl. Fig. 1b). These 
results suggest that PDYN-R212W is more processed into peptides or is more rapidly degraded than PDYN-
wt in the neuronal tissue. Additionally, the expression of PDYN was confirmed also in liver and kidney of 
PDYN-wt and PDYN-R212W mice and similar protein levels were seen in both lines (Suppl. Fig. 1c and d).
To reveal the effect of expression of PDYN on the levels of its opioid peptides, we determined the 
amount of Dyn A, Dyn B and Arg-Leu-enkephalin (Leu-ENK-Arg6) in PDYN-wt and PDYN-R212W cerebella using 
radioimmunoassay and peptide-specific antibodies. While Leu-ENK-Arg6 levels were not changed (Fig. 1e), 
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expression of PDYN led to higher levels of Dyn A and B peptides in the cerebella of both PDYN-wt and PDYN-R212W 
mice (Fig. 1f and g). A 2-3-fold increase in Dyn A levels was observed in SCA23-mutant PDYN-R212W cerebella 
compared to PDYN-wt (Fig. 1g). Altogether, these experiments indicate that SCA23-mutant PDYN-R212W is more 
rapidly processed to opioid peptides than PDYN-wt, and its Dyn A peptides (carrying SCA23 mutation) are more 
stable, resulting in an increase of mutant Dyn A concentration in cerebellar tissue.
Fig. 1 Characterization 
of a conditional transgenic 
mouse model for SCA23.
(A) The transgene-inactive 
casette contained the full 
PDYN cDNA downstream 
of two loxP sites flanking 
a transcription STOP 
signal (three consecutively 
arranged polyadenylation 
sites). In addition, the IRES 
system was employed, 
enabling GFP expression 
whenever PDYN transgene 
is expressed without 
direct fusion of the two 
proteins. After crossing with 
HPRTCre mice expressing 
Cre-recombinase in the 
oocytes, the transgene was 
expressed. (B) Relative 
amount of PDYN mRNA in the 
cerebella of 3-month-old 
controls littermates (WT/Ti), 
PDYN-wt, and PDYN-R212W 
mice (n = 5 per genotype), 
and approximately equal 
expression levels were 
observed. (C) Relative 
amount of endogenous 
(mouse) pdyn mRNA in 
the cerebella of 3-month-
old transgenic mice and 
control littermates (n = 5 
per genotype). Expression of the transgene did not affect pdyn levels. (D) Representative immunoblot and quantification 
graph of relative PDYN protein levels in cerebella of 3-months-old mice (n = 6 per genotype). PDYN-wt and PDYN-R212W 
mice expressed 2.04 ± 0.38 and 0.36 ± 0.09 of PDYN (mean ± SEM), respectively. (E, F, G) Relative peptide levels in the mice 
cerebella at the age of 3-months (n = 2 per genotype), including Leu-ENK-Arg6 (E), Dyn B (F), and Dyn A (G). Peptide levels 
in the cerebella of WT/Ti, PDYN-wt and PDYN-R212W mice were 85.02 ± 36.97, 100.00 ± 48.52, and 87.66 ± 74.81 fmol/μg 
protein (E), 45.43 ± 8.21, 100.00 ± 33.98, and 122.92 ± 30.56 (F), and 30.34 ± 2.15, 100.00 ± 29.74, and 281.36 ± 110.61 (G), 
respectively. The data is expressed as relative (to protein levels in the samples) mean ± SEM, and normalized by PDYN-wt.







Fig. 2 Cerebellar 
morphology of SCA23-
mutant PDYN-R212W mice 
at the age of 3 months.
(A) Photomicrographs of 
toluidine blue-stained 
cerebellar coronal sections, 
comprising of the molecular, 
PC, and granule cell layers, 
showed no differences in 
size between PDYN-wt, 
and PDYN-R212W mice 
and control littermates. 
Scale bar, 2 mm. (B, C) 
I m m u n o f l u o r e s c e n c e 
revealed ubiquitous 
PDYN (B) and Dyn A (C) 
expression in cerebella 
of PDYN-wt, and PDYN-
R212W mice and not in 
control littermates. Robust 
expression of PDYN and Dyn 
A was detected in the soma 
of PCs and dendritic trees as 
was seen by co-localization 
with the PC-specific marker 
Calbindin (overlay). 
P h o t o m i c r o g r a p h s 
of cerebellar overall 
morphology and 20x 
magnification, scale bar, 
100 μm.
 Additionally, no significant changes were detected in expression of genes of opioid receptors, including 
Oprk1, Oprm1 and Oprd1, in PDYN-wt and PDYN-R212W mice compared to control littermates (Suppl. Fig. 2a and b). 
 Histological examination using toluidine blue staining showed unchanged cerebellar size in both PDYN-
wt and PDYN-R212W at the age of 3 months (Fig. 2a). Clear expression of PDYN and Dyn A was detected by 
immunofluorescence in the cerebella using specific anti-human PDYN and anti-Dyn A antibodies (Fig. 2b and 
c, respectively) and strong co-localization was observed in the PC soma with the PC-specific marker Calbindin. 
Additionally, Dyn A was localized more to the dendritic trees in the molecular layer than PDYN.
Thus, we have generated viable transgenic mice that ubiquitously express PDYN-wt or PDYN-R212W. 
Moreover, SCA23-mutant PDYN-R212W mice showed highly elevated Dyn A levels that seem to be a direct 
consequence of enhanced precursor processing as low PDYN levels were detected in these mice.
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PDYN-R212W causes cerebellar ataxia
To assess an effect of SCA23-mutation on motor coordination in PDYN-R212W mice, first, a ledge test was performed 
in 3- to 12-month-old mice. Defects in balance, hindlimb gait, and coordination were scored using a scale from 
0 to 3 (3 for severe impairment; described previously [11]). Already at the age of 3 months, PDYN-R212W mice 
performed significantly worse on the ledge than PDYN-wt and WT/Ti control littermates, and this progressed in 
time, reaching the score of 2 at the age of 12 months (Fig. 3a). However, PDYN-R212W mice exhibited a relatively 
mild motor impairment, as a score of 3 was not reached. Mild age-related motor coordination deficits were also 
detected in the WT/Ti controls by the age of 12 months. 
The progression of cerebellar motor impairment was scored in the hindlimb clasping test (again, scored 
from 0 to 3; [11]). At the 3 months of age, SCA23-mutant mice PDYN-R212W showed retracted hindlimbs to 
the abdomen more often than PDYN-wt mice and WT/Ti controls, reflected by a higher clasping score, and it 
worsened in time-course of disease (Fig. 3b). In this test again, at the age of 12 months, age-related deficits were 
also observed in the control littermates.
 To further study the ataxic phenotype, footprint patterns were analyzed for differences in stride length, 
base width, and overlap between front and hind paws (Fig. 3c). No differences were found in stride length (data 
not shown). Hindlimb base of PDYN-R212W mice was significantly wider compared to PDYN-wt and WT/Ti mice 
(Fig. 3d). Moreover, significant loss of overlap was detected in the footprint pattern of SCA23-mutant PDYN-
R212W mice starting at 6 months of age in contrast to PDYN-wt and WT/Ti mice, which did not display this effect 
(Fig. 3e).
 Finally, to determine motor performance, the accelerating rod test (max. 30 rpm) was performed (see 
Materials and Methods for details). No significant differences between the genotype groups were detected at 
3 to 9 months of age (Fig. 3f). Only at 12 months of age, PDYN-R212W mice spent significantly less time on the 
accelerating rod than PDYN-wt and control littermates (Fig. 3f). We were not able to study motor function decline 
in this particular test, as the PDYN-R212W mice only showed a detectable deficits during the last time point of the 
analysis. Moreover, defects in motor performance were not due to body size variation as there was no significant 
difference in body weight per genotype group (Suppl. Fig. 3).
 Altogether, these data clearly show that SCA23-mutant PDYN-R212W mice exhibit a mild and slowly 
progressive motor coordination impairment reflecting ataxic features of SCA23 patients, including motor 
dysfunction with deficits in balance and step alterations. This is in contrast to the mouse models of polyglutamine-
related SCA, such as SCA1 [13], that show a severe and rapid disease progression, but is similar to the mouse 
models for other SCAs caused by conventional mutations, including SCA5 [14]. 
Loss of Purkinje cells and climbing fiber innervation in PDYN-R212W mice
To reveal whether the ataxic symptoms were caused by PC loss and cerebellar neurodegeneration, the cerebellar 
morphology and PC layer integrity were determined in mice at 12 months of age. No molecular layer thinning 
was detected, however, changes between the genotypes may be missed due to the variability in molecular layer







Fig. 3 Cerebellar ataxia 
in PDYN-R212W mice.
(A) Quantification of 
the ledge tests in time 
using a scoring scale 
from 0 (no phenotype) 
to 3 (severe ataxic 
phenotype). At the 
age of 3 months, 
PDYN-R212W mice 
performed significantly 
worse on the ledge 
than PDYN-wt and WT/
Ti control littermates 
(0.83 ± 0.13 versus 0.22 
± 0.04 and 0.46 ± 0.07, 
respectively). Their 
motor impairment 
progressed in time as 
a score of 1.94 ± 0.24 
was reached at the 
age of 12 month, while 
PDYN-wt mice scored 
1.33 ± 0.12. Significant 
differences, * p < 0.05, 
** p < 0.001, and *** p 
< 10-5. (B) Quatification 
of hindlimb clasping 
in time using scoring 
scale from 0 (no 
clasping) to 3 (severe 
hindlimb retraction to 
the abdomen). Already 
at the age of 3 months, 
PDYN-R212W mice showed significantly higher clasping scores (0.85 ± 0.08) than PDYN-wt (0.62 ± 0.09) and WT/Ti controls 
(0.52 ± 0.05). Significant differences, * p < 0.005, and ** p < 10-5. (C) Representative footprint patterns of 12-month-old 
WT/Ti controls, PDYN-wt, and SCA23-mutant PDYN-R212W mice. Hind paws are in black, and front paws in magenta. (D) 
Quantification of the hindlimb base from footprint patterns showed a significantly wider base  for PDYN-R212W mice (3.2 
± 0.046 cm) than PDYN-wt and control littermates (2.45 ± 0.041 cm and 2.43 ± 0.039 cm) at 12 months of age. Significant 
differences, * p < 0.01, and ** p < 0.005. (E) Quantification of the front and hind paws overlap from footprint patterns showed 
significant loss of overlap in PDYN-R212W mice starting at 6 months of age, which was not observed in PDYN-wt and control 
littermates (-0.84 ± 0.05 cm versus -0.36 ± 0.03 cm and -0.41 ± 0.04 cm, respectively). Significant differences, * p < 0.005, and 
** p < 10-5. (F) Quantification of latency to fall from the accelerating rotarod for the three genotypes at experimental day 4. 
Only at 12 months of age, PDYN-R212W showed decreased latency to fall (52.18 ± 8.38 seconds) comparing to PDYN-wt mice 
(63.84 ± 5.38 seconds) and control littermates (82.63 ± 7.42 seconds). Significant differences, * p < 0.05, and ** p < 0.005. 
Data is expressed as mean ± SEM. Significance of results was tested using One-way ANOVA, followed by HSD tests.
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thickness between or within the various lobules of the cerebellum (Fig. 4a). Nonetheless, clearly reduced PC 
numbers were detected in lobules II, VI and IX, paraflocculus and paramedian lobule of PDYN-R212W mice 
comparing to PDYN-wt and WT/Ti, but not in cerebellar regions sim and crus (Fig. 4b). This was not reflected 
in clear loss of Calbindin levels by Western blot analysis (Fig. 4c). Interestingly, we observed an increase in PC 
number in lobules IV-V in PDYN-R212W mice (Fig. 4b), suggesting potential compensatory effects for PC loss in 
other vermal regions. 
Fig. 4 Purkinje cell loss 
in 12-month-old PDYN-
R212W mice.
(A) Quantification of the 
molecular layer thickness 
in different vermal regions 
of 12-month-old mice 
cerebella did not reveal 
any significant differences 
between the genotypes. 
High variability in 
molecular layer thickness 
was seen between and 




of the cerebellar lobule 
VI, using anti-Calbindin 
antibody, showing the 
PC and molecular layer 
in 12-month-old mice 
(control littermates WT/
Ti, PDYN-wt, and PDYN-
R212W). Scale bar, 80 
μm. PC numbers were 
quantified in lobules II, IV-
V, VI and IX, paraflocculus, 
paramedian lobule, and 
sim and crus among 
the genotypes and 
averaged per 200 μm. 
Approximately 50% of PCs were lost in PDYN-R212W compared to PDYN-wt and WT/Ti controls. Data is expressed as mean ± 
SEM. Significance of results was tested using One-way ANOVA, followed by HSD tests. Significant differences, * p < 0.01, and 
** p < 0.0005. (C) Western blot analysis of cerebellar extracts did not reveal alterations in Calbindin levels.
To assess morphological alterations that could precede PC loss in PDYN-R212W cerebella, we analyzed 
the expression and localization of the glutamate transporter EAAT4, as marked alterations in EAAT4 levels and 
distribution were seen in SCA5 and SCA23 human postmortem material [1, 15]. No changes in EAAT4 localization 







or expression were detected between the genotypes at 3 and 12 months of age (Suppl. Fig 4a and b). However, 
already at 3 months of age, PDYN-R212W mice exhibited marked loss of climbing fiber (CF) synapses on PC 
dendrites in lobules II, VI and IX, paramedian lobule, and paraflocculus (Fig. 5a), which progressed during the 
course of disease (Fig. 5b and Suppl. Fig. 5). Loss of CF innervation was previously seen in SCA1 and SCA7 mice 
[16, 17]. Notably, highly variable VGlut2 levels were measured in cerebellar extracts among the genotypes by 
Western blot analysis (data not shown). The progressive loss of CF innervation suggests active elimination of CF-
PC synapses and preceded PC loss in PDYN-R212W cerebella, indicating that alterations in synaptic transmission 
may underlie ataxic phenotype. 
Fig. 5 Reduced climbing fiber 
synapse innervation at PC 
dendrites in PDYN-R212W mice.
(A) Representative 
photomicropgraphs of 
immunofluorescence analysis of 
the mice cerebella at 3 months 
of age stained with anti-Calbindin 
antibody to visualize the PC 
dendritic trees, and anti-VGlut2 
antibody for CF detection. The 
measured height of VGlut2 
and Calbindin stainings over 
the dendritic tree is indicated 
in the molecular layers. Scale 
bar, 10μm. Quantification of the 
relative height of VGlut2 staining 
(to Calbindin) in lobules II, IV-V, 
VI and IX, paramedian lobule, 
flocculus and paraflocculus 
of 3-months-old mice shows 
decreased CF distribution in 
SCA23-mutant PDYN-R212W 
mice of approximately 10% 
in the affected regions. Data 
is expressed as mean ± SEM, 
normalized to WT/Ti control 
littermates. Significance of 
results was tested using 1-way 
ANOVA, followed by HSD tests, 
* p < 0.01, and ** p < 0.0005. 
(B) Quantification of loss of CF 
synapses between genotypes in 
3- (full bars) and 12-month-old (empty bars) mice. PDYN-R212W mice showed progressive decrease in CF innervation in 
the affected vermal regions (lobule II, VI, and IX) comparing to PDYN-wt and WT/Ti mice. Data is expressed as mean ± SEM 
(VGlut2/Calbindin). Significant differences (One-way ANOVA, followed by HSD tests), * p < 0.05, ** p < 0.005, and £ p < 10-4.




We have generated for the first time a conditional transgenic mouse model for SCA23 expressing PDYN-R212W, 
that mimicks many characteristics of SCA23 human disease, including mild, but progressive balance and gait 
abnormalities, motor dysfunction, and cerebellar PC loss. This work confirms that R212W mutation in PDYN 
underlies the pathology of SCA23. Consistent with our previous in vitro work (Bakalkin et al., 2010), we found 2-3-
fold higher Dyn A levels in the cerebella of PDYN-R212W mice comparing to PDYN-wt, despite similar transcript 
levels in both lines. This suggests that SCA23-mutant PDYN-R212W protein undergoes enhanced processing into 
Dyn peptides or that the SCA23-mutant Dyn A is more stable than wt, and cannot be processed efficiently to Leu-
ENK-Arg6, thus accumulates in the tissue. The mouse model generated by us could provide mechanistic insights 
into the non-opioid neurodegenerative actions of Dyn A peptides.
 Increased concentration or prolonged exposure of Dyn A have already been found to be neurotoxic 
and caused cell death through non-opioid mechanisms via activation of ionotropic glutamate receptors, including 
NMDARs or AMPARs [5, 6]. AMPAR-mediated excitotoxicity was proposed as the underlying mechanism of PCs loss 
in SCA5 [14]. Moreover, Dyn A binds NMDARs and potentiate their currents [6], which may lead to excitotoxicity. 
PCs death through excitotoxic mechanism was linked to CF hyperexcitability before [18, 19]. Our results are 
in line with the hypothesis that Dyn A may cause excitotoxicity acting through ionotropic glutamate receptors, 
either NMDARs or AMPARs, on the CF-PC synapse and cause PCs death. CF-PC synapse elimination might be the 
compensatory mechanism to prevent the hyperexcitability of CF due to elevated Dyn A levels that potentiates 
glutamate currents.
While the most prominent deficits were observed in PDYN-R212W mice, some age-related motor 
decline was seen in PDYN-wt and control littermates. Notably, at the age of 12 months, PDYN-wt mice performed 
significantly better than PDYN-R212W and control littermates in the ledge and clasping tests, suggesting protective 
role of PDYN or opioid peptides. Potential neuroprotective effects of Dyn A were already suggested to be mediated 
through κ-opioid receptor (KOR; encoded by Oprk1) [20], as KOR activation reduces intracellular calcium 
concentrations and may therefore prevent excitotoxicity [21-23]. Slightly reduced Oprk1 levels were detected in 
PDYN-R212W mice at 12 months of age. This could imply that next to pathologically elevated Dyn A levels, loss of 
KOR expression might contribute to the disease pathology. However, since the excitotoxic effects of pathologically 
elevated Dyn A were suggested to be much more potent than the negative effects on opioid signalling [20], it is 
unlikely that loss of KOR is a major component of the etiology of SCA23. Altogether, we believe that pathologically 
elevated Dyn A levels may cause excitotoxicity leading to PC loss and cerebellar ataxia in PDYN-R212W mice. 
We found mild motor deficits in PDYN-R212W mice preceding the PCs loss that coincided with reduced 
CF innervation of PCs dendrites. Loss of CF innervation progressed in time and this suggests active elimination 
of CF-PC synapses, rather than developmental problems of the molecular layer in PDYN-R212W mice. Since loss 
of CF-PC synapses preceded PC loss and coexisted with the first signs of ataxic symptoms, alterations in synaptic 
transmission might underlie the motor impairment in SCA23 pathology. Decreased CF-PC synapse distribution 
seems to be common in SCA pathology and was reported also in mouse models of SCA1 and SCA7 [16, 17, 24]. 







Additionally, in PDYN-R212W mice, the loss of CF termini and PCs was mostly restricted to particular 
lobules of the cerebellar vermis, correlating with a relatively mild pure cerebellar ataxic phenotype. Similarly, 
in the human postmortem SCA23 material atrophy was most pronounced in the frontotemporal region and the 
vermis of the cerebellum [2]. Interestingly, the CF synapses in the anterior lobules IV-V of PDYN-R212W mice were 
not affected at 3 months of age, and only mildly at 12 months, which correlated with an increase in PC number. 
These observations suggest compensatory mechanisms of these lobules to take over motor tasks of the affected 
regions. The regional degeneration is a direct consequence of functional topography of the cerebellum, and is 
consistent with the recent reports that PCs can display different excitability and firing properties within various 
cerebellar regions controlling different tasks [25, 26]. It is noteworthy that SCAs caused by conventional mutations 
usually show a milder disease manifestation and slower disease progression than polyglutamine-related SCA 
types and this is reflected in selective cerebellar degeneration versus widely-spread brainstem degeneration, 
respectively [27-29].
 In conclusion, the PDYN-R212W mouse described here is a new model for ataxia and is the first mouse 
model for SCA23. These SCA23-mutant mice display many disease symptoms seen in SCA23 patients, including 
mild and progressive ataxic phenotype and PCs loss, due to pathologically elevated Dyn A levels, providing 
convincing evidence that the PDYN-R212W mouse model is suitable to study the etiology of SCA23. The elevated 
Dyn A levels in SCA23-mutant mice seem to be responsible for the initiation and progression of the disease via 
excitotoxic damage through CF-PC synapses. Additionally, the PDYN-R212W mice develop symptoms slowly, which 
provides a possibility to study in detail the progression of pure, isolated cerebellar ataxia over time, and display 
elevated Dyn A levels which may be a useful model for studying not only SCA23, but also other Dyn A-controlled 
mechanisms such as pain processing or addiction control.
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(A) Relative amount of PDYN mRNA, both mouse and human, in cerebellar and brain tissue of 3-month-old WT/Ti controls, 
PDYN-wt, and PDYN-R212W mice (n = 5 per genotype, mean ± SEM). (B-D) Representative immunoblots and quantifications 
of relative PDYN protein levels in brain (B), liver (C) and kidney (D) of 3-months-old mice (n = 3 per genotype, mean ± SD, 
relative to Tubulin and normalized by WT/Ti). PDYN-wt and PDYN-R212W mice expressed 12.02 ± 0.93 and 2.86 ± 0.04 of 
PDYN (B), 4.93 ± 2.08 and 4.33 ± 1.51 (C), 2.36 ± 0.47 and 1.84 ± 0.39 (D), respectively.








(A, B) Relative expression of opioid system in the cerebella of 3-month-old (A) and 12-months-old (B) WT/Ti controls, 
PDYN-wt, and PDYN-R212W mice. Data is expressed as mean ± SEM (n = 5 per genotype). No significant results were 
found. oprd1 = δ-opioid receptor, oprk1 = κ-opioid receptor, oprm1 = μ-opioid receptor, enk = proenkephalin-A
Suppl. Fig. 3
Average body weight of WT/Ti controls, PDYN-wt, and SCA23-mutant PDYN-R212W mice in time, showing no significant 
differences that could explain defects in motor performance. Data is expressed as mean ± SEM.




Representative photomicrographs of immunofluorescence analysis of 3-month-old (A) and 12-month-old (B) mice cerebella, 
using anti-Calbindin and anti-EAAT4 antibodies, that showed no differences in EAAT4 levels or distribution in the molecular 
layer between the genotypes.  Scale bar, 75 μm.








(A) Representative photomicrographs of 12-months-old cerebella of WT/Ti controls, PDYN-wt, and hPDYN-R212W mice, 
analyzed with anti-VGlut2 and anti-Calbindin antibodies, showing relative CF distribution in molecular layer. Scale bar, 10μm. 
(B) Quantification of the relative height of VGlut2 staining (to Calbindin) in lobules II, IV-V, VI and IX, paramedian lobule, 
flocculus and paraflocculus of 12-months-old mice shows decreased CF distribution in SCA23-mutant PDYN-R212W mice of 
approximately 20% in the affected regions. Data is expressed as relative to WT/Ti mean ± SEM. Significance of results was 
tested using One-way ANOVA, followed by HSD tests, * p < 0.05, and ** p < 0.005.
Supplementary Table 1
Primer list used for quantitative real-time PCR for expression analysis of opioid signalling proteins
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Abstract
Spinocerebellar ataxia type 23 (SCA23) is caused by missense mutations in the prodynorphin, PDYN, gene, 
which is the precursor protein for the opioid neuropeptides α-neoendorphin, Dynorphin (Dyn) A, and Dyn B. 
Dyn A acts on opioid receptors to induce pain reduction in the spinal cord, but its cerebellar function is largely 
unknown. Increase in Dyn A concentrations or prolonged exposure is neurotoxic mediated through non-opioid 
mechanisms as these deleterious effects cannot be blocked by opioid antagonists. Dyn A peptides bind N-methyl-
D-aspartate receptors (NMDARs) potentiating glutamate currents, that may cause excitotoxicity. We previously 
showed that SCA23 mutations cause elevated Dyn A peptide levels and enhance the intrinsic toxicity of wild type 
Dyn A. In the present study, we investigated the disease mechanisms underlying SCA23-mutant Dyn A peptides. 
SCA23 mutations disrupted the secondary structure of Dyn A, fully ablating the α-helical structure, similarly to 
Dyn A-Y1del (2-17), that correlated with decreased κ-opioid receptor  affinity, altered peptide degradation and 
aggregation. Additionally, the mutant peptides induced NMDAR-mediated cell death in differentiated NG108 
cells. We propose that the pathology of SCA23 results from converging mechanisms of loss of opioid signaling and 
NMDA-induced excitotoxicity.
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Introduction
Missense mutations in prodynorphin (PDYN) gene cause spinocerebellar ataxia type 23 (SCA23), in which patients 
suffer from relatively slowly progressive motor coordination impairment due to Purkinje cells death in the 
cerebellum [1, 2]. PDYN is the precursor protein for opioid neuropeptides α-neoendorphin, Dynorphin (Dyn) 
A, and Dyn B, which are inhibitory neurotransmitters and function in pain processing and addition control [3]. 
Dyn A peptide acts on opioid receptors and preferentially binds to κ-opioid receptor (KOR) [3]. While Dyn A role 
has been extensively studied regarding the pain and addiction, the cerebellar function of this peptide, by which 
SCA23-mutant Dyn A can mediate ataxic phenotype, is largely unknown. 
There is growing evidence that pathophysiological changes in Dyn A production, concentration or 
processing can contribute to maladaptive neuroplastic changes and neurodegeneration (reviewed in [4]). The 
deleterious effect of Dyn A seen in secondary neuronal injury is mediated through non-opioid mechanisms as 
it cannot be blocked by opioid antagonists [5]. The finding that MK801, specific blocker of N-methyl-D-aspartate 
receptor (NMDAR) is able to prevent negative consequences of Dyn A elevated concentrations or prolonged exposure 
indicates that non-opioid mechanisms of Dyn A are mediated through this receptor [6]. Dyn A peptides were shown 
to bind NMDARs and potentiate their glutamate currents [7]. Dyn A peptides may have dichotomous actions as 
the peptide can be neuroprotective acting via opioid receptors and can be neurotoxic through NMDARs [6]. The 
neuroprotection mediated through Dyn A interaction with KOR might be the consequenc of reduced intracellular 
calcium concentrations upon KOR activation by Dyn A [8, 9]. Whereas neurodegenerative actions of Dyn A via NMDAR 
activation probably involve a pathological intracellular calcium increase in neurons leading to excitotoxicity.
Dyn A, a 17-aminoacid-long peptide, displays a stable N-terminal α-helical structure, which spreads 
from Phe4 to Pro10, and C-terminal β-turn, formed by aminoacids Trp14 to Gln17 [10]. However, Dyn A structurize 
only in the membrane environment and in the aquaous solution it is unfolded [11]. Moreover, structure-activity 
analyses indicated that Tyr1, Leu5 and Arg6-Lys11 are important for KOR binding [12, 13]. 
Previously, we showed that three SCA23 mutations located in Dyn A-coding region lead to enhanced 
levels of the Dyn A peptide in transiently transfected cells (with precursor PDYN cDNA). Additionally, two of these 
mutations, R6W and R9C, increased the intrinsic toxicity of wild type Dyn A in cultured striatal neurons, whereas 
in contrast L5S did not [2], suggesting different underlying mechanism for the various mutant Dyn A peptides.
Here, we aimed to unravel the disease mechanisms underlying the SCA23-mutant Dyn A peptides L5S, 
R6W, and R9W. We showed that all SCA23-mutant Dyn A peptides displayed altered secondary structures that 
correlated with lower peptide binding efficiencies to KOR. Dyna A-R6W and Dyn A-R9W peptides were more 
resistant to degradation, whereas in contrast Dyn A-L5S was very rapidly degraded. This finding coincided 
with increased aggregation kinetics for the Dyn A-R6W and Dyn A-R9C peptides, that was absent in Dyn A-L5S. 
Notably, all peptides exhibited NMDAR-mediated neurotoxic effects leading to enhanced NG108 cell death. We 
hypothesize that the Dyn A-R6W and Dyn A-R9C peptides display a toxic gain of function, whereas loss-of-function 
may underlie Dyn A-L5S pathology. Moreover, the pathology of SCA23 may result from a convergence of two 
mechanisms: loss of opioid signaling-mediated neuroprotection and NMDAR activation leading to excitotoxicity.








Modeling of the secondary structure and interaction of Dyn A with POPC membranes
The interaction of Dyn A mutants with palmitoyl-oleyl phosphatidylcholine (POPC) membranes was simulated using 
the GROMACS software package version 4.5, the GROMOS43A1 force field, and parameters for the phospholipids 
adapted from Berger et al. [14, 15]. Simulations were carried out for at least 200 ns. The systems were composed 
by a single peptide molecule, a 104 POPC membrane patch, 3428 water molecules and either 3 or 4 countering 
chloride ions, depending on the formal charge of the mutant. Prior to production runs, the system with the wild 
type (wt) Dyn A peptide was equilibrated for 5 µs using the MARTINI coarse-grain force field [16]. Mutations were 
also performed at the (more robust) coarse-grain level, after which the system was again briefly equilibrated for 
2 ns before being converted to a fine grain representation following a procedure described elsewhere [17]. At 
the fine grain level the systems were energy-minimized and then equilibrated for 0.5 ns at a 0.5 fs time step and 
pressure coupling time of 0.5 ps, and then again for 1 ns at 1 fs time step with a pressure coupling time of 0.05 
ps. Secondary structure analysis was done using the DSSP tool (CMBI version of April 4, 2000; [18]). Visualization 
was done using the VMD package [19].
Peptide synthesis
SCA23-mutant and wt Dyn A peptides were synthesized by solid phase strategies using an automated multiple 
peptide synthesizer (SyroII, MultiSyntech). For the quenched Dyn A peptides, a Cystein was inserted to Dyn A 
sequence in between two Glycines at the N-terminus and a fluorescein (Fl) was introduced by covalent coupling 
of fluorescein-5-iodoacetamide (5-IAF, Fluka) to the Cysteine. Quenching of Fl fluorescence was performed by 
a dabcyl group that had been introduced in the peptide by coupling of Fmoc-L-Lys (Dabcyl)-OH (NeoMPS). 
Peptides were purified by size exclusion chromatography and Reversed phase (RP)-HPLC (>95% pure) and 
showed the expected molecular mass as determined by mass spectrometry (Maldi Tof, Voyager, ABI). Peptides 
were dissolved in 100% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma), aliquoted, dried under vacuum in a 
SpeedVac (Eppendorf) and stored at -20°C.
KOR competitive binding assay 
The competitive binding assay of Dyn A peptides to KOR was performed as described before [20]. Briefly,  Dyn 
A binding was assessed in the presence of radioactively labeled U50,488 in cerebellar membrane fractions 
using different concentrations of Dyn A peptide. Unlabeled U50,488 was used to decrease unspecific binding 
and generate standards. Bound radioactivity was counted on a Wallac Beta-plate Liquid Scintillation Counter 
(Piscataway, NJ). Non-linear regression analysis of the competition curves fitted best by using a two sites analysis, 
of which the high affinity site represents the KOR. 
Quenched Dyn A peptide degradation assay
The degradation assay was performed as described before [21]. In short, HFIP-treated aliquots of Dyn A peptides 
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were resuspended in DMSO followed by sonication for 10 minutes, immediately before addition to 5 µg protein 
from the mouse cerebellum extracts or human liquor in KMH buffer (110 mM KAc, 2 mM MgAc and 20 mM Hepes-
KOH, pH 7.2) to a total volume of 50 µl. Degradation of the peptide was analyzed at 37°C using a fluorescence 
plate reader (FLUOstar OPTIMA, BMG Labtec.). 
Electron microscopy
Dyn A peptide (150 ng/ml in water) preparations were adsorbed on 300-mesh formar/copper grids for 2 minutes 
and excess of fluid was filtered off. Upon staining with 2.5% uranyl acetate for 2 minutes, grids were analyzed with 
a transmission electron microscope (Tecnai-12 G2, FEI).
Cell culturing
Neuroblastoma-glioma NG108 cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, 
Gibco, Bleiswijk, the Netherlands) implemented with 10% fetal bovine serum (FBS) and 5% penicillin (100 U/ml) 
and streptomycin (100 mg/ml). The cultures were maintained at 37°C in an atmosphere of 5% CO2. The cells were 
detached using trypsinization and same number of cells were plated in 96-well plates. The differentiation was 
conducted by addition of 50 μM 3-Isobutyl-1-methylxanthine (IBMX, Sigma) and 100 μM 5’-N-ethyl-carboxamide-
adenosine (NECA, Sigma) in the low-FBS medium for at least 5 days, until long protrusions were seen.
Peptide-induced toxicity assay
The differentiated NG108 cells were cultured in 96-well plates in presence of propidium iodide (PI; 5 μg/ml) 
and stimulated with various Dyn A peptides at different concentrations. Cell death was measured by following 
enhanced fluorescence of PI upon its incorporation into nuclei of dying cells. The PI fluorescence was monitored 
for 72 hours after addition of Dyn A peptides using a fluorescence plate reader (Synergy HT, BioTEK). As negative 
controls  NG108 cells without peptide stimulation were used, and cells stimulated with 0.25% Triton X-100, 15 
mM EDTA, or poly-D-Lysine (all purchased from Sigma) were used as positive controls.
Statistical analysis
All data are expressed as the mean of at least three independent experiments. The statistical significance were 
tested using unpaired Student’s t-test.
Results
SCA23 mutations interfere with the secondary structure of Dyn A peptides
To gain insight into the mechanism underlying SCA23 mutations in Dyn A-coding region, we first examined the 
impact of the L5S, R6W, and R9C mutations on the secondary structure of Dyn A by computational modeling of 
these mutant peptides in the presence of membrane. The simulation was carried out for at least 200 ns enabling 
us to follow the stability of peptide secondary structures in time. Our data confirmed the N-terminal α-helix in 







the secondary structure of Dyn A-wt upon interaction with POPC membranes (Fig. 1A, Suppl. Fig. 1A), validating 
our modeling approach. The Dyn A-wt secondary structure was stable across the whole simulation. All mutations 
resulted in a loss of α-helical structures in the Dyn A peptides (Fig. 1 B-D, Suppl. Fig. 1B-D), suggesting that 
these aminoacids are important for the α-helix formation. Moreover, Dyn A-R6W showed a relatively stable 
β-bridge between aminoacids Arg9 and Lys13 in its secondary structure (Fig. 1C, Suppl. Fig. 1C). Additionally, a 
membrane in-depth profile of each peptide was generated upon interaction with POPC membranes that showed 
no marked differences between the SCA23 mutants and wt profiles, reflecting only little alteration in positioning 
of the peptides in the membrane (Fig. 2). Altogether, these data show that SCA23 mutations disrupt the native 
conformation of Dyn A peptides, but do not markedly change the positioning in the membrane.
SCA23-mutant Dyn A peptides exhibit reduced κ-opioid receptor (KOR) affinities
Since Tyr1, Leu5 and Arg6-Lys11 are important for KOR binding as indicated by structure-activity analyses of Dyn A 
peptide [12, 13], we hypothesized that SCA23-mutant Dyn A peptides may exhibit decreased receptor affinity. To 
test this hypothesis, we analyzed the κ-opioid receptor binding affinities of the various mutant Dyn A peptides 
in vitro in a competitive binding assay using the selective KOR antagonist (U50,488) as a competitor (Fig. 3). The 
competition analysis showed that all mutant Dyn A peptides have 5-10 times lower KOR affinity than Dyn A-wt (IC50 
values: L5S: 2,59 nM, R6W: 4.91 nM, and R9C: 3.12 nM versus wt: 0,63 nM, respectively), indicating that partial 
loss of KOR-mediated neuroprotection might contribute to SCA23.
 As the SCA23-mutant Dyn A peptides clearly displayed lower KOR affinities and loss of α-helical 
secondary structure, we hypothesized that the formation of the α-helix in Dyn A peptide may be important for KOR 
interaction. Therefore, we modeled the secondary structure of Dyn A-Y1del, lacking Tyr1, that is known to have no 
affinity for opioid receptors, including KOR, and exhibit only non-opioid functions [22]. Our results showed that 
Dyn A-Y1del also did not display the α-helical structure at the N-terminus (Fig. 4), similarly as was observed for the 
various SCA23-mutant Dyn A peptides (Fig. 1, Suppl. Fig. 1). This indicates that the α-helical structure in Dyn A is 
important for KOR interaction, but it is not the sole determinant of this interaction as the SCA23-mutant peptides 
still showed quite some KOR interaction. Additionally, the membrane positioning of the Dyn A-Y1del peptide also 
did not change much compared to Dyn A-wt, suggesting that other mechanisms must underlie the complete loss 
of KOR interaction for this peptide (Suppl. Fig. 2).
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Fig. 1 Secondary structures of SCA23-mutant Dyn A peptides upon interaction with POPC membranes over time.
(A) Dyn A-wt exhibits α-helical conformation between aminoacids 4 and 9, that is relatively stable in time. (B-D) Conversely, 
the mutations L5S, R6W, and R9C caused loss of the α-helix and the resulting mutant structures were overall extended, 
though β-bridge stabilization was occasionally observed in one case (C). 
The graphs show adopted secondary structures per aminoacid residue (Y axis) in time (X axis). Computational modeling of 
various Dyn A peptides interacting with a POPC membrane was conducted for at least 200 ns after the different mutations 
were performed.







Fig. 2 SCA23-mutant Dyn A peptides position in membrane.
The graph represents averaged distance of Cα carbons of each residue of wild type and SCA23-mutant Dyn A peptides to 
the center of the POPC bilayer. The simulation was carried out for 80 ns. The gray line indicates the average depth of the 
phosphate groups. The insertion depth of SCA23-mutant peptides seems to be little affected during the studied time scale.
Fig. 3 Binding affinity of SCA23-mutant Dyn A peptides to KOR.
The quantification graph of competitive binding assays for various Dyn A peptides and the highly selective KOR antagonist 
U52,488. All SCA23-mutant Dyn A peptides exhibited lower potential to displace the antagonist from the high affinity binding 
site compared to Dyn A-wt. Data is shown as a mean of four independent experiments (± SD). The table shows binding 
affinities (Ki) of the wild type and SCA23-mutant Dyn A peptides and the half maximal inhibitory concentration in nM.
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Fig. 4 Secondary structures of Dyn A-Y1del upon interaction with POPC membranes over time.
(A-B) Deletion of the first tyrosine in Dyn A peptide also leads to loss of the α-helical structure. For complete legend see Fig. 
1 and Suppl. Fig. 1.
SCA23 mutations affect the degradation efficiency of Dyn A peptides
We previously observed highly elevated SCA23-mutant Dyn A levels in vitro [2], and since SCA23 mutations disrupt 
the native conformation of Dyn A peptide, we hypothesized that alterations in the secondary structure of the 
SCA23-mutant Dyn A peptides affect proper peptide degradation. To test this idea, we determined breakdown 
of the mutant Dyn A peptides in mouse cerebellar extracts and human liquor in real time. For this purpose, 
we generated Dyn A peptides with a small fluorescent group at the N-terminus and a quenching dabcyl group 
introduced to medial/C-terminal part of Dyn A peptides [23]. The quenched Dyn A peptides become fluorescent 
upon separation of the fluorophore and quencher due to degradation of the peptide. Upon addition of the 
peptides to cerebellar extracts, a marked increase in fluorescence signal for Dyn A-wt and Dyn A-L5S was detected 
in time, but in contrast almost no fluorescence signal was observed for Dyn A-R6W and Dyn A-R9C (Fig. 5A and C). 
Notably, Dyn A-L5S was much more rapidly degraded than Dyn A-wt. 
 To further study the breakdown of the SCA23-mutant Dyn A peptides, we also determined their 
stability in human liquor, which contains many metabolic enzymes including hydrolases and peptidases. In these 
conditions, the degradation of Dyn A-wt and Dyn A-L5S was less rapid than in cerebellar extract, but similar 
profiles were generated and again Dyn A-L5S exhibited elevated fluorescence signals, and once more strongly 
reduced fluorescence signals were observed for Dyn A-R6W and Dyn A-R9C (Fig. 5B and D).
 







Fig. 5 Degradation rate of SCA23-mutant Dyn A peptides.
(A-B) Degradation curves of wild type and SCA23-mutant Dyn A peptides in time as measured by the increase in fluorescence 
intensity upon separation of the quencher and fluorophore. The assay was carried out in mouse cerebellar extract (A) or in 
human liquor (B) for 200 cycles of 5 minutes. (C-D) Quantification of the degradation slope of SCA23-mutant Dyn A peptides 
relative to Dyn A-wt (100%) in the lysates of mouse cerebellar tissue (C) and human liquor (D). The data is expressed as a 
mean of three independent experiments. 
These data clearly show that the R6W and R9C mutations impair proper Dyn A degradation, whereas L5S 
seems to increase Dyn A breakdown. The degradation of Dyn A-wt and Dyn A-L5S peptides were more efficient in 
cerebellar extract compared to human liquor, suggesing the presence of cerebellar-specific peptidases that can 
degrade Dyn A with high efficiency.
As we observed higher stability of Dyn A-R6W and Dyn A-R9C, we wondered if these mutants could 
assemble into oligomeric structures that may decrease their degradation rate. Therefore, we investigated the in 
vitro oligomerization of the SCA23-mutant Dyn A peptides in vitro at various time points by electron microscopy. 
Dyn A-wt formed some oligomeric structures after 4 hours of incubation in aquaous solution (Fig. 6), but a marked 
increase in oligomerization was observed for Dyn A-R6W and Dyn A-R9C compared to Dyn A-wt, but not for Dyn 
A-L5S. All SCA23-mutant peptides assembled into oligomeric structures faster than Dyn A-wt .
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Fig. 6 Oligomerization of SCA23-mutant Dyn A peptides in time.
Electron microscopy images showing increased oligomerization of Dyn A-R6W and Dyn A-R9C comparing to Dyn A-wt at 37°C 
in time (0 and 4 hours), whereas in contrast no large oligomeric structures were observed for Dyn A-wt and Dyn A-L5S. Scale 
bars are 1 μm (upper panel; 0 hours) and 500 nm (lower panel; 4 hours).
Altogether, these data indicate that the R6W and R9C mutations increase the half-life of Dyn A, that could 
cause enhanced oligomerization. The very rapid degradation of L5S suggests a loss of this particular peptide and 
indicates that not all SCA23 mutations display the same underlying disease mechanism.
SCA23-mutant Dyn A exhibit increased neurotoxic effects via the NMDAR
Recent work has shown that Dyn A non-covalently binds NMDAR and can potentiate its excitatory currents [7]. 
Additionally, high concentrations or prolonged exposure of Dyn A has been shown to cause neuronal cell death 
via non-opioid mechanisms [5, 6]. Given the elevated Dyn A levels in SCA23 pathology, we hypothesized that the 
mutant peptides may induce neurotoxicity through NMDAR activation leading to enhanced cell death.
 To test this hypothesis, the various Dyn A peptides were added to differentiated NG108 cells and 
cultured with propidium iodide (PI; 5 μg/mL), enabling cell death measurements in time. In this assay, Dyn A-wt 
was not toxic for the differentiated NG108 cells, but SCA23-mutant Dyn A peptides showed marked concentration-
dependent toxicity reflected by increased cell death (Fig. 7A and B). Forty-eight hours after addition of 1 μM 
peptide, Dyn A-L5S and Dyn A-R9C caused  a 2-fold increase in cell death (2.3 ± 0.10 and 1.97 ± 0.76 versus 
1.04 ± 0.10) and Dyn A-R6W a 9-fold  (8.9 ± 0.38) increase compared to Dyn A-wt (Fig. 7A). This effect was even 
more pronounced at 72 hours after cell exposure to peptides. The toxicity of all mutant Dyn A peptides was 
concentration-dependent as 100 nM peptide was not toxic to differentiated NG108 cells in time and 10 μM Dyn A 
peptides caused more pronounced cell death than 1 μM (Fig. 7B).







Fig. 7 Toxicity induced by SCA23-mutant Dyn A peptides.
(A-B) Quantification of cell death og differentiated NG108 cells in the presence of various Dyn A peptides in time. The analysis 
showed high toxicity of SCA23-mutant peptides compared to Dyn A-wt after 48h and 72h after addition of peptides. (A) Cell 
death induced by various Dyn A peptides (1uM). Dyn A-R6W showed the highest toxicity. The data is presented as mean ± 
SEM. Significant differences (unpaired t-test) are indicated as * p < 0.05, ** p < 0.005 (B) Induction of cell death by SCA23-
mutant Dyn A is concentration-dependent. * p < 0.005. 
 To test whether mutant Dyn A caused neurotoxicity and cell death via NMDAR activation, cell death was 
measure in differentiated NG108 cells upon treatment with (1μM) wt or SCA23-mutant Dyn A peptides and NMDA 
(50 μM). The specific stimulation of NMDARs by NMDA caused more pronounced cell death in presence of SCA23-
mutant peptides than peptides treatment alone , especially in case of Dyn A-R6W, and this effect was completely 
blocked by the NMDAR antagonist, MK801 (Fig. 8A and B). MK801 also partially blocked SCA23-mutant peptide 
induced toxicity as cells treated with MK801 (added 24 hours after peptide) showed decreased PI fluorescence 
than cells treated with peptide only (Fig 8B). These data confirms that Dyn A peptides exhibit neurotoxicity through 
NMDAR activation as it could be blocked by MK801, indicating that excitotoxicity may underlie the Dyn A-induced 
pathology in SCA23.
 Additionally, we stimulated NMDARs with the co-agonists, Glycine or D-Serine, in the presence of 100 
nM (non-toxic concentrations) Dyn A peptide. High concentrations (10 mM) of these co-agonists are able to 
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activate different subunits of NMDAR [24], D-Ser (like NMDA) acts mainly on synaptic NMDARs (containing NR2A), 
and Glycine on extra-synaptic NMDARs (containing NR2B) [25]. Only 10 mM D-Serine in the presence of mutant 
Dyn A resulted in markedly increased cell death compared to Glycine activation. This indicates that synaptic rather 
than extra-synaptic NMDARs contribute to SCA23 neurotoxicity (Fig. 8C).
Fig. 8 Toxic effects of 
SCA23-mutant Dyn 
A mediated through 
NMDAR pathway.
(A-B) Time-course 
of the cell death 
of differentiated 
NG108 cells cultured 
with PI in the 
presence of various 
1 μM Dyn A peptides, 
stimulated with 50 
μM NMDA with or 
without specific 
NMDAR antagonist, 
MK801 (10 μM). 
C o - s t i m u l a t i o n 
with SCA23-mutant 
peptides and NMDA 
led to a significant 
increase in cell 
death, that could be 
completely blocked 
by the addition of 
MK801. Again, Dyn 
A-R6W showed the 
highest toxicity. 
MK801 was added 
20 minutes before 
NMDA to effectively 
block NMDA 
receptors. Significant 
d i f f e r e n c e s 
(unpaired t-test) are 
indicated as (A) * p < 0.05, ** p < 0.005, between SCA23-mutant peptides and Dyn A-wt, (B) * p < 0.05, ** p < 0.01, *** p 
< 0.005. (C) Quantification of toxicity caused by NMDARs stimulation in the presence of the various Dyn A peptides at non-
toxic concentrations (100 nM) in time. NMDAR stimulation was conducted at high concentration of co-agonists (10 mM), by 
which Glycine targets extra-synaptic NMDARs and D-Serine – synaptic NMDARs. Significant differences (unpaired t-test) are 
indicated as * p < 0.05, ** p < 0.01, *** p < 0.005. G – Glycine, D-Ser – D-Serine. 
The data is presented as mean ± SEM. Stimulation with NMDA or Glycine and D-Serine was conducted 24 hours after addition 
of Dyn A peptides.







To study the effect of SCA23-mutant Dyn A peptides on opioid signaling-mediated neuroprotection, 
we treated differentiated NG108 cells with 100 nM Dyn A peptides (non-toxic concentration) and blocked opioid 
or NMDAR pathways using specific antagonists, naloxone and MK801 (respectively), and followed cell death in 
time. Interestingly, after 72 hours of  naloxone treatment markedly decreased cell viability in presence of 100 nM 
mutant peptides was observed, which was the most pronounced for Dyn A-R6W (15.52 ± 0.92 versus 0.00 ± 0.08 
for Dyn A-wt; Fig. 9). These findings further support the hypothesis that the opioid pathway may play a crucial role 
in modulating the SCA23 pathology via neuroprotection.
Fig. 9 Toxicity of SCA23-mutant Dyn A peptides during inhibition of opioid pathway.
The quantification graph shows the cell death of differentiated NG108 cells cultured with PI induced by 10 μM naloxone 
(antagonist of opioid receptors) and by 10 μM MK801 in the presense of in non-toxic Dyn A concentrations (100 nM). Naloxone 
clearly induced strong cell death after 4 to 72 hours of stimulation. The strongest effect was observed in the presence of Dyn 
A-R6W. Naloxone and MK801 were added 20 minutes before peptides. The data is presented as mean ± SEM.
Discussion and conclusions
In the present study we showed that SCA23 mutations located in Dyn A disrupt the peptide secondary structure 
that is important for KOR binding, and lead to non-opioid neurotoxic actions of Dyn A via the NMDAR.
 All SCA23 mutations disrupted the formation of the N-terminal α-helix, similarly to Dyn A-Y1del mutant, 
suggesting that these aminoacids take part in α-helix formation. This loss of helical structure correleted with 
reduced KOR affinity. Additionally, Tyr1, Leu5, Arg6, and Arg9 were already shown to be important for KOR binding 
in structure activity analyses [12, 13]. Thus, the α-helix at the N-terminus is important for KOR binding, but it 
cannot be the sole determinant for proper KOR interaction, as the SCA23-mutant Dyn A peptides were still able to 
bind to KOR.
Furthermore, the data obtained by us support the hypothesis of opioid signaling neuroprotection, as 
SCA23-mutant Dyn A peptides showed lower affinity to KOR and blocking of opioid signaling in differentiated 
NG108 cells markedly increased toxicity of SCA23-mutant Dyn A peptides. These data indicate that partial loss of 
neuroprotection through opioid signaling may contribute to the pathogenesis of SCA23. 
A clear hallmark of SCA23 in our previous work was the increase in mutant Dyn A levels [2]. This could 
be the consequence of slower degradation of the Arginine-mutant Dyn A peptides, R6W and R9C, that also 
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formed stable oligomeric structures in vitro. Stable β-bridge in Dyn A-R6W secondary structure or introduced 
Cysteine in Dyn A-R9C, which may form disulfide bonds, might contribute to increased oligomerization seen for 
these mutants. Yet, physiological relevance of this findings is hard to assess, as the oligomerization assays were 
performed in aquaous solution, without presence of membranes. It, however, may suggest that Arg-mutant Dyn A 
peptides may form additional interactions, either accumulating in higher molecular weight species or interacting 
with unknown partners.
 We proved that the SCA23-mutant peptides are toxic in our cell model system in a concentration-
dependent manner and confirmed that Dyn A-R6W is the most pathogenic peptide, as seen before [2]. Moreover, 
the mutant Dyn A toxicity was mediated through NMDAR, as neuronal cell death could be blocked with NMDAR-
specific antagonist. Additionally, our results suggest that synaptic NMDARs contribute more to toxicity than extra-
synaptic receptors. Still, further work need to show the direct interaction between Dyn A and NMDARs of various 
composition or that blocking of the Dyn a toxicity can be achieved by the use of subunit-specific antagonists. Taking 
into account that Dyn A can potentiate glutamate-evoked currents of NMDARs [7] and the increased cell death 
upon NMDA stimulation in presence of SCA23-mutant Dyn A peptides observed in this study, we suggest that Dyn 
A toxicity in SCA23 is caused by excitotoxic mechanism through NMDAR.
Notably, Dyn A-wt did not display toxic effects in differentated NG108 cells. Maybe these immortalized 
cells are more resistant to Dyn A peptide-induced toxicity than primary neuronal cultures as has been used before, 
and higher concentrations or longer exposure of Dyn A-wt may be needed to observe the cell death. However, we 
cannot exclude that Dyn A toxicity in SCA23 is specific for particular populations of neurons, and different effects 
would be seen for striatal neurons and neuronal-like cell lines, and physiologically relevant Purkinje cells.
 We provide further evidence that the Arginine mutations in Dyn A (R6W and R9C) have different 
mechanism of pathology than L5S. The Arginine-mutant Dyn A peptides were more resistant to degradation and 
formed oligomeric structures compared to DynA-wt and L5S, supporting our hypothesis that these mutations 
exhibit gain-of-function mechanism. Dyn A-L5S was rapidly degraded, and did not oligomerize that fast. Thus 
in case of L5S mutations, loss of Dyn A function rather than toxic gain of function might underlie the disease 
pathology, which is in line with mild ataxic phenotype that started at the age of 73, compared to the R6W and R9C 
mutations that were correlated with a more severe phenotype and younger age of onset [2].
 In conclusion, we showed that SCA23-mutant Dyn A peptides have disrupted secondary structures, 
which may lead to decreased affinity to KOR and loss of opioid receptors-mediated neuroprotection. The mutant 
peptides exhibited marked toxicity through NMDAR pathway, probably by excitotoxic actions of SCA23-mutant Dyn 
A peptides on these receptors.
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Suppl. Fig. 1 Representative configurations of wild type and SCA23-mutant Dyn A peptides interacting with a POPC membrane 
at 0ns and 200ns.
The backbone residues of various Dyn A peptides, including (A) Dyn A-wt, (B) Dyn A-L5S, (C) Dyn A-R6W, and (D) Dyn A-R9C, 
are drawn according to a ribbon representation of a DSSP-assigned structure and the top leaflet phosphate groups are 
depicted as translucid spheres. It is clear that the wild-type peptide retains its secondary structure whereas the rest of the 
mutants depart from it. However, the insertion profile into the membrane seems hardly affected by the mutations during 
the studied time scale. 
Suppl. Fig. 2 Dyn A-Y1del peptide position 
at the membrane.
For complete legend see Fig. 2.
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Gene/mutation identification in unknown SCA types
Currently, only 70% of the Dutch SCA families can be diagnosed by mutation analysis of the eight known SCA genes 
(SCA1-3, 6, 7, 12, 14 and 17) that are relatively more common. The identification of causal mutations and novel 
genes in the group of families who cannot be diagnosed genetically would not only help to improve the diagnostic 
possibilities for these patients, but would also provide more insight into the underlying pathological pathways 
leading to cerebellar neurodegeneration and SCA disease.
 The genetic diagnosis of SCA is complicated because there are 32 known SCA types, some of which 
are very rare, and not all the SCA genes have yet been identified for each reported disease locus. The rarer SCA 
types, like SCA11, 23, or 28, or the new SCAs for which the prevalence has not yet been established (e.g. SCA19, 
SCA36), are not usually included in the diagnostic testing due to the relatively high cost of screening and the low 
probability of identifying mutations. One could also ask if it is really worth including the rare SCA types in the DNA 
diagnostic tests. It would be preferable to have a tool with lower  screening costs that could test every SCA gene, 
independent of the SCA type frequency. The best alternative would be to generate a custom-made capturing 
array that would include all the known SCA genes, followed by high-throughput sequencing (next-generation 
sequencing (NGS) approach). With the falling cost of NGS, this method is now affordable and has already proven 
useful for diagnosing cardiomyopathies [1]. However, NGS data analysis can be difficult for dominant disorders, 
as the variants that occur in one allele are relatively common in the genome. Nonetheless, it can also be successful, 
as shown in Chapter 3 and [2, 3], especially when using a family-based NGS approach in which the sequencing 
results can be validated by studying co-segregation of the phenotype with the variants identified in the family. The 
success rate of NGS also depends on whether the disease locus has already been mapped, as in the case of SCA19 
(Chapter 3). The SCA19 locus was large, ~32 Mbp in size and contained approximately 500 genes [4], and we 
did not identify the mutation responsible for SCA19 using Sanger sequencing of the candidate genes (Chapter 3). 
However, for linkage regions containing a reasonable number of genes, Sanger sequencing can be successful, as 
we showed for SCA23 (Chapter 4). SCA23 locus was mapped to chromosomal region 20p12.3-p13 and was ~6.1 
Mbp in size, containing 97 genes [5], of which 54 are expressed in the cerebellum. After excluding 32 prioritized 
genes by Sanger sequencing [6], we identified the causative mutation as localized in PDYN. However, our 
prioritization of candidate genes for mutation screening based on known and common underlying mechanisms 
did not help because SCA23 was, to our knowledge, the first to be reported as linking neuropeptides to a SCA 
disorder. For the first time, mutated neuropeptide precursor protein was shown to be directly responsible for 
the neurodegeneration. Therefore, it may be better to use a hypothesis-free approach as the outcome might be 
surprising (as in the case of SCA23). In conclusion, at the moment, NGS is the best, unbiased and most efficient 
method to identify new mutations/genes without prioritizing them first, and it yields data in a hypothesis-free 
manner.
The rare SCAs caused by conventional mutations are growing in number as new platforms for gene/
mutation identification are being developed and large, multi-centre studies are being performed. In the last 
decade, the causative mutations were identified in SCA5, 13, 14, 19/22 (Chapter 3), 20, 23 (Chapter 4), 26, 







28, and 35 [2, 3, 7-11]. Some remaining questions are: how many more types of SCAs are there? Will we be 
able to identify them all? Are all SCA types the same disease or are different biological routes involved in their 
aetiology? Common underlying pathomechanisms for SCAs have already been suggested by multiple reports [12-
15], and our studies imply that problems with synaptic transmission underlie the pure cerebellar SCAs caused 
by conventional mutations (see discussion below). One of the current challenges is to identify the disease genes/
mutations in small families and in isolated ataxia cases. With the outcome of our work, an array capturing all 
the synapse-associated genes – with a special focus on the CF-PC synapse, but also including other synaptic and 
extra-synaptic proteins that are important for neuronal transmission – could be generated and used in research 
and diagnostics in order to find new mutations responsible for SCA.
Mechanisms underlying Purkinje cell death in SCAs
Despite more than two decades of research, the mechanisms underlying SCA disease have still not been solved. 
As the neurological phenotype of the various SCAs is quite homogenous, there may well be common disease 
mechanisms underlying the genetically different SCA types. In contrast to other SCA types, the SCAs caused by 
conventional mutations, like SCA14 (Chapter 2), SCA19 (Chapter 3) and SCA23 (Chapter 4-7), usually exhibit 
a purer, more isolated cerebellar phenotype, with neuronal loss restricted to the cerebellum. Therefore, this 
group presents a more accurate model for studying the patho mechanisms underlying selective PC loss. Alterations 
in neuronal signalling leading to Ca2+ imbalance represent one of the possibilities proposed; they seem to be 
common in SCAs caused by mutations with different genetic mechanisms, including coding polyQ expansions and 
conventional mutations. Since PC loss is the pathology shared by all the SCAs, Ca2+ imbalance may be a key in the 
pathomechanism specifically underlying PC death and cerebellar degeneration, rather than other accompanying 
symptoms. In this thesis, all the SCA genes studied encode for neuronal signalling proteins, including PKCγ in 
SCA14 (Chapter 2), Kv4.3 in SCA19 (Chapter 3) and PDYN in SCA23 (Chapters 4-7).
SCA14
PKCγ is abundantly expressed in PCs [16] and phosphorylates many targets, including ionotropic 
glutamate receptors and potassium channels [17-19], leading to their inactivation or internalization. Moreover, 
Purkinje cell dendritic development critically depends on the activity of PKCγ, which triggers functional changes 
as well as anatomical maturation of the PC dendritic tree during cerebellar development at different time levels 
[20]. SCA14 is caused by missense mutations in PRKCG encoding for PKCγ. One of the hallmarks of SCA14 is 
PKCγ protein insolubilization, due to a changed structure of the mutant protein that leads to impaired protein 
processing (Chapter 2). This suggests that loss of functional kinase from the soluble pool may underlie the disease 
pathology. However, it is possible that SCA14-mutant PKCγ has a dominant-negative effect on wt-PKCγ and causes 
its insolubilization as well [21]. Moreover, the loss of PKCγ kinase activity was shown for other SCA14 mutants 
earlier [22]. Altogether, these data imply that loss of active kinase in PCs underlies SCA14.
Moreover, SCA14-mutant PKCγ causes PC malfunction by disrupting the elimination of CF synapses 
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during development, which leads to altered synaptic transmission [21]. Problems with developmental synapse 
elimination caused increased numbers of CF synapses in the proximal dendrites and soma of PCs, which may 
result in PC overexcitation and cell death due to excitotoxicity. Additionally, aberrant PKCγ signalling due to SCA14 
mutations, leading to reduced phosphorylation of targets such as the Ca2+ channel TRPC3, was associated with 
elevated intracellular Ca2+ concentrations in vitro [19, 22]. Loss of TRPC3 phosphorylation would lead to sustained 
Ca2+ influx and altered intracellular Ca2+ homeostasis [19].
However, we cannot exclude the possibility that SCA14-mutant PKCγ causes oxidative stress, as PKCγ 
can also be activated by reactive oxygen species (direct oxidation of the C1B domain by H2O2) and subsequently 
phosphorylates connexins, resulting in disassembly of gap junctions between cells [23]. SCA14-mutant PKCγ 
proteins carrying mutations in the C1B domain lack the ability to respond to H2O2 and increase cell susceptibility 
for H2O2-induced apoptosis in lens due to oxidative damage [24, 25].
SCA19
Voltage-gated potassium channels participate in fast spiking of PCs and modulate their action potential 
firing [26, 27]; they therefore also play a crucial role in motor control. Kv4.3, a subunit of the voltage-gated potassium 
channel, is highly expressed in the cerebellum and is thought to be important for cerebellar development [28]. 
SCA19 mutations in KCND3 encoding for Kv4.3 cause impaired channel trafficking, reduced protein stability, and 
affect channel activity, leading to formation of inactive (or highly reduced activity of) channel complexes if located at 
the plasma membrane (Chapter 3). Altogether, these data suggest that loss of Kv4.3 function may underlie SCA19. 
However, KCND3 knock-out mice have been generated and they did not display any neurological impairment or 
motor coordination deficiency [29], probably due to redundancy of other Kv4 family members. This suggests 
that the SCA19-mutant Kv4.3 must have a dominant negative effect on the maturation or activity of the wild type 
Kv4.3 subunit or on other Kv4 α subunits such as Kv4.1 and Kv4.2. Loss of functional Kv4 channel complexes on the 
plasma membrane would abrogate neuronal repolarization leading to longer duration of action potentials. This 
could change intracellular Ca2+ homeostasis and may trigger PC death. Additionally, SCA19-mutant Kv4.3 subunits, 
trapped in ER, may lead to ER stress and induction of the unfolded protein response, contributing to PC death.
SCA23
The cerebellar function of neuropeptide Dyn A, or its precursor PDYN, is largely unknown. They were 
previously studied only in relation to pain processing and addiction [30]. Although at physiological levels the 
actions of Dyn A are mainly mediated through opioid receptors, elevated Dyn A levels can display cytotoxic and 
neurodegenerative effects, which cannot be inhibited by opioid antagonists [31]. Interestingly, these neurotoxic 
effects can be prevented by NMDAR-specific antagonists [32], suggesting a role of these receptors in non-opioid 
actions of Dyn A peptides. Dyn A can interact directly with the NMDAR and potentiate their currents [33]. Enhanced 
stimulation of NMDARs may cause excitotoxicity leading to neuronal cell death (reviewed in [34]).
SCA23 mutations were identified in the PDYN, and resulted in elevated Dyn A peptide levels and toxicity 







in vitro (Chapters 4 and 5). Increased levels of Dyn A were also detected in the SCA23 mouse model that we 
developed and were found to correlate with PC loss and cerebellar ataxia (Chapter 6). Moreover, SCA23-mutant 
Dyn A was found to be more resistant to degradation, probably due to changes in its secondary structure (Chapter 
7). Specific stimulation of NMDARs caused more pronounced cell death in the presence of SCA23-mutant peptides 
(Chapter 7), which is in line with the finding that Dyn A is able to potentiate NMDAR glutamate currents [33]. 
These findings support the hypothesis of an excitotoxic mechanism underlying SCA23.
In addition, it was implied that Dyn A actions through κ-opioid receptor (KOR) are neuroprotective [35], 
as Dyn A interaction with KOR decreases intracellular Ca2+ concentrations [36, 37], preventing excitotoxicity. Our 
results support this hypothesis, as blocking of the opioid pathway increased the toxicity of SCA23-mutant Dyn A 
peptides (Chapter 7).
The importance of glutamate/Ca2+ homeostasis in dynorphin signalling in the cerebellum is underscored 
by altered EAAT4 glutamate transporter insolubilization, which was found in material from SCA23 patients 
(Chapter 4). Reduced expression of EAAT4 transporters on the membrane of the PC would lead to synaptic 
accumulation of glutamate and may contribute to excitotoxic damage. Although, we did not detect altered EAAT4 
distribution in SCA23-mutant mice (Chapter 6), we did observe decreased CF-PC synapses that may cause deficits 
in movement control leading to ataxic phenotype. However, as loss of CF innervation may account for alterations 
in PC glutamatergic signalling and ataxia, it cannot fully explain the PC death and progressiveness of the disease. 
Since it was reported that PC death correlates with CF hyperexcitability [38, 39] and Dyn A potentiates glutamate 
currents of NMDARs [33], elevated Dyn A levels in our SCA23 mouse model may cause excitotoxic damage at CF-
PC synapses and PC death. The progressive elimination of CF-PC synapses during the course of the disease would 
serve as a compensatory mechanism.
Alternatively, loss of PDYN or haploinsufficiency might also underlie SCA23 as we identified a truncating 
mutation leading to complete loss of Dyn peptides (Chapter 5). The identification of the R138S mutation, localized 
to the non-opioid region of PDYN, also suggests that the precursor protein PDYN, and not only its peptide 
derivatives, may have an unknown cerebellar function that is also important for PC survival.
Clearly, additional studies are needed to assess the pathological actions of SCA23-mutant Dyn A, as 
well as the PDYN-dependent neurodegenerative mechanism, but a comprehensive model of neurotoxic, non-
opioid Dyn A actions in SCA23 is now emerging. Future research will show if SCA23 Dyn A peptides are able to 
over-stimulate NMDARs and cause excitotoxicity that can be rescued by anti-excitotoxicity compounds or subunit-
specific NMDAR blockers. The latter would also prove which NMDAR subunit is responsible for Dyn A-mediated 
current potentiation.
Excitotoxicity as a common pathology underlying SCAs
Taken together, a common pathology of aberrant glutamate/Ca2+ signalling leading to excitotoxicity is emerging 
(summarized in Fig. 1). Pathological increase in intracellular Ca2+ concentrations cause activation of various enzymes 
leading to fragmentation of DNA, cytoskeleton and membranes components, and subsequently cell death.
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Figure 1 Neuronal mechanisms possibly leading to excitotoxicity in Purkinje cells. 
TRPC = transient receptor potential channel, iGluR = ionotropic glutamate receptor, mGluR = metabotropic glutamate 
receptor, Kv = voltage-gated potassium channel, PLC = phospholipase C, PMCA = plasma membrane calcium ATPase, DAG = 
diacylglycerol, OR = opioid receptor 
Similarly to SCA14, impaired elimination of CF synapses during development was reported in a SCA1 
mouse model [40]. Moreover, sustained CF excitation causes PC neurodegeneration [38, 39], suggesting that 
increased CF innervation of PCs may lead to excitotoxicity.
Impairment of glutamate re-uptake from the synaptic cleft, due to reduced expression of glutamate 
transporters at the PC membrane (analogous to SCA23), has been implicated in SCA5 [23], and also in the polyQ-
related SCA types SCA1 and SCA7 [41, 42]. Decreased glutamate re-uptake would lead to extensive activation 
of glutamate receptors leading to increased intracellular Ca2+ influx and activation of apoptotic pathways [43]. 
Mutations in the gene encoding for the plasma membrane Ca2+ ATP-ase PMCA3 were recently associated with 
X-linked cerebellar ataxia [44]. Loss-of-function mutations disrupted the PMCA3 channel function and may lead 
to elevated intracellular Ca2+ levels in neuronal cells. Moreover, the Ca2+ stabilizer, dantrolene, was capable of 
mitigating the motor deficits observed in SCA2 and SCA3 mouse models, indicating that maintaining balanced 
intracellular Ca2+ concentrations prevents dysfunctional Ca2+ signalling and subsequent PC degeneration in these 
mice [45, 46].







Furthermore, SCA13 mutations in KCNC3, a gene encoding for Kv3.3 subunit of potassium channel and 
required for the high-frequency firing of action potentials in PCs and Ca2+ spike termination [47, 48], result in 
non-functional Kv3.3 subunits [49]. Similarly to SCA19, these mutant subunits act with a dominant-negative effect 
on other subunits of the Kv3 family, leading to a loss of Kv3 channels function [50]. KCNC3 knock-out mice display 
a marked increase in the duration of PC action potential and a disrupted function of the olivo-cerebellar circuit, 
leading to mild motor coordination problems [51].
Together, these findings underscore the importance of Ca2+ homeostasis in PCs and imply a common 
mechanism for PC degeneration in the genetically different SCA types that involves defects in glutamate/Ca2+ 
synaptic transmission and excitotoxic damage, leading to PC death and subsequent cerebellar ataxia. Future 
research will prove if excitotoxicity is a common underlying mechanism of all SCA types.
Therapeutic strategies in SCAs
Although the first SCA was discovered in 1993 [52, 53], and enormous research efforts have been made since 
then to understand the molecular pathomechanism underlying different SCAs, the disease remains incurable. 
The currently available treatments only reduce symptoms and no effective cure exists that can prevent the 
disease or modify its progression (reviewed in [54]). Some benefits regarding alleviation of ataxic symptoms 
were reported in SCA2 and SCA3 patients who took NMDAR modulators or antagonists, or dopaminergic and 
anticholinergic drugs that decrease tremor or dystonia (reviewed in [54]). Benzodiazepines and β-blockers 
are used in ameliorating tremor, and magnesium, chinine or mexiletine are used to reduce muscle cramps in 
SCA1, 3, and 7 [54]. Lithium carbonate improved motor function and neuronal morphology in a SCA1 mouse 
model [55], and clinical trials were recently conducted in SCA1, 2 and 3 (NCT00683943, NCT00998634, and 
NCT01096082, respectively; http://clinicaltrials.gov, National Institutes of Health, USA). These trials showed that 
lithium carbonate was safe and improved the quality of life for ataxic patients, reducing neurological symptoms, 
ataxia and depression. A follow-up study is underway. Additionally, Ca2+ signalling blockers, including specific 
antagonists of NMDAR subunit NR2B, mGluR5 or IP3R, or Ca
2+ stabilizers such as dantrolene have proved partially 
beneficial in treating neurological symptoms in various SCA types [45, 46].
These treatments may relieve patients’ ataxic symptoms, but they do not provide a cure for the disease. 
In gene therapy, the disease gene can be replaced by the wild-type gene or the mutant allele can be specifically 
silenced (reviewed in [56]). This approach is feasible for monogenic disorders such as the SCAs. In SCA1, an RNA 
interference (RNAi) approach has been tested to downregulate the mutated allele and inhibit neurodegeneration. 
Viral injections of RNAi constructs targeting the mutant allele improved movement control, cerebellar morphology, 
and protein misfolding in a SCA1 mouse model [57]. Similar effects were seen upon mutant allele silencing in 
SCA3 rats [58]. However, these promising results from animal models have not yet been followed up by clinical 
trials in humans. This might be due to the fact that the delivery of the RNAi constructs by viral vectors carries the 
risk of a sustained immunological response and off-target effects, as interference with the expression of unknown, 
possibly important, targets can be anticipated. This innovative approach therefore needs to be tested further for 
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intrinsic toxicity. The major advantage of gene therapy is that it targets the primary problem, the gene mutation, 
without requiring a full knowledge of the molecular mechanisms underlying the disease. This is in contrast to 
drug-based therapies which target specific molecular pathways.
Given our results, the drugs against excitotoxicity may prove useful to treat and cure SCAs. Agents 
inducing anti-excitotoxic effects, like riluzole, partially alleviated ataxic symptoms in patients with cerebellar 
ataxias [59] and are currently being tested in clinical trials (recruiting phase; NCT01104649, http://clinicaltrials.
gov, National Institutes of Health, USA).
 The current therapies focus on the more frequent SCA types, namely the polyQ-related SCAs, but neglect 
the rare SCAs caused by conventional mutations. However, the progress being made in learning more about the 
common molecular pathologies that underlie the genetically different types of SCA will contribute greatly to the 
development of therapeutic interventions that can target all the SCA types.
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Rozdział 1 zawiera opis ataksji rdzeniowo-móżdżkowych (ang. spinocerebellar ataxia, SCA), które są chorobami 
neurodegeneracyjnymi dziedziczonymi autosomalnie dominująco i charakteryzują się atrofią komórek Purkiniego 
w móżdżku. Ataksje rdzeniowo-móżdżkowe są spowodowane mutacjami o różnym mechanizmie genetycznym, 
którymi są: ekspansje ciągu poliglutaminowego, niekodujące ekspansje ciągów powtórzeń oraz mutacje klasyczne 
(mutacje niesynonimiczne, delecje itp.). Do tej pory odkryto 32 rodzaje ataksji rdzeniowo-móżdżkowych, jednak 
tylko dla 22-óch typów zostały znalezione mutacje sprawcze. Badania mające na celu identyfikację nowych mutacji 
odpowiedzialnych za ataksje rdzeniowo-móżdżkowe o nieodkrytym do tej pory podłożu genetycznym nie tylko 
poszerzają możliwości diagnostyczne ataksji, ale również prowadzą do szerszego zrozumienia mechanizmów ko-
mórkowych odpowiedzialnych za tę chorobę i odkrycia możliwych terapii.
 W Rozdziale 2 zostały przedstawione badania wpływu mutacji V138E na aktywację i dezaktywację kinazy 
PKCγ w kontekście ataksji rdzeniowo-móżdżkowej typu 14 (SCA14), która wywoływana jest mutacjami  w genie 
kodującym PKCγ. Mutacja V138E prowadziła do zmiany konformacji kinazy PKCγ, powodując deficyt w jej defosfo-
rylacji oraz degradacji, i w konsekwencji wewnątrzkomórkową akumulację PKCγ. Wyniki naszych badań sugerują, 
że ilościowy deficyt aktywnej kinazy PKCγ w rozpuszczalnej frakcji komórkowej jest przyczyną ataksji SCA14 oraz że 
białka modyfikujące rozpuszczalność oraz aktywację/dezaktywację PKCγ, takie jak PDK1, mogą w przyszłości przy-
czynić się do stworzenia terapii dla ataksji SCA14.
 Rozdział 3 opisuje identyfikację trzech mutacji w genie KCND3 odpowiedzialnych za ataksję SCA19. 
Pierwsza mutacja została zidentyfikowana z użyciem sekwencjonowania nowej generacji dla próbek DNA od 
dwóch pacjentów z tej samej rodziny. Pozostałe dwie mutacje zostały znalezione metodą denaturacji DNA z wysoką 
rozdzielczością (ang. high-resolution melting) w grupie 230 pacjentów z ataksją o nieznanym podłożu genetycz-
nym. Gen KCND3 koduje kanał potasowy Kv4.3, odpowiedzialny za aktywny transport potasu na zewnątrz komórki 
podczas przesyłania potencjału czynnościowego (impulsu elektrycznego) w układzie nerwowym. Kv4.3 występu-
je w komórkach móżdżku w dużej ilości i bierze udział w wyciszaniu potencjału czynnościowego w dendrytach 
komórek Purkiniego. Badania morfologii móżdżku pacjenta z ataksją SCA19 ujawniły wyraźną atrofię komórek 
Purkiniego w regionie vermis, który jest najsilniej zaatakowany również w innych ataksjach spowodowanych mu-
tacjami klasycznymi (SCA13, SCA15/16, SCA23, and SCA28). Zmutowane białka Kv4.3 w ataksji SCA19, niosące 
różne mutacje, były zlokalizowane głównie w retikulum endoplazmatycznym i nie docierały do błony. Wykazywały 
również obniżoną stabilność proteolityczną oraz bardzo ograniczoną zdolność do transportu jonów potasowych 
(gdy były zlokalizowane w błonie). Nasze wyniki wykazują, że brak kanału potasowego w błonie może być przyczyną 
degeneracji móżdżku i ataksji.
 W Rozdziałach 4, 5 i 6 znajduje się opis badań in vitro oraz in vivo nad ataksją SCA23. Jako pierwsi ziden-
tyfikowaliśmy mutację odpowiedzialną za ataksję SCA23 w genie PDYN (kodującym białko prodynorfinę, PDYN) 
w sprzężonym z chorobą regionie położonym na chromosomie 20 (20p13) z użyciem sekwencjonowania metodą 
Sangera (Rozdział 4). Badania przesiewowe  grupy 800 pacjentów z ataksją o nieznanym podłożu genetycznym 
doprowadziły do identyfikacji kolejnych trzech mutacji w regionie kodującym peptyd dynorfinę (Dyn) A. PDYN 











jest prekursorem neuropeptydów opioidowych, między innymi Dyn A, które regulują odczuwanie bólu oraz biorą 
udział w szlakach metabolicznych prowadzących do uzależnień. Funkcja peptydów opioidowych w móżdżku jest 
jednak nieznana. W przeprowadzonych przez nas doświadczeniach mutacje zlokalizowane w regionie kodującym 
Dyn A powodowały zwiększoną ilość oraz toksyczność tego peptydu w kulturach pierwszorzędowych komórek 
nerwowych prążkowia. Dodatkowo, jedna mutacja została zidentyfikowana w regionie niekodującym peptydów 
opioidowych i prowadziła do zmian w ekspresji składników szlaku opioidowego oraz glutaminianowego. Ana-
liza białkowa tkanki nerwowej pacjenta z ataksją SCA23 wykazała między innymi zmniejszoną ilość transportera 
glutaminianu EAAT4 w błonie komórkowej oraz patologiczną wewnątrzkomórkową akumulację tego białka. Brak 
działających poprawnie cząsteczek EAAT4, których główną funkcją jest usuwanie nadmiaru glutaminianu ze szcze-
liny synaptycznej, prowadziłby do zwiększenia stężenia glutaminianu i w konsekwencji do nadmiernej aktywacji 
neuronów, zwanej ekscytotoksycznością. Wyniki naszych badań są zgodne z poprzednimi doniesieniami o zmia-
nach w ekspresji i lokalizacji transportera EAAT4 w ataksjach SCA1 i SCA5, a także wskazują na wspólny mechanizm 
patologii w ataksjach z rodzaju SCA (autosomalnych dominujących).
 W celu zbadania częstotliwości ataksji SCA23 w Europie przeprowadzone zostały badania przesiewo-
we w grupie pacjentów z ataksją o nieznanym podłożu genetycznym (Rozdział 5). Choroba ta okazała się bardzo 
rzadka, odpowiadając jedynie za 0,1% przypadków wśród ataksji z rodzaju SCA. Podczas badań przesiewowych 
zidentyfikowaliśmy w genie PDYN dodatkowe trzy substytucje oraz jedną delecję prowadzącą do przesunięcia ram-
ki odczytu i pojawienia się przedwczesnego kodonu stop. Dwie z wykrytych substytucji prowadziły do zwiększonej 
ilości peptydu Dyn A. Jednakże analiza kosegregacji choroby z substytucjami nie była jednoznaczna, dlatego nie 
byliśmy w stanie dowieść patologii tych zmian i wykazać czy substytucje są mutacjami czy tylko polimorfizmami. Z 
kolei delecja znaleziona u jednej rodziny prowadziła do całkowitego zaniku ekspresji peptydów Dyn A, co wskazuje 
na to, że utrata funkcji przez białko PDYN lub jego niedobór (w wyniku braku jednego allelu) mogą również powo-
dować ataksję SCA23. Dodatkowo wyniki naszych badań sugerują, że region kodujący Dyn A może być tzw. gorącym 
miejscem (ang. hot-spot) dla mutacji SCA23.
 Chcąc dowieść patologii znalezionych przez nas mutacji in vivo oraz zbadać mechanizmy komórkowe 
odpowiadające za ataksję SCA23, stworzyliśmy model zwierzęcy tej choroby – mysz transgeniczną posiadającą 
jeden allel ludzkiego genu PDYN z mutacją R212W (Rozdział 6). Mutacja ta wykazywała najbardziej toksyczne efekty 
w naszych wcześniejszych badaniach in vitro. Analiza modelu ataksji SCA23 w czasie (1 rok) potwierdziła patogen-
ność mutacji R212W. Myszy PDYN-R212W wykazywały objawy typowe dla ataksji SCA23 u ludzi, włącznie z wolno 
postępującymi, łagodnymi problemami z koordynacją ruchową i chodzeniem oraz zanikiem komórek Purkiniego 
w móżdżku w późniejszym stadium choroby. Zaraz po wystąpieniu pierwszych objawów choroby wykryliśmy zwięk-
szoną ilość peptydu Dyn A w móżdżkach myszy PDYN-R212W, która była powiązana ze spadkiem ilości zakoń-
czeń nerwowych CF (ang. climbing fiber) na komórkach Purkiniego. Ta zmiana postępowała w czasie przebiegu 
choroby, wskazując na aktywną eliminację zakończeń CF, a nie na problemy w rozwoju embrionalnym układu 
nerwowego w modelu SCA23. Biorąc pod uwagę zwiększoną ilość Dyn A w móżdżku oraz doniesienia, że Dyn A 
może zwiększać aktywność receptorów glutaminianowych, zaproponowaliśmy hipotezę, według której zmutowane 
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peptydy Dyn A powodują nadmierną aktywację komórek Purkiniego i ekscytotoksyczność, prowadzącą do atrofii 
komórek móżdżku i ataksji.
 Żeby zweryfikować tę hipotezę i poznać mechanizmy, za pośrednictwem których Dyn A powoduje śmierć 
komórek, użyliśmy modelowej linii komórkowej NG108 zróżnicowanej do neuronów oraz zbadaliśmy wpływ mu-
tacji zlokalizowanych w regionie kodującym Dyn A na strukturę i funkcję tego peptydu (Rozdział 7). Zmutowane 
peptydy Dyn A wykazywały zmienioną strukturę drugorzędową na błonach, podobną do struktury peptydu Dyn 
A-Y1del, który nie oddziałuje z receptorami opioidowymi. Peptydy Dyn A niosące mutacje SCA23 wiązały się z 
receptorami opioidowymi, ale oddziaływanie to było osłabione. Dodatkowo dwie z trzech mutacji powodowały 
podwyższoną stabilność peptydów Dyn A, co mogłoby wyjaśniać zwiększoną ilość Dyn A w naszych poprzednich 
badaniach in vitro i in vivo. Zmutowane peptydy Dyn A powodowały śmierć modelowych komórek nerwowych, 
wykazując toksyczność zależącą od stężenia. Toksyczność zmutowanych peptydów DynA wynikała głównie z ich 
oddziaływania na receptory glutaminianowe NMDA, gdyż użycie specyficznych antagonistów tych receptorów blo-
kowało ten efekt. Ponadto nasze wyniki potwierdziły hipotezę, że szlak opioidowy jest potrzebny do utrzymywania 
homeostazy i jego aktywacja ma właściwości neuroprotekcyjne, gdyż blokowanie tego szlaku doprowadziło do 
śmierci modelowych komórek nerwowych w obecności nietoksycznych stężeń peptydów Dyn A. Dlatego też za-
proponowaliśmy , że zmutowane peptydy Dyn A mogą powodować neurotoksyczność poprzez dwa mechanizmy: 
zmniejszoną aktywność neuroprotekcyjnego szlaku opioidowego oraz ekscytotoksyczność poprzez oddziaływanie 
na receptory glutaminianowe NMDA.
 Rozdział 8 obejmuje dyskusję na temat wspólnych mechanizmów komórkowych prowadzących do śmier-
ci komórek Purkiniego w ataksjach z rodzaju SCA. Z naszych badań wynika, że jednym z tych mechanizmów może 
być ekscytotoksyczność, czyli nadmierna aktywacja receptorów glutaminianowych. Prowadzi ona do zwiększenia 
wewnątrzkomórkowego stężenia jonów wapnia, aktywujących liczne enzymy, w tym fosfolipazy, endonukleazy i 
proteazy, które uszkadzają struktury komórkowe, poprzez fragmentację składników cytoszkieletu, błon komórko-
wych oraz DNA. Z tego powodu, związki blokujące ekscytotoksyczność lub aktyrujące anty-ekscytotoksyczne szlaki 
np. będący na etapie prób klinicznych riluzol (ang. riluzole),  stanowią obiecujące źródło terapii ataksji. 
 Podsumowując, ataksje typu SCA tworzą grupę chorób o różnym podłożu genetycznym, jednakże po-
dobne objawy choroby sugerują wspólne podłoże molekularne/komórkowe. W tej pracy doktorskiej opisane 
zostały trzy rodzaje ataksji typu SCA spowodowane mutacjami klasycznymi w różnych genach. Ataksje typu SCA 
spowodowane mutacjami klasycznymi stanowią bardziej odpowiedni model do badania tej choroby, ponieważ 
pierwotna atrofia neuronów ogranicza się do móżdżku, a inne regiony mózgu nie są zaatakowane (jak w rodzajach 
ataksji typu SCA o innym podłożu genetycznym). Z naszych badań wynika, że ekscytotoksyczność może być wspól-
nym patologicznym mechanizmem w ataksjach SCA14, SCA19 i SCA23, w których zmutowane białka prowadzą do 
problemów w przewodnictwie synaptycznym, powodując zwiększenie stężenia jonów wapnia w komórkach ner-
wowych. Szersze zrozumienie mechanizmów prowadzących do ekscytotoksyczności i śmierci komórek Purkiniego 
może się przyczynić do wynalezienia terapii ataksji typu SCA.











In Hoofdstuk 1, presenteer ik een korte inleiding over spinocerebellar ataxias (SCAs). Dit zijn autosomaal domi-
nante neurodegeneratieve aandoeningen, gekarakteriseerd door atrophie van Purkinje cellen in het cerebellum. 
Ik review de onderliggende genetische en moleculaire mechanismen van SCA, die uit drie genetische verschillen-
de groepen bestaan: polyglutamine repeat expansies, niet-coderende repeat expansies of conventionele muta-
ties. Tot nu toe zijn 32 SCA types bekend, die gelokaliseerd zijn op verschillende genetische loci. Voor 22 types 
zijn de ziekte veroorzakende genen en mutaties geïdentificeerd. Het vinden van de causale mutaties in de groep 
van SCA families zonder genetische diagnose verbeterd niet alleen de diagnostische mogelijkheden voor deze 
patiënten maar levert ook verdere inzichten in de onderliggende pathologische wegen van SCA dat bijdraagt aan 
nieuwe therapeutische ontwikkelingen.
 In Hoofdstuk 2 wordt de impact van de V138E mutatie op de levenscyclus van PKCg bestudeerd in de 
context van SCA14, dat veroorzaakt wordt door missense mutaties in het gen coderend voor protein kinase C 
gamma, PKCg. We observeerden dat SCA14-mutant PKCg  een veranderd eiwit structuur heeft, wat leidt tot ver-
minderde defosforylatie en afbraak en ophoping van de mutante moleculen in de Triton-onoplosbare cellulaire 
fractie. Ons werk suggereert dat verminderde hoeveelheden van actief PKCg  kinase in de oplosbare cellulaire 
fractie de SCA14 pathologie veroorzaakt. Moleculen die de verwerking van PKCg beïnvloeden, zoals PDK1, die het 
verlies tegengaan van actief en gefosforyleerde PKCg eiwitten in de onoplosbare pool, zijn potentiële kandidaten 
voor een nieuwe therapeutische interventie voor SCA14.
 In Hoofdstuk 3 werden missense mutaties in KCND3 geïdentificeerd die SCA19 veroorzaakten via exo-
om sequencing in twee aangedane personen van de als eerste gerapporteerde SCA19 familie. KCND3 codeert 
voor Kv4.3, een voltage-gereguleerd kalium kanaal die de kortdurende, naar buiten gerichte kalium stromen in 
zenuwcellen reguleert. Kv4.3 komt hoog tot expressie in het cerebellum en draagt bij aan het verminderen van 
post-synaptische potentialen in de dendrieten van Purkinje cellen. Het screenen van twee honderd en dertig 
ataxie patiënten, zonder mutaties in de bekende SCA genen, voor mutaties in KCND3 via High-Resolution Melting, 
zorgde voor de identificatie van 2 nieuwe mutaties. SCA19 autopsie materiaal liet duidelijke degeneratie zien 
van Purkinje cellen in de cerebellaire vermis, net zoals de pathologie in andere SCA typen veroorzaakt door co-
nventionele mutaties (SCA13, 15/16, 23 en 28). Alle SCA19-mutante Kv4.3 subunits zaten in het endoplasmatisch 
reticulum (ER) door verminderd transport, wat verminderde plasma membraan lokalisatie en verminderde eiwit 
stabiliteit veroorzaakte. De regulaire subunit KChIP2 redde de lokalisatie afwijkingen en de eiwit stabiliteit in 2 
van de 3 mutante Kv4.3 kanaal complexen. Echter, hiermee werd slechts gedeeltelijk of helemaal niet de kanaal 
functie hersteld. Onze resultaten laten zien dat verlies van Kv4.3 kanalen, die alleen nodig zijn om de snelle repo-
larisatie van neuronen tegen te gaan, genoeg is om cerebellaire neurodegeneratie te veroorzaken. 
 De Hoofdstukken 4, 5 en 6 beschrijven de identificatie van mutaties die SCA23 veroorzaken gevolgd 
door in vitro en in vivo studies. De eerste SCA23 mutatie was geïdentificeerd in prodynorphin, PDYN, via Sanger 
sequencen van kandidaat genen in het linkage interval op de chromosomale regio 20p13-12.3 (Hoofdstuk 4). 
Het screenen van het Nederlandse ataxie cohort (n = 800) leidde tot de ontdekking van drie andere missense 
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mutaties, die zich in het neuropeptide Dynorphin (Dyn) A bevonden. PDYN is een voorloper eiwit voor de opioid 
neuropeptides a-neoendorphin, Dyn A and B. Dynorphins reguleren pijn verwerking en moduleren het beloning 
gevoel van verslavende middelen via opioid signalering, maar hoe Dyn A neurodegeneratie in het cerebellum kan 
veroorzaken is niet bekend. De SCA23 mutaties in Dyn A leiden tot verhoogde peptide niveaus en twee van de drie 
mutaties verhoogde de intrinsieke toxiciteit van normaal (gezond) Dyn A in gekweekte striatale zenuwcellen. Eén 
mutatie bevond zich in het niet-opioid gerelateerde domein van PDYN en kwam overeen met veranderde expres-
sie van componenten van het opioid en glutamaat systeem zoals EAAT4, zoals duidelijk werd na proteoom analyse 
van SCA23 autopsie materiaal. Verlies van EAAT4 functie op de Purkinje cel membraan kan leiden tot ophoping 
van excitatoir glutamaat in de synaptische groeve en zal bijdragen aan excitotoxische schade. Onze bevindingen 
komen overeen met eerdere werk waarin veranderingen in expressie en lokalisatie van EAAT4 in SCA1 en SCA5 
gerapporteerd werden, en duiden erop dat de acties van Dyn A kunnen leiden tot veranderingen in glutamaat en/
of calcium signalering wat SCA23 kan veroorzaken. 
 Om de SCA23 ziekte frequentie in Europa te bepalen, werden dominante cerebellaire ataxie patiënten, 
van voornamelijk Franse achtergrond, gescreend voor mutaties in PDYN (Hoofdstuk 5). Variaties in PDYN bleken 
zeldzaam te zijn in Kaukasische ataxie patiënten. We identificeerden drie nieuwe missense variaties en een af-
kappende mutatie (een 2 basenpaar deletie) wat leidde tot een vervroegd stop codon. Twee missense variaties 
kwamen overeen met verhoogde Dyn A niveaus waarvan één niet co-segregeerde met het ziektebeeld en voor 
de ander kon co-segregatie niet worden vast gesteld. Daarom konden we niet concluderen dat deze missense 
variaties ziekte veroorzakend zijn. Geheel verlies van de Dynorphin peptides door de afkappende mutatie geeft 
een sterke aanwijzing dat haploïnsufficientie of verlies van functie ook SCA23 kan veroorzaken. Verder lijkt Dyn A 
een “hotspot” te zijn voor SCA23 mutaties, wat het belang van Dyn A’s functie onderstreept in het cerebellum. 
 Om de rol van PDYN te kunnen bestuderen in cerebellaire neurodegeneratie en ataxie en om inzichten 
te krijgen in de ziekte mechanismen van SCA23, werd er een voorwaardelijk transgeen muismodel gemaakt die 
overal menselijk PDYN-R212W tot expressie brengt (Hoofdstuk 6). Deze mutatie liet de ernstigste pathogene 
effecten zien in ons eerdere in vitro werk. We bevestigden dat PDYN-R212W cerebellaire ataxie veroorzaakt in vivo, 
als de transgene muizen de ziekte symptomen lieten zien van SCA23 patiënten zoals langzaam verergerende motor 
coördinatie en loopgang afwijkingen en Purkinje cel verlies op de leeftijd van 12 maanden. De SCA23-mutante 
transgene muizen hadden verhoogde Dyn A niveaus in het cerebellum dat gekoppeld leek te zijn met verminderde 
klimvezel innervatie van de Purkinje cellen. Dit tekort in klimvezel synaps distributie begon al vroeg in het ziekte 
proces en verergerde in tijd, wat suggereert dat deze vezels actief verwijderd worden in plaatst van problemen 
in de aanleg tijdens de ontwikkeling. Gezien het verhoogde Dyn A niveau, dat N-methyl-D-Aspartaat (NMDA) 
receptoren stromen kan potentiëren, veronderstelden wij dat SCA23 wordt veroorzaakt door Dyn A gedreven 
excitoxische schade via NMDA receptor activatie.
 Om de neurodegeneratieve mechanismen aangestuurd via de SCA23-mutante Dyn A peptiden te on-
derzoeken, bestudeerden we de effecten van de SCA23 mutaties op de secondaire structuur van Dyn A, opioid 
receptor affiniteit, en celdood gebruik makend van selectieve antagonisten en agonisten voor zowel opioid als 










NMDA receptoren (Hoofdstuk 7). Alle SCA23-mutante Dyn A peptiden lieten sterke veranderingen zien in hun 
secondaire structuur in de aanwezigheid van membranen. Dit kwam overeen met de secondaire structuur van 
Dyn A-Y1del, een peptide dat niet meer interacteert met k-opioid receptoren. Voor twee van de drie mutaties 
leidde de veranderingen in de secondaire structuur tot stabielere peptiden die bijna geheel immuun waren 
tegen peptidase afbraak en lieten in vitro verhoogde oligomerisatie zien. SCA23-mutant Dyn A veroorzaakte duide-
lijk dosis afhankelijke neurotoxiciteit in gedifferentieerde NG108 cellen, dat hoofdzakelijk veroorzaakt werd via 
NMDA receptoren als specifieke antagonisten in staat waren om deze effecten te verminderen. Tevens vonden 
we bewijs voor de hypothese dat opioid signalering beschermend kan zijn voor zenuwcellen, als naloxone, een 
opioid receptor anagonist in de aanwezigheid van niet-toxisch SCA23-mutant Dyn A peptides ernstige celdood 
veroorzaakte. Dus SCA23-mutant Dyn A peptiden hebben dichotome neurotoxische activiteiten, als eerste via 
verlies van bescherming van neuronen gereguleerd via opioid receptoren en als tweede via excitotoxische acties 
aangestuurd door NMDA receptoren. 
 Hoofdstuk 8 bevat de discussie over de gemeenschappelijke ziekte mechanismen van de verschillende 
SCA types, met als focus die SCAs veroorzaakt door conventionele mutaties zoals SCA14, SCA19 en SCA23. Onze 
data samenvattend lijkt excitotoxiciteit de gemeenschappelijke noemer te zijn die Purkinje celdood veroorzaakt 
in SCA. Excitotoxiciteit is gekoppeld met de pathologische activatie van ionotrofe glutamaat receptoren (zoals 
NMDA receptoren), wat een verhoging van de intracellulaire calcium concentratie veroorzaakt en tot activatie leidt 
van verschillende enzymen zoals endonucleasen, fosfolipasen en proteasen wat DNA, cytoskelet en membraan 
component fragmentatie veroorzaakt. Verbindingen die excitotoxiciteit blokkeren kunnen bruikbaar zijn in to-
ekomstige therapieën voor SCA. Anti-excitatoire drugs zoals riluzole lieten al gedeeltelijke vermindering zien van 
de ataxtische symptomen in patiënten met cerebellaire ataxie en worden momenteel getest in klinische trials. 
 In conclusie, de SCAs vormen een genetisch heterogene groep van ziekten maar toch lijkt er een geme-
enschappelijke moleculaire pathologie te zijn sinds patiënten van verschillende SCA typen een overeenkomstig 
ziektebeeld laten zien. In dit proefschrift werden SCA14, SCA19 en SCA23 bestudeerd, allen veroorzaakt door 
conventionele mutaties in verschillende en schijnbaar functioneel niet-gerelateerde genen. SCA typen veroorzaakt 
door conventionele mutaties laten meestal een puur, wat meer geïsoleerd cerebellair fenotype zien, met beperkt 
zenuwcel verlies in het cerebellum. Daarom is deze groep een beter en meer nauwkeuriger model dan de andere 
SCA typen om de ziekte mechanismen achter het selectieve Purkinje cel verlies te bestuderen. Ons werk wijst naar 
excitoxiciteit als gemeenschappelijke pathologie voor SCA14, SCA19 en SCA23, als de mutante eiwitten betrokken 
zijn bij defecten in de synaptische signaal overdracht dat verhoogde intracellulaire calcium niveaus en vervolgens 
celdood veroorzaakt. Beter begrip van de excitotoxische mechanismen veroorzaakt door de verschillende mutante 
SCA eiwitten zal bijdragen aan toekomstige therapeutische interventie. 




In Chapter 1, I present a brief background on spinocerebellar ataxias (SCAs), which are autosomal dominant 
neurodegenerative disorders, characterized by atrophy of Purkinje cells in the cerebellum. I review the underlying 
genetic and molecular mechanisms of SCAs, consisting of three genetically different groups: caused by polygluta-
mine repeat expansions, non-coding repeat expansions or conventional mutations. Up to date, 32 types of SCAs 
are known, each mapped to a different genetic locus. For 22 of them the disease causing genes and mutations 
were identified. The identification of the causal mutations in the group of genetically undiagnosed SCA families 
does not only improve the diagnostic possibilities for these patients, but also provides additional insights into the 
underlying pathological pathways of SCA disease contributing to new therapeutic developments.
In Chapter 2, the impact of the V138E mutation on PKCγ lifecycle in context of SCA type 14 was studied, 
which is caused by missense mutations in the gene encoding for protein kinase C γ, PKCγ. We observed that 
SCA14-mutant PKCγ-V138E exhibited a changed protein structure, resulting in impaired dephosphorylation and 
degradation that led to accumulation of the mutant molecules in the Triton-insoluble fraction. Our work suggests 
that decreased levels of active PKCγ kinase in the soluble cellular fraction underlies the SCA14 pathology. Ad-
ditionally, modifiers of PKCγ processing, like PDK1, are potential candidates to prevent the loss of active and still 
phosphorylated PKCγ proteins in the insoluble pool and present new therapeutic opportunities for SCA14.
 In Chapter 3, missense mutations in KCND3 were identified to cause SCA19, using exome sequencing in 
two affected members of the originally reported SCA19 family. KCND3 encodes for Kv4.3, a voltage-gated potassium 
channel, which regulates the transient outward potassium current in the neurons. Kv4.3 is highly expressed in the 
cerebellum and participates in decreasing the postsynaptic potentials in dendrites of Purkinje cells. Screening of 
two hundred and thirty ataxia patients, without mutations in known SCA genes, for mutations located in KCNC3 
using high-resolution melting led to identification of two additional mutations. SCA19 brain autopsy material 
showed pronounced degeneration of Purkinje cells in the cerebellar vermis, similarly to the pathology seen in 
other SCA types caused by conventional mutations (SCA13, 15/16, 23 and 28). All SCA19-mutant Kv4.3 subunits 
exhibited endoplasmatic reticulum retention, due to impaired trafficking, leading to loss of plasma membrane 
localization and reduced protein stability. The regulatory subunit KChIP2 was able to rescue localization deficits and 
the stability of two of the three mutant Kv4.3 channel complexes, however, this did not restore channel function 
or only partially. Our results show that loss of Kv4.3 channels, only required to prevent the fast repolarization of 
neurons, is sufficient to cause cerebellar neurodegeneration.
The Chapters 4, 5 and 6 describe the identification of mutations underlying SCA23, and following in vitro, 
and in vivo studies. The first SCA23 mutation was identified in prodynorphin, PDYN, by Sanger sequencing of candi-
date genes in the linkage interval located at chromosomal region 20p13-12.3 (Chapter 4). Screening of the Dutch 
ataxia cohort (n = 800) led to the discovery of three additional missense mutations, located in the neuropeptide 
Dynorphin (Dyn) A. PDYN is a precursor protein for the opioid neuropeptides α-neoendorphin, Dyn A and B. Dyn-
orphins regulate pain processing and modulate the rewarding effects of addictive substances via opioid signaling, 
but the mechanisms by which Dyn A can mediate neurodegeneration in the cerebellum are unknown. The SCA23 







mutations in Dyn A-coding region led to enhanced peptide levels and two of the three mutations enhanced the 
intrinsic toxicity of wild-type Dyn A in cultured striatal neurons. One mutation was located in the non-opioid region 
of PDYN and correlated with altered expression of components of the opioid and glutamate system, including 
EAAT4, as was evident from proteomic analysis of SCA23 autopsy tissue. Lack of EAAT4 function on the Purkinje 
cell membrane may cause the accumulation of excitatory glutamate in the synaptic cleft contributing to excitotoxic 
damage. Our findings are consistent with previous reports demonstrating alterations in expression and localiza-
tion of EAAT4 in SCA1 and SCA5, and indicate that mutant Dyn A actions may lead to changes in glutamate/calcium 
signaling that results in SCA23 pathology.
To reveal the SCA23 disease frequency in Europe, dominant cerebellar ataxia patients of mostly French 
origin were screened for mutations in PDYN (Chapter 5). PDYN variations turned out to be rare in Caucasian ataxia 
cases. We identified three novel missense variations and a truncating mutation (heterozygous 2 bp deletion), 
leading to premature stop codon. Two missense variations correlated with enhanced Dyn A levels of which one did 
not co-segregated with the disease and for the other co-segregation could not be established. Therefore we could 
not conclude that these missense variations are indeed pathogenic. The complete loss of the Dynorphin peptides 
in case of the truncating mutation strongly suggests that haploinsufficiency or loss of function may also underlie 
SCA23. Additionally, Dyn A-coding region seems to be a hotspot for SCA23 mutations, underlining the importance 
of Dyn A function in the cerebellum.
 To study the role of PDYN in cerebellar neurodegeneration and ataxia and to get insights into the dis-
ease mechanisms underlying SCA23, a conditional transgenic mouse model was generated that ubiquitously ex-
presses human PDYN-R212W (Chapter 6). This mutation showed the most pathogenic effects in our previous in 
vitro work. We confirmed that PDYN-R212W causes cerebellar ataxia in vivo, as the transgenic mice displayed the 
disease symptoms of SCA23 patients including slowly progressive, mild motor coordination and gait deficits, and 
Purkinje cell loss at the age of 12 months. The SCA23-mutant transgenic mice exhibited elevated Dyn A levels in 
the cerebellum that seemed to be associated with decreased climbing fiber innervation of the Purkinje cells. 
This deficiency in climbing fiber synapses distribution started early in the course of disease and progressed in 
time, suggesting active elimination of climbing fiber synapses rather than developmental problems. Given the 
increased levels of Dyn A, which can potentiate N-methyl-D-aspartate (NMDA) receptors currents, we hypothesize 
that SCA23 is caused by Dyn A-mediated excitotoxic damage via NMDA receptors activation.
To further investigate the neurodegenerative mechanisms mediated by SCA23-mutant Dyn A peptides, 
we studied the effects of SCA23 mutations on secondary structure of Dyn A, opioid receptor affinity and cell death 
using selective antagonists and agonists for opioid and NMDA receptors (Chapter 7). All SCA23-mutant Dyn A 
peptides displayed marked changes of the secondary structure in the presence of membranes, mimicking the 
structure of Dyn A-Y1del, a peptide that does not interact with κ-opioid receptors. The SCA23-mutant peptides 
still interacted with κ-opioid receptor but showed reduced affinity. Additionally, for two out of three mutations, 
changes in the secondary structure led to more stable peptides that were almost resistant for peptidase degra-
dation, and showed enhanced oligomerization in vitro. SCA23-mutant Dyn A caused marked dose-dependent 
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neurotoxicity in differentiated NG108 cells, mainly mediated via NMDA receptors, as specific antagonists were 
able to reverse these effects. We also found evidence supporting the hypothesis that opioid signaling could be 
neuroprotective as naloxone, an opioid receptors antagonist, in the presence of non-toxic SCA23-mutant Dyn A 
peptide concentrations caused pronounced cell death. Thus SCA23-mutant Dyn A peptides may exhibit dichoto-
mous neurotoxic effects, the first through loss of neuroprotection mediated by opioid receptors, and second by 
excitotoxic actions via NMDA receptors.
Chapter 8 contains the discussion of the common pathomechanisms underlying the different types 
of SCAs, with a main focus on SCAs caused by conventional mutations such as SCA14, SCA19, and SCA23. Taken 
together all our results, excitotoxicity appears as a common mechanism underlying Purkinje cell death in SCA. 
Excitotoxicity is associated with pathological activation of ionotropic glutamate receptors (like NMDA receptors), 
which cause an increase of intracellular calcium concentrations that activates various enzymes, such as endo-
nucleases, phospholipases, and proteases, resulting in fragmentation of DNA, and cytoskeleton and membranes 
components. Compounds blocking excitotoxicity may be useful in future therapies of SCAs. Anti-excitotoxic drugs 
like riluzole already have been shown to partially alleviate ataxic symptoms in patients with cerebellar ataxias and 
are currently being tested in clinical trials.
To conclude, the SCAs form a genetically heterogeneous group of diseases; however, a common mo-
lecular pathology may exist as patients with different SCA types display similar disease phenotypes. In this thesis, 
SCA14, SCA19 and SCA23 were studied, all caused by conventional mutations, but in different, and seemingly 
functionally non-related genes. The SCAs caused by conventional mutations usually exhibit purer, more isolated 
cerebellar phenotype, with neuronal loss restricted only to the cerebellum. Therefore, this group is a more ac-
curate model to study pathomechanisms underlying selective Purkinje cell loss than other SCA types. Our work 
points into excitotoxicity as a common pathology underlying SCA14, SCA19 and SCA23, as all mutant proteins are 
associated with defects in synaptic transmission that may lead to elevated intracellular calcium concentrations and 
subsequent neuronal cell death. Better understanding of the excitotoxic mechanisms caused by various mutant 
SCA proteins will contribute greatly to future therapeutic interventions.
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